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Abstract
Pigment Epithelium-derived Factor (PEDF), a natural protein possessing 
both neuroprotective and anti-angiogenic properties, is a very unique and attractive 
candidate as a therapeutic agent in the management of pathological neovascular 
diseases, such as tumours, age-related macular degeneration (AMD) and diabetic 
retinopathy. While it is well-known that PEDF can exert powerful effects on various 
tissues and cells, the underlying mechanism of PEDF’s action is not well 
understood. This study investigated the relationship between vascular endothelial 
growth factor (VEGF)/PEDF and VEGFR-l/VEGFR-2 by exploring Presenilin- 
l(PS-l) dependent regulated intramembrane proteolysis (RIP). Work on this non- 
classical pathway was initiated by Cai et al., (2006) using in vitro models of bovine 
retinal microvascular endothelial cells (BRMECs). Current study used BRMECs and 
human retinal pigment epithelial (HRPE) cells.
In this study, BRMECs and HRPE cells were isolated and cultured. 
BRMECs were used as an angiogenic cell type while HRPE cells were used as an 
angiogenic regulator cell type. The characteristics of endothelial and epithelial cells 
and the localisation of VEGFR-1, VEGFR-2 and PS in BRMECs and HRPE cells 
were determined using immunocytochemistry techniques. The effects of VEGF and 
PEDF on VEGFR-1, VEGFR-2 and PS were assessed using immunocytochemistry 
and Western blotting, y-secretase activity in BRMECs and HRPE cells treated with 
various growth factors were analysed using a y-secretase activity kit. The role of 
VEGF on the production of PEDF and the expression of VEGFR-1, VEGFR-2 and 
PS in HRPE cells was investigated at both the transcriptional and translational levels. 
The techniques, VEGF-small interfering ribonucleic acid (VEGF-siRNA), reverse 
transcription-polymerase chain reaction (RT-PCR), Western blotting and Enzyme- 
linked immunosorbent assay (ELISA) were used for the investigation.
Results obtained from the project showed that PEDF had a regulatory role in 
the counterbalance of VEGFR-1 and VEGFR-2 expression in cultured BRMECs. 
PEDF upregulated y-secretase activity and PS-1 expression in BRMECs while 
VEGF acted as an antagonist of the effect of PEDF. In contrast, in HRPE cells, 
VEGF upregulated y-secretase activity and PEDF acted as an antagonist of the effect 
of VEGF. VEGF-siRNA induced a reduction of PEDF at both transcriptional and 
protein levels and a reduction of VEGFR-1 at the protein level. The effects of 
VEGF and PEDF on VEGFR-1 and VEGFR-2 may be cell type dependent.
This study strengthens the view that PEDF can exert different regulatory 
effects on the same molecule (s) in different cell types. PEDF acts either 
antagonistically to VEGF or synergistically dependent upon the target molecule. 
Deciphering the cellular and molecular mechanisms underlying these interactions 
will not only contribute to our understanding of PEDF’s action but also provide the 
foundation to maximise the therapeutic potential of this protein.
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1. Introduction
Neovascularisation, the formation of blood vessels, is one of the most vital 
biological processes required for the formation and physiological function of 
virtually all organs in both normal and disease conditions (Visconti, et al., 2002; 
Schmid and Varner, 2007). In a broad range of pathological conditions including 
those with an enhanced or insufficient blood supply, neovascularisation is a key 
event (Distler, et al., 2002). In some human diseases such as in cancer and ocular 
retinopathies, aberrant neovascularisation can potentially be blocked 
therapeutically to prevent disease progression (Folkman, 1995). In other diseases, 
such as in heart ischemia, brain infarction and wound healing, the process of 
neovasculatisation can be used to restore the vital function of the affected organs 
(Isner, 2002).
1.1 Neovascularisation
1.1.1 Definition
Neovascularisation is the formation of blood vessels in areas that were 
previously avascular, and it occurs by both vasculogenesis and angiogenesis 
(Chang et al., 2001; Schmid and Varner, 2007; Afzal et al., 2007).
Vasculogenesis is the coalescence of new blood vessels from individual 
endothelial cells or progenitor cells. The formation of the initial vascular tree 
during embryonic vascular development and the formation of new blood vessels 
by circulating endothelial progenitor in adult animal are examples of 
vasculogenesis (Schmid and Varner, 2007). Vasculogenesis was thought to occur 
only in early embryogenesis. However, it has been found that in adults, 
vasculogenesis occurs as endothelial precursor cells (EPC) derived from the bone 
marrow (BM) enter the circulation and to be incorporated into neovascular foci 
in injured corneas, ischemic hindlimbs and tumour vasculature (Takahashi et al., 
1999; Afzal et a/., 2007).
Angiogenesis is defined as the sprouting of new blood vessels from the pre­
existing microvasculature and the modification of the initial irregularly organized
1
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endothelial tubular network into a structured three-dimensional network of 
branching vessels, result in a functional circulatory system (Carmeliet, 2000; 
Yancopoulos, et al., 2000; Distler, et al., 2002; Coultas et a l, 2005). Angiogenic 
sprouting is responsible for vascularising certain structures during normal 
development, such as the neural tube or the retina, and for most new vessel 
formation in the adult (Moore, 2002).
Angiogenesis was considered the sole mechanism of blood vessel formation in 
postnatal life, until recently accumulating evidence suggests that endothelial stem 
cells are pres ent in adults and participate in new blood vessel formation in 
normal and pathological states, including tumours.
1.1.2 The process of neovascularisation
During embryogenesis, neovascularisation is initiated from vasculogenesis, i.e. 
formation of a functional circulation from EPC. It is initiated as the appearance 
of mesodermal cells with vascular endothelial growth factor receptor 2 (VEGFR- 
2 or Flk-1) positive in the posterior primitive streak (PPS); VEGFR-2 positive 
cells in the PPS give rise to both blood and endothelium (haemangioblasts), but 
are restricted to haematopoietic or angiogenic fate after emigrating into extra- 
embryonic sites [extra-embryonic ectoderm (EXE), yolk sac and allantois) and 
intra-embryonic sites [embryonic ectoderm (EEC)]. In the yolk sac, these 
progenitors aggregate into endothelial-lined blood islands that then fuse to 
generate a primary capillary plexus. The primary capillary plexus undergoes 
remodelling along with intra-embryonic vessels to form a mature circulation. 
Intra-embryonic angioblasts migrate along distinct pathways before aggregating 
directly into the dorsal aorta or cardinal vein, without a plexus intermediate. The 
primary vessels (capillary plexus, dorsal aorta and cardinal vein) then remodel, 
together with the extra-embryonic plexus, to form a mature vasculature, which 
along with VEGF and Notch involves the angiopoietins and Tie receptors. Mural 
cells (pericytes and smooth-muscles cells) proliferate and differentiate in 
response to TGF-p, and are recruited to vessels by PDGF secreted by endothelial
2
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cells (reviewed by Coultas et al., 2005). The formation of a functional circulation 
from endothelial progenitors is shown in Fig. 1.1.
In adulthood, the EPC mobilised from the bone marrow can enter into the blood 
circulation and may be recruited and incorporated into sites of active 
neovascularisation during tissue ischemia, vascular trauma, or tumour growth. 
Moreover, expansion and mobilisation of EPC may augment the resident 
population of endothelial cells (ECs) competent to respond to exogenous 
angiogenic cytokines (Isner and Asahara, 1999; reviewed by Ribatti, 2007) 
(Fig. 1.2).
The process of angiogenesis occurs as an orderly cascade of events (see Figl.2). 
It is initiated from the production and release of angiogenic stimulators, such as 
vascular endothelial growth factor (VEGF), from the tissues by certain 
physiological or diseased conditions. These angiogenic stimulators diffuse into 
the nearby tissues and bind to the receptors on the ECs that are located on the 
nearby pre-existing blood vessels to activate signal transduction pathways. The 
activated ECs produce new molecules including enzymes, resulting in the 
dissolving the basement membrane of the existing blood vessels; and increasing 
the vasodilatation and endothelial permeability. The activated ECs proliferate 
and migrate towards the diseased tissue, with the help of adhesion 
molecules/integrins (a vP3 , a vPs) to pull the sprouting new blood vessel forward. 
Meanwhile matrix metalloproteinases (MMPs) dissolve the tissue in front of the 
sprouting vessel tip to accommodate the sprouting process. Sprouting ECs roll up 
to form a blood vessel tube (lumen formation), and individual blood vessel tubes 
connect to form blood vessel loops that can circulate blood. Smooth muscle cells 
and pericytes join in to stabilise vessels and blood flow begins 
(http://www.angio.org/understanding/content_understanding.html>accessed on: 
3rd Feb. 2004; Distler, et al., 2002).
As a dynamic multistep process, angiogenesis can be summarised by the 
following steps: the degradation of the extracellular matrix (ECM) surrounding
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the pre-existing vessels by proteolytic enzymes, endothelial cells migration 
toward an angiogenic stimulus and their proliferation, formation of the tube-like 
structure, fusion of the formed vessel and initiation of blood flow (Cao, 2001)
1.1.3 Neovascularisation in health and disease
1.1.3.1 Neovascularisation in health
Neovascularisation is an important event in embryonic development initiated by 
vasculogenesis and completed by angiogenesis. In healthy adulthood, 
neovascularisation is in a quiescent state for most organs and tissues, and it is 
only switched on in certain physiological settings, such as the female 
reproductive system in response to ovulation or gestation, the normal hair cycle, 
chronic inflammation and wound healing (Iruela-Arispe and Dvorak, 1997). 
Within the wound, neovascularisation occurs because of local factors that 
stimulate adjacent cells (angiogenesis) and because of recruited circulating BM 
derived EPCs that contribute to existing and new vascular channels 
(vasculogenesis) (Velazquez, 2007). At the physiological level, endothelial cell 
proliferation is tightly regulated in a spatial and temporal manner (Liekens, et al., 
2001).
1.1.3.2 Neovascularisation in disease
1.1.3.2.1 Tumour neovascularisation and metastasis
Tumours are populations of host-derived cells that have lost the ability to 
regulate growth and therefore proliferate aberrantly. Tumour cells, like normal 
cells, require an adequate supply of oxygen and nutrients and an effective means 
to remove waste in order for metabolic processes to occur and survival to be 
maintained. Normal cells and tissues rely on physiological vasculogenesis and 
angiogenesis to provide them with a vasculature that fulfils their metabolic 
demands. Tumour cells, on the other hand, can induce their own blood supply 
from the pre-existing vasculature in a process that mimics normal angiogenesis 
(Papetti and Herman, 2002). Without angiogenesis, tumour cells can only 
proliferate to a certain size and remain in a dormant state (Cao, 2001). The 
‘angiogenic switch’ can be turned on by hypoxia and tumour derived growth
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factors (Folkman, 1995). Recent studies have also shown that vasculogenesis 
also occurs during tumour neovascularisation (Lyden et a l, 2001; Asahara et al., 
1997; Garmy-Susini, 2005; Schmid and Varner, 2007). EPCs may be mobilised 
from the bone marrow by tumour tissue-derived cytokines, such as VEGF 
(Asahara and Kawamoto, 2004; Dome et al., 2007). Recruitment of EPC to 
tumour neovascularisation takes place in five steps: 1) active arrest and homing 
of the circulating cells within the angiogenic micro vasculature; 2) 
transendothelial extravasation into the interstitial space; 3) extravascular 
formation of cellular clusters; creation of vascular sprouts and cellular networks 
and 5) incorporation into a functional microvasculature (Ribatti et al., 2007).
Tumours become cancerous when they metastasise, i.e. the cells migrate from a 
primary location to a distant secondary location and re-grow into a new tumour, a 
process mediated by penetration of the blood or lymphatic vessels. Neovascular 
channels allow tumour cells to metastasise hematogenously (Ribatti et al., 2007).
1.1.3.2.2 Corneal, retinal and choroidal neovascularisation
Ocular neovascularisation is the leading cause of blindness in a variety of clinical 
conditions (Das and McGuire, 2003; Afzal et al. 2007). Corneal 
neovascularisation is usually associated with inflammatory or infectious 
disorders of the ocular surface (Chang et al., 2001). Neovascularization arising 
from the retinal circulation is seen commonly in proliferative diabetic retinopathy 
(PDR), retinal vein occlusion, retinopathy of prematurity (ROP), and sickle cell 
retinopathy (Das and McGuire, 2003). All these conditions can result in 
intraocular haemorrhage and tractional retinal detachment leading to severe 
visual loss. PDR is the most common cause of early-onset vision loss in young 
people in developing countries (Aiello, 2003), and retinal neovascularization is a 
significant contributory factor to this vision loss (Das and McGuire, 2003). In 
addition, hyperglycaemia indirectly regulates the synthesis of a variety of 
angiogenic factors in retinopathy (Cai and Boulton, 2002). In elderly people, age- 
related macular degeneration (AMD) is the most common cause of severe vision 
loss in the USA, and choroidal neovascularization (CNV) is seen in the majority
7
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of AMD patients with severe vision loss (20/200 or worse) (Das and McGuire, 
2003; Afzal et al. 2007).
Although retinal neovascularisation is thought to be due to the proliferation of 
endothelial cells from the existing blood vessels by angiogenesis, recent evidence 
suggests that adult haematopoietic stem cells can enter the circulation and reach 
the areas of angiogenesis, and can clonally differentiate into endothelial cells 
(Grant et al., 2002).
1.1.4 Regulation of neovascularisation
Neovascularisation, a complex process involving extensive interplay between 
cells, soluble factors, and ECM components (Liekens, et al., 2001), is under 
stringent regulation by both endogenous activators and inhibitors (Hanahan et al., 
1996). A wide range of angiogenic inducers, including growth factors, 
chemokines, angiogenic enzymes, endothelial specific receptors, and adhesion 
molecules are involved in the neovascularisation process. When sufficient 
neovascularization has occurred, angiogenic factors are down-regulated or the 
local concentration of inhibitors increased. As a result, the endothelial cells 
become quiescent, and the vessels remain or regress if no longer needed. 
Therefore, neovascularisation is a highly ordered process under tight control and 
the normal healthy body retains a perfect balance between the release of 
angiogenic stimuli and angiogenic inhibitors (Liekens, et al., 2001). When 
angiogenic stimuli are produced in excess of the inhibitors, the balance is tipped 
in favour of blood vessel formation and vice versa (Fig 1.3).
Since each step in the angiogenic cascade involves a great variety of enzymes, 
cytokines, and receptors, neovascularisation presents a range of possible targets 
for therapeutic intervention (Liekens, et al., 2001). On the other hand, anti- 
angiogenic therapy, which targets activated endothelial cells, offers several 
advantages over therapy directed against tumour cells. First, endothelial cells 
are a genetically stable, diploid, and homogenous target, and spontaneous 
mutations rarely occur. Also, turnover of tumour endothelial cells may be 50
8
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times higher than that of endothelium in normal quiescent tissues, and activated 
blood vessels express specific markers, such as integrin a vp3 , Tie, and VEGF 
receptors. Because anti-angiogenic therapy is directed at activated endothelial 
cells, its target should be easily accessible by systemic administration. Finally, 
different tumour cells are sustained by a single capillary, and associated 
endothelial cells contribute to both endothelial and associated cell growth by 
releasing autocrine and paracrine factors. Consequently, the activated 
endothelium presents a more specific target than the associated cells, and 
inhibition of a small number of vessels may affect the growth of many associated 
cells (Kerbel, 1991; Liekens, et al., 2001).
1.1.5 Regulators of neovascularisation
1.1.5.1 Neovascularisation stimuli
A variety of neovascularisation stimuli have been described (Liekens, et al.,
2001). Tablel.l listed some of them. Among them, the VEGF/VEGF receptor 
(VEGFR) family is the most studied regulator o f vascular development, and it is 
also the central focus of this study. The angiopoietin/Tie system controls vessel 
maturation and quiescence (Eklund and Olsen, 2006) while the eph/Ephrin 
system controls positional guidance cues and arterio-venous asymmetry (Heroult 
et al., 2006).
1.1.5.2 Neovascularisation inhibitors
A number of endogenous inhibitors have been identified and Tablel.2 listed 
some of them. The most studied negative regulators include angiostatin (O’Reilly 
et al., 1994), endostatin (O’Reilly et al., 1997), and thrombospondin (Dameron et 
al., 1994). PEDF in particular will be discussed in detail later.
1.2 Ligands and receptors of VEGF family
1.2.1 Ligands of VEGF family
The ligands of VEGF family currently consist of seven secreted glycoproteins 
that designated as: VEGF-A (or VEGF), VEGF-B, VEGF-C, VEGF-D, orf virus 
VEGF (VEGF-E), placental growth factor (P1GF) (Veikkola and Alitalo, 1999;
10
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Table 1.1 Endogenous inducers of angiogenesis (Induction of EC 
proliferation, migration, and differentiation was measured in vitro).
Inducers E C
proliferation
EC
migration
EC
differentiation
References
Heparin binding peptide growth factors
VEGF Yes Yes Yes Veikkola & Alitalo, 
1999; Ferrara, 1999.
P1GF W eak Yes ? Bussolino et al. 1996.
PDGF Yes Yes Yes Heldin &
W estemmark, 1999
Non- heparin binding peptide growth factors
TGF-a Yes Yes Yes Bussolino et al. 1996; 
Jackson et al. 1997.
EGF Yes Yes Yes Bussolino et al. 1996; 
Sato et al. 1993.
IGF-I Yes Yes Yes Sato et al. 1993; Bar et 
al. 1988.
Inflammatory mediators
TNF-ct Inhibition N o Yes Jackson et al. 1997.
IL-8 Yes Yes ? Keane & Strieter, 1999
Enzymes
COX-2 No Yes Yes Daniel et al. 1999.
Angiogenin No Yes Yes Badet, 1999
Hormones
Oestrogens Yes Yes Yes Schnaper et al. 1996.
Proliferin ? Yes ? Jackson et al. 1994.
Cell adhesion molecules
VCAM-1 No Yes ? Koch et al. 1995
E-selectin No Yes Yes Koch et al. 1995 ; 
Nguyen et al. 1993
Hematopoietic factors
Erythropoietin Yes ? Yes Ribatti et al. 1999
Others
Angl No Yes Yes Hayes et al., 1999 
Eklund & Olsen, 2006
EphrinB Positioning o f  ECs; ECs interacting with 
neighboring cells
Heroult et al., 2006
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Table 1.2 Endogenous inhibitors of angiogenesis. Downwards arrow Q) 
represents inhibition or reduction; upward arrow ( |)  represents stimulation or
induction.
Inhibitor Mechanism of action References
P rotein  fragm ents
Angiostatin
(fragment o f  plasminogen)
I  EC proliferation, 
t  EC apoptosis
O ’Reilly et al. 1994; 
Cao, 1999
Endostatin
(fragment o f  collagen XVIII)
I  EC proliferation, 
T EC apoptosis
O ’Reilly et al. 1997.
aa AT
(fragment o f  antithrombin 3)
I  EC proliferation, 
T EC apoptosis
O ’Reilly et al. 1999.
Prolactin (16 kDa fragment) I  EC proliferation 
I  FGF-2-induced 
angiogenesis
Struman et al. 1999.
Soluble m ediators
TSP-1 i  EC proliferation, 
T EC apoptosis
Iruela-Arispe and 
Dvorak, 1997
Troponin I i  EC proliferation Moses et al. 1999
IFN-oc I  EC proliferation, 
T EC apoptosis 
I  FGF-2-induced 
angiogenesis
Dinney et al. 1998
IFN-y ■I EC proliferation, T IP-10 Sato et al. 1990
PEDF I  EC migration 
'i- FGF-2-induced 
angiogenesis
Dawson et al. 1999
IP -10 I  EC proliferation Moore et al. 1998
I  FGF-2 and IL-8 induced 
migration
PF-4 I  EC proliferation 
I  FGF-2 and IL-8 induced 
migration
Moore et al. 1998
IL-12 T i f n -y, T i p -10 Sgadari et al. 1996
IL-4 I  EC migration Volpert et al. 1998
VEGI i  EC proliferation Zhai et al. 1999
TIMP-1,-2 I  MM P activity Gomez et al. 1997
Retinoic acid I  EC migration, transcription 
factor
Diaz et al. 2000; 
Lingen et al. 1996
Ang-2 i  Blood vessel maturation, 
antagonist o f Ang-1
Maisonpierre et al. 
1997
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Liekens, et a l,  2001) and VEGF-F (Suto et al., 2005). Each of these proteins 
contains a signal sequence that is cleaved during biosynthesis. Alternative 
splicing of their corresponding pre-mRNAs generates multiple isoforms of 
VEGF, VEGF-B, and P1GF. The VEGF family plays an integral role in 
angiogenesis, lymphangiogenesis, and vasculogenesis (Roskoski, 2007).
VEGF-A (VEGF)
VEGF was first identified by Senger et al (1983) as a vascular permeability 
factor secreted by tumour cell, and is a 46 kDa homodimeric glycoprotein with 
both vasopermeability and angiogenic properties (Keck, et al., 1989; Senger et 
al, 1990; Ferrara et a l, 1991a & b).
VEGF is a mitogen and survival factor for vascular ECs (Ferrara and Henzel, 
1989; Alon et a l,  1995; Gerber et al. 1998), and also promoting vascular ECs 
and monocyte motility (Waltenberger et a l,  1994; Barleon et a l,  1996). 
Moreover, VEGF selectively and reversibly permeabilises the endothelium to 
plasma and plasma proteins without leading to injury (Senger et a l,  1990; 
Dvorak, 2005; Roskoski, 2007). VEGF acts not only on the resident vasculature 
but also modulates EPC function (Adamis et a l, 1994; Ferrara, 2004; Coultas et 
a l, 2005; Afzal et a l,  2007). Active VEGF signalling is required for normal 
development of progenitors o f the vascular and haematopoietic system; and plays 
an important role in shaping the vascular system, organs signal to the vessels that 
serving them, influencing the endothelial cells to adopt functional specialties, 
such as the blood-brain barrier and fenestrated endothelium in the kidney 
glomeruli (Nikolova and Lammert, 2003)
The VEGF gene is located on the short arm of chromosome 6 , and is a single 
gene composed of eight exons and is differentially spliced to yield nine mature 
isoforms: VEGF121, VEGF 165, VEGF 189, VEGF206, VEGF 145, VEGF183, - 
165b(an inhibitory isoform), -162, and -148 (Tischer et a l, 1991; Neufeld et a l, 
1999; Robinson and Stringer, 2001). The numeric designation of the isoforms 
denotes the number of amino acids in the molecule. VEGF 165 a secreted
13
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heparin-binding protein being the predominant form followed by the 189 and 121 
residue molecules as determined by cDNA analysis of a variety of cell types, 
tissues, and tumour specimens (Ferrara, et al., 2003; Roskoski, 2007).
VEGF is expressed in different tissues, including brain, kidney, liver, and spleen, 
and by many cell types including, endothelial cells, macrophages, glial cells, 
keratinocytes, tumour cells (Rousseau et al., 2000 a & b; Liekens, et al., 2001), 
and HRPE cells (Ohno-Matsui et al., 2003). Transcription of VEGF mRNA is 
induced by different growth factors and cytokines, including PDGF, EGF, TNF- 
a, TGF-p, and IL-ip (Veikkola and Alitalo, 1999; Akagi, et al., 1999; Enholm, 
et al., 1997; Liekens, et al., 2001). VEGF levels are also regulated by tissue 
oxygen tension. Exposure to hypoxia induces VEGF expression rapidly and 
reversibly, through both increased transcription and stabilization of the mRNA 
(Mukhopadhyay, et al. 1995; Ikeda, et al., 1995). In contrast, normoxia down- 
regulates VEGF production and even causes regression of some newly formed 
blood vessels.
VEGF binds to two related high affinity cell surface tyrosine kinase receptors: 
VEGFR-1 and VEGFR-2 (Yancopoulos, et al., 2000). In addition to these 
receptors, VEGF interacts with a family of co-receptors, the neuropilins (Ferrara 
et al., 2003).
1.2.2 VEGF receptor family
1.2.2.1 General properties
The VEGF receptor family consists of five members, three receptor protein- 
tyrosine kinases [VEGFR-1 (Fit-1, fms-like tyrosyl kinase-1, where fms refers to 
feline McDonough sarcoma virus), VEGFR-2 (KDR in humans, Kinase Domain- 
containing Receptor /Flk-1 in mice, Fetal liver kinase-1) and VEGFR-3 (Flt-4)] 
(Galland, et al. 1993; Mustonen and Alitalo, 1995; Shibuya, et al. 1999; Shibuya 
and Claesson-Welsh, 2006) and two non-enzymatic receptors (neuropilin-1 and - 
2) (Ferrara et a l ,  2003; Roskoski, 2007).
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VEGFR-1, VEGFR-2 and VEGFR-3 are highly homologous to each other in 
overall structure (Shibuya, et al. 1990; Alitalo and Carmeliet, 2002), and all three 
consist of an extracellular ligand-binding domain (a seven Ig-like domain), a 
transmembrane domain, an intracellular tyrosine kinase domain and downstream 
carboxyl terminal region (Shibuya, et a l 1990; Terman et al. 1992 and Millauer 
et al. 1993) (see Figl.4-Aa). The binding site for VEGF(-A) is located in the 
second Ig-like domain in VEGFR-1 and the second/third Ig-like domains in 
VEGFR-2. The downstream structure from the fourth to seventh Ig-like domains 
in these receptors plays a major role in receptor dimerization and activation 
(Keyt et al., 1996; Fuh et al., 1998). Among these receptors, VEGFR-1 has 
highest affinity to VEGF, VEGFR-2 binds with less affinity, and VEGFR-3 
shows essentially no binding to VEGF, although it binds VEGF-C and VEGF-D 
(Veikkola and Alitalo, 1999; Shibuya, 2001a).
Neuropilins are glycoproteins with a molecular weight of 120 -140 kDa (Chen et 
al. 2000). The neuropilins contain a large extracellular component, a 
transmembrane segment, and short (~ 40 amino acid residue) intracellular 
portion (Mamluk et al., 2002). Neuropilins act as co-receptors with large (~ 250 
kDa) transmembrane plexins that transduce semaphoring signalling and as co­
receptors with VEGFR-1, VEGFR-2 and VEGFR-3 that transduce VEGF family 
signalling (Roskoski, 2007).
The VEGF receptor signal transduction pathway remains unclear. Most 
approaches used for study are based on the classical tyrosine kinase receptor 
pathway, and have focused on the recognition of the element(s) that are involved 
in it. Classically, signals from a tyrosine kinase receptor are initiated by binding 
of a ligand (usually a growth factor) to the receptor, which then forms a dimer. 
This dimer adds phosphate groups to itself (autophosphorylation), resulting in the 
creation of docking sites that bind to downstream signal transduction molecules 
containing Src homology 2 (SH2) domain. Upon ligand binding, a number of 
signalling pathways can be activated, each one consisting of a chain of
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Fig 1.4 A schematic representation of the structure of VEGFRs. (A) the
full-length of VEGFR-1(a) and soluble form of VEGFR-1(b); B) shows the 
interaction between VEGF family and their receptors (Modified from 
Yancopoulos et al., 2000).
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signalling molecules that indirectly alter the expression of target genes in the 
nucleus (Heldin and Ericsson, 2001). Several adapters such as Nek, Grb2, SHP2 
and Crk have been shown to associate with VEGFR-1 (Ito et al., 1998). 
However, the tyrosine kinase activity of VEGFR-1 is usually weak, about one 
tenth that of VEGFR-2 kinase. Without starving cells of serum, VEGF-dependent 
autophosphorylation is often difficult to detect (Waltenberger, et al., 1994; 
Seetharam et al., 1995).
1.2.2.2 VEGFR-1 (Flt-1)
VEGFR-1 (Flt-1) is structurally a typical tyrosine kinase receptor (Shibuya, 
2001b). Human VEGFR-1 protein consists of 1338 amino acid residues 
including a signal peptide. Its nascent polypeptide is expected to be about 150 
kDa without modification (Shibuya, et al. 1990; De Vries, et al. 1992), but is 
rapidly glycosylated to form an intermediate form of approximately 170 kDa, 
and further glycosylated for expression on the cell surface as a mature protein of 
180-185 kDa. Only this mature form is autophosphorylated in response to VEGF 
and to other VEGFR-1 specific ligands (Davis-Smyth, et al. 1996; Davis-Smyth, 
etal. 1998).
Another important feature o f VEGFR-1 is that the gene encodes not only the 
mRNA for a full-length receptor but also a short mRNA for a soluble form of the 
VEGFR-1 protein, which consists of the l st-6 th Ig-like domain together with an 
additional 31 amino acid residue (Shibuya, et al. 1990; Kendall and Thomas, 
1993) (Figure 1.4-Ab). It remains unknown whether this soluble form of 
VEGFR1 is also produced from cleavage. The VEGFR-1 gene in mice consists 
of 30 exons spanning more than 150 kb (Kondo, et al. 1998). Each of the 1st and 
2nd Ig-like domains is split into two exons. The soluble form of VEGFR-1 is 
found to be derived from the first 13 exons and the down-stream 5 ’-region of 
intron 13 in this gene (Kondo, et al. 1998). Therefore, the VEGFR-1 gene 
appears to carry two physiologically meaningful ‘exonl3’s, one for the soluble 
form of VEGFR-1 and the other for the receptor form. The mRNA and the
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protein of VEGFR-1 gene are specifically expressed in most vascular ECs 
(Barleon, et al. 1994).
Recently, two groups (Lyden et al., 2001; Kaplan et al., 2005) identified 
VEGFR-1 positive haematopoietic progenitor cells that multiply in the bone 
marrow, mobilise to the peripheral blood along with VEGFR-2 positive EPCs, 
and incorporate into pericapillary connective tissue. More interestingly, these 
cells seem to home in before the tumour cells arrive, promoting metastatic 
growth by forming niches where cancer cells can locate and proliferate.
1.2.2.3 VEGFR-2 (Flk-1 or KDR)
VEGFR-2 protein consists o f 1338 amino acids in humans, and is expressed 
mostly on vascular endothelial cells. VEGFR-2 is a marker for the earliest 
progenitors of the vascular and haematopoietic system, the loss of both vascular 
and haematopoietic cells in Flk-1 mutants is one of many pieces of information 
linking endothelial and haematopoietic development through a possible common 
progenitor, the haemangioblast (reviewed by Ema and Rossant, 2003; Coultas et 
al., 2005). VEGFR-2 is also expressed at a significantly lower level in neuronal 
cells; osteoblasts, pancreatic duct cells, retinal progenitor cells, megakaryocytes 
(Matsumoto and Claesson-Welsh, 2001), HRPE cells and a fraction of 
haematopoietic cells which might be the progenitor for endothelial cells (Asahara 
et al., 1999; Lyden et al., 2001). The biological role of VEGFR-2 in these non- 
endothelial cells remains to be clarified. In the tumour vasculature VEGFR-2 
expression is 3-5-fold higher than in the normal vasculature (Plate et al., 1994). 
On the other hand, most tumour cells or leukaemia/lymphoma cells do not 
express VEGFR-2 except for Kaposi sarcoma cells in AIDS patients (Montaldo 
et al., 2000). Within the tumour tissue, the tumour cells themselves and activated 
stroma cells express a high level of VEGF but little VEGFR-2, whereas the 
endothelial cells in the tumour vasculature exhibit an upregulated VEGFR-2 
expression, which strongly suggest a paracrine loop of VEGF and VEGFR-2 
between tumour cells and vascular endothelial cells for the stimulation of
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pathological angiogenesis (Ferrara and Davis-Smyth 1997; Alitalo and 
Carmeliet, 2002; Shibuya and Claesson-Welsh, 2006; Shibuya, 2006a).
VEGFR-2 is the major positive signal transducer for both physiological and 
pathological angiogenesis. Upon stimulation with VEGF, VEGFR-2 is 
autophosphorylated and then PLCy is tyrosine phosphorylated, resulting in the 
activation of the downstream PKC-c-Raf-MEK-MAP-kinase pathway 
(Takahashi et al., 2001); an adaptor molecule, TSAd (T-cell specific adapter) 
also can be activated, resulting in the stimulation of a migration signal (Zeng et 
a l, 2001; Matsumoto et al., 2005). VEGFR-2 is also known to interact with VE- 
cadherin and integrins such as avp3, and regulates many steps of angiogenesis 
(Stupack and Cheresh, 2004).
So far it is known that VEGF, P1GF and VEGF-B are the ligands that bind and 
activate VEGFR-1 (Maglione, et al. 1991; Olofsson, et al. 1998). The affinity of 
VEGFR-1 is highest for VEGF (10-30 pM) and much weaker for P1GF (about 
200 pM) and VEGF-B. The positive signal o f VEGF for endothelial proliferation 
and vascular permeability from VEGFR-1 contribute about one tenth of the total 
signal, the major signal is through VEGFR-2. The soluble form of VEGFR-1 has 
potent negative activity against VEGF-dependent phenomena on ECs because of 
its strong ligand binding activity. A 10-fold or more excess of soluble VEGFR-1 
over VEGF efficiently suppresses the VEGF-induced endothelial cell growth and 
vascular permeability (Tanaka, et al. 1997; Kendall and Thomas, 1993). Thus, 
the VEGFR-1 gene exerts two opposing biological activities, one positive and the 
other negative, in angiogenesis. This dual function may be tightly regulated and 
important for the fine tuning of the formation and maintenance of the blood 
vessel structure (Shibuya, 2001b). Figure 1.4-B shows the interaction between 
VEGF family and their receptors.
1.2.2.4 Relationship of VEGFR-1 and VEGFR-2 in angiogenesis
VEGFR-1 and VEGFR-2 are both expressed on vascular endothelial cells 
(Neufeld et al. 1999; Ferrara, 2002), and closely involved in the formation of
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tube-like structures, blood vessels and lymphatic vessels. VEGFR-1 has been 
shown to heterodimerise with VEGFR-2 leading to autophosphorylation, 
activation of VEGFR-2, and angiogenesis (Autiero et al. 2003; Rahimi, 2006; 
Afzal et al. 2007). However, the relationship between VEGFR-1 and VEGFR-2 
is still unclear. Several studies have indicated that VEGFR-1 and VEGFR-2 have 
different signal transduction properties (Liekens, et al., 2001). Interaction of 
VEGF with VEGFR-2 is critical for VEGF induced biological responses. By 
using chimeric receptors containing the extracellular domain of human CSF-1R/ 
c-fms fused with the entire transmembrane and cytoplasmic domains of murine 
VEGFR-1 and VEGFR-2, Meyer and Rahimi (2003) dissected the biological 
importance of VEGFR-1 and VEGFR-2 and their signal transduction relay in 
angiogenesis. It was demonstrated that selective activation of chimeric VEGFR- 
2, but not chimeric VEGFR-1, stimulated endothelial cell growth, migration, and 
differentiation. Stimulation o f cells co-expressing chimeric VEGFR-1 and 
VEGFR-2 suppressed VEGFR-2-mediated endothelial cell growth. Their results 
also indicate that VEGFR-1, unlike VEGFR-2, is unable to undergo ligand- 
dependent tyrosine phosphorylation and kinase activation (Rahimi et al., 2000). 
Using site-directed mutagenesis they demonstrated that tyrosines 799 and 1173 
are required for VEGFR-2-mediated endothelial cell growth and activation of PI3 
kinase. Further site-directed mutagenesis demonstrated that tyrosine 1212, 
located in the carboxyl tail o f VEGFR-2, is required for the ligand-dependent 
autophosphorylation of the receptor and its ability to activate signalling proteins. 
Studies have shown that there is considerable “cross-talk” between VEGFR-1 
and VEGFR-2 and that this plays a critical role in regulating VEGFR-2-mediated 
signalling (Rahimi et al., 2000; Burkhardt and Zacharias, 2001; Zeng et al.,
2001), and dependent on conditions, VEGFR-1 can act as a pro- or anti- 
angiogenic regulator o f VEGFR-2.
1.2.2.5 VEGFR-3 (Flt-4)
VEGFR-3 has only six Ig-homology domain (Pajusola et al., 1994). It 
preferentially binds VEGF-C and VEGF-D. VEGFR-3 shows a more restricted 
expression pattern when compared with VEGFR-1 or VEGFR-2. It is expressed
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in lymphatic ECs, fenestrated capillaries and veins in endocrine organs as well as 
in monocytes/macrophages (reviewed by Saharinen et al., 2004). VEGFR-3 is 
involved in the regulation of both blood and lymphatic vessel function (Shibuya 
and Claesson-Welsh, 2006). It is believed that VEGFR-3 play various roles in 
cardiovascular development and remodelling of primary vascular networks 
during embryogenesis and enhancing lymphangiogenesis in adulthood. 
Inactivation of VEGFR-3 gene results in embryonic death at E9.5, due to 
abnormal remodelling o f the primary vascular plexus (Dumont et al, 1998).
VEGFR-3 signal transduction is still relatively unexplored. However, evidence 
suggests that heterodimerization of VEGFR-2/VEGFR-3 may direct biological 
signalling such as lymphatic vessel sprouting (reviewed by Shibuya and 
Claesson-Welsh, 2006). Certain human pathological conditions involve either 
dysfunction or increased activation of VEGFR-3. Increased expression of 
VEGF-C and VEGFR-3 plays a role in prostate cancer progression and lymph 
nodes metastasis (Jennbacken et al., 2005).
1.3 Gamma-secretase (y-secretase): a role in neovascularisation?
1.3.1 General properties of y-secretase
y-secretase is an unusual aspartyl multimeric protease complex responsible for 
the intramembranous cleavage of a variety of type I integral membrane proteins, 
including the P-amyloid precursor protein (APP), Notch, ErbB4 (Ni et al. 2001; 
Lee et al., 2002), E-cadherin (Marambaud et al. 2002), and CD44 (Lammich,
2002). This protease complex consists of four different integral membrane 
proteins: presenilin, nicastrin, Aph-1 (anterior pharynx defective-1) and Pen-2 
(presenilin enhancer -2) (LaVoie, et al. 2003) (Fig. 1.5). y-secretase is involved in 
development, signal transduction, protease biochemistry and is central to the 
pathogenesis of Alzheimer’s disease (AD) and appears to play a role in 
vasculogenesis and angiogenesis (Lukiw et al., 2001; Nakajima et al., 2003; 
Sainson et al., 2005; Semeels et al. 2005; Cai et al. 2006; Shi and Harris, 2006; 
Williams et al., 2006).
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Figurel.5 A schematic representation of the complex of y-secretase. PS is
presented using the 8 -TM structural model. (Reproduced from LaVoie et al.,
2003).
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Presenilin (PS)
Presenilin, the active site of the protease complex, was the first member of the y- 
secretase complex to be identified (De Strooper et al., 1998). PS are multipass 
proteins. Several different topography models for PS have been proposed, either 
6 - transmembrane (TM), 7-TM, 8 -TM or 9-TM domains (Dewji, 2005; Laudon 
et al., 2005; Oh and Turner, 2005). The 8 -TM structural model, where the N- 
terminal and C-terminal ends as well as the hydrophilic loop between TM6  and 
TM7 are located at the cytoplasmic face of the plasma membrane, has been the 
most widely accepted (Fig 1.5).
PS is endogenous to almost every type of mammalian cell (Thinakaran et al., 
1996; Iwatsubo, 2004) and localises predominantly in the endoplasmic reticulum 
(ER) and Golgi compartments (Annaert, et al. 1999). PS is initially expressed as 
an unstable holoprotein of about 50kDa, with a half-life of -1 h (Ratovitski, et 
a/. 1997). By endoproteolysis mediated by a presenilinase, PS holoprotein 
undergoes cleavage to yield an N-terminal fragment (NTF; -28 kDa) and a C- 
terminal fragment (CTF; -22 kDa) that remain associated (Ratovitski, et al. 1997; 
Thinakaran, et al. 1996). This PS heterodimer is significantly more stable than the 
PS holoprotein, having a half-life of -30 h, and is thought to be the biologically 
active form of the protein (Ratovitski, et al. 1997; Yu, et al. 1998 and Iwatsubo,
2004). In the mature active form of y-secretase complex PS is present as an 
NTF-CTF heterodimer (Levitan et al., 2001). The mature form of PS (the 
heterodimer) has been found at the cell surface in complex with the membrane- 
associated C-terminus of another y-secretase substrate, Notch (Ray et al., 1999), 
and with nicastrin (Kaether et al., 2002). However, PS alone is not sufficient for 
protease activity.
Nicastrin (NCT)
Nicastrin (NCT) is a type I membrane protein that possesses many potential 
glycosylation sites within its large ectodomain. Three principal forms of NCT 
exist in cells, the unglycosylated, nascent protein (-80 kDa), an “immature” N- 
linked glycosylation endoglycosidase H-sensitive (iNCT, -110 kDa), and a
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“mature” N-linked isoform, complex N-linked glycosylation endoglycosidase FI- 
resistant (mNCT -150 kDa) that is formed after entering the Golgi apparatus 
(Kaether, et al. 2002). This mNCT is associated with active y-secretase 
(Kimberly, et a l 2002), and importantly, PS is required for the full post- 
translational generation o f this mNCT species (Kaether, et al. 2002; Kimberly, et 
al. 2002). Therefore, like PS, NCT undergoes a maturation process that could 
regulate its association with the y-secretase complex.
Aph-1 and Pen-2
Accumulating evidences suggest that both Aph-1 and Pen-2 are physical 
members of the active protease and not transient interactors merely involved in 
assisting y-secretase assembly or protein folding (Takasugi, et al. 2003).
Aph-1 is conserved from nematodes to humans. It has a predicted molecular 
weight of -29 kDa and is predicted to be a 7-TM protein (Goutte et al., 2002). 
Aph-1 has been found to form a subcomplex with NCT and stabilise the presence 
of the PS holoprotein within the complex (Takasugi et al. 2003; Hu and Fortini, 
2003; LaVoie et al., 2003). Down-regulation of Aph-1 (Francis et al., 2002; Lee 
et al., 2002) by RNA interference (RNAi) is associated with reduced levels of PS 
NTF/CTF heterodimers and deficient y-secretase function.
Pen-2 is a membrane protein with two putative TM helices. It consists 101 amino 
acids with a molecular weight of -10  kDa (Francis et al., 2002). Down- 
regulation of Pen-2 (Francis et al., 2002; Steiner et al., 2002) by RNAi is 
associated with reduced levels of PS NTF/CTF heterodimers and deficient y- 
secretase function. Evidence suggests that Pen-2 is required for the 
endoproteolytic processing of PS (Luo et al., 2003; Takasugi et al., 2003); the 
stabilisation of the resulting NTF and CTF, and the subsequent activation of the 
y-secretase core complex (Takasugi et al., 2003; Kimberly, et al. 2003; Hu and 
Fortini, 2003; Luo et al., 2003; Prokop et al., 2004).
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The molecular mass o f y-secretase complex varies depending on different 
preparations (LaVoie et al. 2003). By using Blue Native Polyacrylamide Gel 
Electrophoresis, Steiner et al. (2002) reported the molecular mass of the y- 
secretase complex to be ~500 kDa, while LaVoie et al. (2003) identified it as ~ 
250-~270 kDa using BN-PAGE and Western blotting, corresponding to the 
apparent combined molecular masses of PS, NCT, Aph-1 and Pen-2 (Kimberly, 
et al. 2003). These two different molecular masses may be from dimeric or 
monomeric complexes (LaVoie, et al. 2003).
By using both biochemical co-immunoprecipitations and confocal 
immunofluorescence microscopy in Chinese hamster ovary cells, Baulac and 
colleagues (2003) identified that PS-1, nicastrin, Aph-1, and Pen-2 interact in the 
Golgi/trans-Golgi network (TGN)-enriched compartments. Using immuno­
fluorescence techniques, they provide further evidence for localisation of the y- 
secretase components in the Golgi/TGN compartment, rather than in the ER. By 
using a stepwise experiment, Takasugi et al. (2003) demonstrated that Aph-1 
stabilises the PS holoprotein in collaboration with NCT, whereas Pen-2 elicits the 
final maturation of the y-secretase complex, conferring its activity and inducing 
endoproteolysis of PS; they also concluded that PS, NCT, Aph-1 and Pen-2 
represent the set of proteins that comprise the major framework of y-secretase.
The mechanism of y-secretase action is still unclear. By using inhibitor cross­
competition kinetics and competition ligand binding, Tian et al. (2003) provide 
evidence that suggests y-secretase has physical separation of the sites for 
substrate binding and catalysis. Another unique feature of the y-secretase 
cleavage, reported by Gu et al. (2001), is the multiplicity of the cutting positions: 
one in the middle of the transmembrane domain that creates the carboxyl- 
terminus of Ap (classical y-cleavage), and the other close to the inner leaflet of 
the membrane that liberates Notch intracellular domain (NICD) (notch site-3 
cleavage), or APP ICD (AICD; y’- or s- cleavage of APP).
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1.3.2 y-secretase and RIP
An emerging model, Regulated Intramembrane Proteolysis (RIP), has been 
proposed by Kimberly and Wolfe (2003) for the normal biological function of y- 
secretase: PS-dependent RIP. In this generalised model, a cell surface receptor 
protein (such as Notch, APP or ErbB-4) binds to its ligand (hypothetical for 
APP), which permits a disintegrin metalloprotease - ADAM to cleave the 
ectodomain just outside of the membrane. The resultant CTF serves as a 
substrate for y-secretase cleavage, which cuts within the transmembrane domain. 
Release of the intracellular domain then permits translocation to the nucleus, 
interaction with appropriate cellular factors, and alteration of target gene 
transcription (see Fig. 1.6)
Ligand-
Receptor
binding
i  1* cleavage 2nd
t r by ADAM by y
2nd cleavage 
by y-secretase
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tered gene transcripti*
icd
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Fig 1.6 A schematic representation of the model of RIP
(Simplified from Kimberly and Wolfe, 2003).
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1.3.3 Common Features of RIP
RIP was defined as the process by which transmembrane proteins can be cleaved 
within the plane of the membrane to liberate cytosolic fragments that enter the 
nucleus to control gene transcription (Brown, et al. 2000). This mechanism 
influences processes as diverse as cellular differentiation, lipid metabolism, and 
the response to unfolded proteins (Brown, et al. 2000).
RIP is mediated by at least three distinct families of intramembrane proteases, 
which cleave substrates within their TM domains: 1) the presenilin-type aspartyl 
proteases, including the PS-dependent y-secretase (Wolfe et al., 1999a & b) and 
the signal peptide peptidase (SPP) which is essential for generation of signal 
peptide-derived HLA-E epitope in humans (Ponting et al., 2002; Martoglio and 
Golde, 2003; Xia and Wolfe, 2003); 2) the site-2 protease (S2P) family, zinc- 
metalloproteases that cleave and activate sterol regulatory element binding 
proteins (SREBPs) (Rawson et al., 1997); 3) the rhomboid serine proteases that 
use a catalytic triad to cleave transmembrane ligand substrates, such as the main 
EGF ligand Spitz (Urban et al., 2001; Freeman, 2004).
Two major mechanisms regulate the proteolytic cleavage mediated by 
intramembrane protease: for PS, SPP, or S2P-dependent RIP, the removal of a 
certain protein domain by prior cleavage regulates subsequent RIP cleavage 
(Brown et al., 2000; Struhl and Adachi, 2000). In contrast, rhomboids directly 
cleave target substrates without a need for a prior cleavage and rhomboid activity 
appears to be tightly controlled by protein trafficking (Urban and Freeman, 2003; 
Freeman, 2004)
Table 1.3 lists the reported y-secretase substrates to date (reviewed by Landman 
and Kim, 2004; Vetrivel et al., 2006). These substrates share several 
characteristics: a) they all span the membrane bilayer at least once, though in 
different directions, b) they can be type I membrane-spanning proteins oriented 
with their NH2 termini in the lumen and their COOH termini in the cytosol; or 
type II membrane protein with its NH2 terminus in the cytosol;
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Table 1.3 Reported y-secretase substrates
Yadan Zhang
Substrate Putative proteolysis function References
APP N uclear signaling in complex with 
Fe65/Tip60
McLoughlin & Miller et al., 1996;
APLP 1/2 Nuclear signaling Eggert et al., 2004; 
Scheinfeld et al., 2002
Notch 1-4 Nuclear signaling in complex with 
transcription factors (e.g. CSL)
Struhl and Greenwald, 1999; 
Song et al., 1999; Handler et al., 
2000; Mizutani et al., 2001; 
Kimberly et al., 2003
Jagged and 
Delta-1
Nuclear signaling (via AP-1) LaVoie and Selkoe, 2003 
Bland et al., 2003
ErbB-4 Nuclear signaling in complex with YAP; 
disassembly o f  high affinity heteromeric
N i et al., 2001; Lee et al. ,2002
DCC Nuclear signaling? Taniguchi et al., 2003
CD44 Nuclear signaling (via CBP supression) Murakami et al., 2003
LRP Nuclear signaling in complex with Tip60 May et al., 2003
N-Cadherin Nuclear signaling (via CBP supression) Marambaud et al., 2003
NRG-1 Nuclear signaling Bao et al., 2003
E-Cadherin Disassembly o f  adherence junctions; nuclear 
signaling through liberation o f  a / P catenins?
Marambaud et al., 2002
Nectin-1 Disassembly o f  adherence junctions Kim et al., 2002
p75NTR Disassembly o f  high affinity heteromeric 
neurotrophin receptor complex
Jung et al., 2003
Syndecan-3 Disassembly o f  synaptic receptor complexes 
and / or nuclear signaling via interaction with 
CASK?
Schulz et al., 2003
GluR subunit 3 Modulation o f  synaptic receptor function? Meyer et al., 2003
Na channel 
P2-subunit
Regulates N avl a-subunit levels and controls 
cel 1-surface sodium current densities
Kim et al., 2007
Tyrosinase Disrupt the melanosomal localisation and 
melanin synthesis activity
Wang et al., 2006
TNF a Trigger IL-12 production Friedmann et al., 2006
VEGFR 1 Regulates angiogenesis Cai et al., 2006
IGF-1 receptor Nuclear signaling? McElroy eta l., 2007
IL-1 receptor2 ? Kuhn et al., 2007
LRP6 Binding directly with GSK3 and attenuating 
its activity; Nuclear signaling?
Mi and Johnson, 2007
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or two membrane-spanning regions that are inserted in the bilayer in a helical 
hairpin fashion.
PS-dependent y-secretase and rhomboids cleave only type-I membrane 
substrates, while S2P and SPP cleave type-II membrane proteins (Weihofen et 
al., 2002; Lemberg and Martoglio, 2002).
1.3.4 RIP and Classic Receptor Tyrosine Kinases
Several recent reports suggest that a classic receptor tyrosine kinase, ErbB-4, 
may also signal through RIP (Ni et a l, 2001; Lee et a l, 2002). Like the other 
RIP substrates, ErbB-4 undergoes two cleavage events. The initial cleavage in 
the extracellular domain is mediated by the metalloprotease TACE (ADAMI7) 
(Rio et al, 2000). This is followed by intramembrane cleavage mediated by y- 
secretase /presenilin, which results in translocation of the C-terminal domain to 
the nucleus. However, it remains to be determined whether endogenous ErbB-4 
mediates nuclear signalling. It is still possible that y-secretase cleavage might 
facilitate ErbB-4 signalling through activation of protein kinase C, MAP kinase, 
or PI3 kinase, known targets of ErbB-4 signalling in the cytoplasm. 
Nevertheless, these findings raise the intriguing possibility that the same receptor 
may signal through both classic kinase cascades and RIP (Ebinu and Yankner,
2002). Very recently, Cai et a l (2006) showed evidence that PEDF inhibits 
VEGF-induced angiogenesis in vitro and this closely correlates to the cleavage of 
VEGFR-1 via y-secretase activity. This suggests that VEGFR-1 may be also 
involved in RIP.
1.3.5 A new non-classical signal pathway for VEGF action?
Considering the evidences reviewed above, a new non-classical signal pathway 
for VEGF action can be postulated as follows: upon the ligand binding (e.g. 
VEGF, VEGF-B or P1GF), an enzyme (possibly one of the MMPs) cleaves a 
portion of the extracellular domain of the VEGFR-1; this 1st cleavage initiates y- 
secretase to cleave the cytosolic domain of the VEGFR-1, allowing this fragment
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to translocate to the nucleus o f the endothelial cells to promote angiogenesis (see 
Fig 1.7).
VEGF
Extracellular
space
VEGFR1
Ci<Zjl)
Cell 
membrane
Cytosol
1st cleavage 
by ? enzyme
2nd cleavage by Presenilin 
mediated- y-secretase
Regulation of 
angiogenesis Nucleus
Fig 1.7 A schematic representation of the hypothesis -  the effect 
of VEGF on VEGFR-1 /VEGFR-2.
30
Qhapterl Yadan Zhang
1.4. Pigment Epithelium-Derived Factor (PEDF)
1.4.1 General features of PEDF
Pigment Epithelium-Derived Factor (PEDF), a 50 kDa of glycoprotein with 
pleiotropic functions, is naturally occurring in the eye and considered as crucial 
to prevent pathological angiogenesis. PEDF was first identified as a neurotrophic 
factor possessing neuronal differentiating activity against Y-79 retinoblastoma 
cells in conditioned medium obtained from foetal human retinal pigment 
epithelium (HRPE) cell culture (Tombran-Tink and Johnson, 1989)
PEDF is expressed during embryonic development, suggesting an involvement in 
cell patterning and possibly in early vasculogenesis. As a factor that can bind to 
the ECM, PEDF could help in the spatial definition of developing vessel 
pathways (Tombran-Tink and Barnstable, 2003a).
PEDF is expressed in the RPE cells o f the retina and in the interphotoreceptor 
matrix sequestered between the RPE layer as well as in the adjacent 
photoreceptors of the human foetal and bovine eyes (Karakousis, et al., 2001; 
Tombran-Tink and Barnstable, 2003a); in ganglion cells (Karakousis, et al., 
2001; Ogata, et al., 2002; Behling, et al., 2002) and ciliary epithelium of the 
adult human and rat eye; and in bovine retinal ECs (Tombran-Tink, et al. 2004).
PEDF transcript is expressed in most regions of the nervous system of adult 
human brain and spinal cord (Tombran-Tink, et al., 1995; Bilak, et al. 1999; 
Tombran-Tink, et al. 1996; Tombran-Tink and Barnstable, 2003a). Ependymal 
cells are likely to be a major source of PEDF in the human CSF, suggesting that, 
like the retina, much o f the brain is bathed in this neurotrophic factor (Bilak, et 
al. 1999; Tombran-Tink and Barnstable, 2003a). It is also expressed in a number 
of non-neural tissues including skeletal muscle, bone, heart, placenta and liver 
(Tombran-Tink, et al. 1996; Tombran-Tink and Barnstable, 2003a).
The PEDF gene was independently identified as one that is post-transcriptionally 
and very markedly (> 100-fold) up-regulated (Coljee, et al. 2000) during Go
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phase in young but not senescent cultured fibroblasts (Pignolo, et a l 2003; 
Tombran-Tink, et a l  1995), giving rise to an alternative name of “early 
population doubling level cDNA”, suggesting additional roles in both the cell 
cycle and senescence.
1.4.2 Biology of PEDF
1.4.2.1 Structure
The human PEDF gene contains 8  exons and a 5’ flanking region that is unusual 
because it contains a dense cluster of alu repeats (Tombran-Tink, et al 1996). 
The PEDF promoter region contains several key regulatory elements including a 
retinoic acid receptor motif, which may be important in the regulation and cell 
differentiation function of the gene. The PEDF gene was mapped to human 
chromosome 17pl3 (Tombran-Tink, et a l 1996; Tombran-Tink, et a l 1994; 
Goliath, et a l 1996), a hot spot for many retinal degenerative diseases that are 
characterized by loss of photoreceptor function and subsequent visual 
impairment, e.g. retinitis pigmentosa (RP13), leber’s congenital amaurosis and a 
type of cone-rod dystrophy (CORD5). The PEDF gene encodes a 418 amino acid 
protein (predicated molecular weight of 46.3 kDa) with a hydrophobic signal 
characteristic of secreted proteins. PEDF contains a single carbohydrate side 
chain that raises its apparent molecular weight to a 50kDa single band seen on a 
silver-stained SDS gel (Dawson, et a l 1999) or doublet bands (Tombran-Tink, et 
a l , 1991).
The crystal structure o f PEDF was determined using purified recombinant human 
PEDF expressed in hamster cells (Simonovic, et a l , 2001). PEDF has structure 
and sequence homology to members of the serpin family of proteinase inhibitors 
and contains a characteristic serpin reactive loop (RCL) (Steele, et a l, 1993). 
PEDF, however, does not exhibit inhibitory activity against any known 
proteinases, possibly due to differences in the sequence of the RCL (Simonovic, 
et a l, 2001; Steele, et a l,  1993). The RCL in PEDF is unusual because it is 
exposed in the native state so that the central region is largely uncovered, a 
feature that may allow rapid binding to regulatory proteins. PEDF has a unique
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asymmetric charge distribution, that is, the basic residues are concentrated on 
one surface, and the acidic residues are concentrated on the opposite surface 
(Simonovic, et al. 2001). The PEDF molecule contains two sites for interactions 
with ECM molecules. By utilising residue-specific chemical modification and 
site-directed mutagenesis techniques, Yasui, et al. (2003) revealed the acidic
  TOO
amino acid residues on PEDF (Asp , Asp , and Asp ) are critical for 
collagen binding whilst the three clustered basic amino acid residues (Arg145, 
Lys146, and Arg148) are necessary for heparin binding. A 44-amino PEDF peptide, 
corresponding to position 78-121, was shown to have neuroprotective activity on 
motor neurons, whereas an adjacent 34 amino acid peptide, corresponding to 
positions 44-77, did not (Bilak, et al., 2002).
1.4.2.2 Biological functions
1.4.2.2.1 A natural angiogenesis regulator
Dawson, et al. (1999) showed that PEDF inhibited angiogenesis process in vitro 
and was more effective than the well-studied angiogenesis inhibitor angiostatin. 
Biochemically purified recombinant forms of PEDF potently inhibited 
neovascularization in the rat cornea. In an in vitro assay, PEDF inhibited 
endothelial cell migration in a dose-dependent manner with a median effective 
dose (ED50) of 0.4 nM, slightly more active than pure angiostatin, 
thrombospondin-1 (ED50 o f 0.5 nM), and endostatin (ED50 of 3 nM), placing it 
among the most potent natural inhibitors of angiogenesis. At doses of 1.0 nM or 
greater, PEDF also inhibited basic fibroblast growth factor (bFGF) induced 
proliferation of capillary endothelial cells by 40% (Dawson, et al. 1999). PEDF 
inhibited endothelial cell migration toward the angiogenic inducers, such as, 
PDGF, VEGF, interleukin-8 , acidic FGF (aFGF), and lysophosphatidic acid -  
indicating that PEDF exerts its inhibitory function even in the presence of 
proangiogenic factors (Dawson, et al. 1999).
A recent study has shown that PEDF can inhibit the migration of microvascular 
cells, and it acts on endothelial cells forming new vessels to induce their 
apoptosis without harming the pre-existing vasculature (Stellmach, et al. 2001).
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To an extension, Volpert, et al. (2002) demonstrated that PEDF derives this 
specificity for activated endothelial cells from their dependence on Fas/Fas 
ligand (FasL) mediated apoptosis. Proliferating endothelial cells are the only 
targets identified so far in which PEDF promotes cell death. This might be due to 
a unique type of receptor on endothelial cells or to the regulation of different 
signal transduction pathways by PEDF (Tombran-Tink and Barnstable, 2003b).
1.4.2.2.2 Neurotrophic and Neuroprotective properties
The first function of PEDF that was identified is its differentiating effect on 
retinoblastoma cells in the conditioned-medium of foetel human RPE cells 
(Tombran-Tink and Johnson, 1989; Tombran-Tink, et a l 1991). PEDF promotes 
the transformation of dividing retinoblastoma cells into differentiated neurons. 
The expression of PEDF in the human retina is seen as early as 7.4 weeks of 
gestation, a stage when retinal neurons are differentiating (Karakousis, et al. 
2001).
PEDF is an effective neuroprotective factor in many parts of the nervous system. 
In the eye, for example, PEDF 1) reduces apoptosis induced by H2O2 or light 
damage in rat photoreceptors (Cao, et al. 2001). 2) preserves the spatial 
organisation, morphology and function of photoreceptors after RPE detachment 
in a Xenopus model o f retinal degeneration (Jablonski, et al. 2001), and protects 
retinal neurons from injuries caused by increased intra-ocular pressure from 
transient ischemic reperfusion (Ogata, et al. 2001). Increased pressure within the 
eye is a major risk factor for glaucoma and its associated ganglion cell death. 
Experimental pressure-induced ischemia and subsequent reperfusion leads to 
extensive retinal cell death in the absence of PEDF (Tombran-Tink and 
Barnstable, 2003a).
Glutamate-mediated excitotoxicity is thought to be an important factor in many 
acute neurodegenerative conditions such as stroke and epilepsy. In cultured 
neurons, apoptotic cell death can be induced by micromolar concentrations of 
glutamate (Otori, et al. 1998). PEDF at low nanomolar concentrations
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significantly prevents glutamate-induced apoptotic cell death in cultures of 
cerebella granule cells (Taniwaki, et al. 1995; Araki, et al. 1998), hippocampal 
neurons (DeCoster, et al. 1999; Houenou, et al. 1999) and spinal motor neurons 
(Bilak, et al. 1999; Houenou, et al. 1999). Whether PEDF alters the sensitivity 
of glutamate receptors, the intracellular movements of calcium or the down­
stream response of mitochondria to glutamate is still not known.
1.4.2.2.3 PEDF in non-neuronal cells
Increasing evidence shows that PEDF might also have important effects on non­
neuronal cells. PEDF prevents alterations in the morphology of Muller cell (the 
main glial cell type present in the retina) by attenuating the spatial 
disorganisation of the inner nuclear layer. PEDF might also mitigate the 
progression of photoreceptor degeneration by improving biosynthetic activity in 
Muller cells such as by restoring physiological levels of glutamine synthetase 
(Jablonski, et al. 2001). In cultures of rat brain microglia, PEDF caused changes 
in morphology and an increase in metabolic activity (Sugita, et al. 1997). PEDF 
also has strong autocrine effects in cells such as the RPE. In neonatal rat cultures, 
PEDF stimulated RPE cells increased in cytoplasmic area, pigment granule 
content, and in the development of cell-cell contacts (Malchiodi-Albedi, et al. 
1998). All of these changes are indicative of normal RPE maturation. Tombran- 
Tink and Barnstable (2003a) provided evidences suggest that PEDF might not 
only act on neighbouring cells, but might also be important for maintaining key 
functional processes in the cells that secrete it.
1.4.2.2.4 In ageing and disease
Recently it has been shown that there is a decrease in PEDF expression with 
ageing. The levels of PEDF protein decline when primary cells in culture reach 
senescence (DiPaolo, et al. 1995), mirror findings in RPE cells, where PEDF 
synthesis and secretion declined with time in culture (Tombran-Tink, et al. 1995; 
Hjelmeland, et al. 1999). This decline can be reset in cloned animals (Lanza, et 
al. 2000). The exact mechanism that regulates PEDF levels is unclear, but some
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evidence supports a post-transcriptional regulation of mRNA stability (Coljee, et 
al 2 0 0 0 ).
In some diseases, PEDF levels increase, such as in the CSF of patients with 
Amyotrophic Lateral Sclerosis and in rodent retinas after laser-induced retinal 
injuries (Ogata, et al. 2001). These increases might constitute an attempt of the 
tissue to limit neuronal damage. In contrast, in macular degeneration or diabetic 
retinopathy, PEDF expression decreased. PEDF also exerts a powerful action on 
tumours. PEDF promotes differentiation and antiproliferation activity in human 
retinoblastoma cells (Tombran-Tink and Johnson, 1989; Tombran-Tink, et a l 
1991). In addition, PEDF treated tumours had less neovascularisation, due to 
the antiangiogenic action of this factor. Ek et a l (2006) reported the 
multitargeted role of PEDF in the inhibition of growth, angiogenesis and 
metastasis of two orthotopic models of osteosarcoma (rat UMR 106-01 and 
human SaOS-2). Through stable plasmid-mediated gene transfer of full-length 
human PEDF, they show that PEDF overexpression significantly reduced tumour 
cell proliferation and Matrigel invasion and increased adhesion to collagen type- 
1 in vitro. In vivo, PEDF overexpression dramatically suppressed orthotopic 
osteosarcoma growth and the development of spontaneous pulmonary 
metastases. Furthermore, tumours overexpressing PEDF exhibited reduced 
intratumoral angiogenesis, evidenced by a significant decrease in microvessel 
density.
On the other hand, other factors such as VEGF that are secreted by the tumour 
cells promote tumour expansion. A finely tuned balance of mitogenic stimulators 
and inhibitors might therefore control the progression or regression of such 
tumours (Tombran-Tink and Barnstable, 2003a & b).
1.4.3 Therapeutic potential of PEDF
From the studies that have been reviewed above, it is clear that PEDF could be 
used as a therapy to limit ocular angiogenesis that endangers vision. Support 
comes from the observations in that: 1) PEDF is effective against multiple
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inducers of angiogenesis (Dawson, et al., 1999), including the VEGF and IL-8 
that are thought to play important roles in inducing ocular angiogenesis 
(Yoshida, et al., 1998), and it is very effective against ischemia-induced retinal 
angiogenesis (Dawson, et al., 1999). 2) Changes in ocular concentration of 
PEDF appear likely to occur and to be important in facilitating human eye 
diseases (Bouck, 2002). 3) In using PEDF, it is just simply replacing the protein 
that is naturally present in healthy tissue but has been lost because of disease 
(Bouck, 2002). A further advantage of these molecules is that they are tolerated 
in the body and are unlikely to produce the toxic side effects of synthetic 
inhibitors (Tombran-Tink and Barnstable, 2003b). 4) PEDF has strong 
neuroprotective effects on neurons from a wide range of brain areas and eye. 
The protection is effective against many insults including ischemia, 
excitotoxicity, axotomy and oxidising agents (Tombran-Tink and Barnstable, 
2003b). This becomes a desirable side-effect of PEDF.
1.4.4 Mechanism(s) of PEDF action
How does PEDF exert its action? To date, a receptor for PEDF has not yet been 
identified*, but a putative 80-85 kDa PEDF-binding protein has been identified 
by two studies using affinity chromatography (Alberdi, et al. 1999; Aymerich, et 
al. 2001). In one study, radiolabelled [125I] PEDF binds to a single class of 
binding sites on retinoblastoma and cerebellar granule cells with Kd values of 
1.7-3.6 nM and 3.2 nM, respectively, indicating that the activity of PEDF might 
be mediated by its interaction with a single receptor type (Alberdi, et al. 1999). 
In the second study, a single class of binding site was detected with a Kd of 2.5 -
6.5 nM on retinal membranes (Aymerich, et al. 2001). Whether this protein 
represents a receptor for PEDF or is a regulatory protein that is important to its 
functions, remains unknown.
Three possible signalling pathways have been related to PEDF by examination of 
the molecules that PEDF activates. First, in cerebellar granule cells, PEDF
A lipase-linked cell membrane receptor for PEDF has been identified by Notari et al. (2006).
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stimulates phosphorylation of IkB [inhibitor of nuclear factor kB (NF-kB)], 
leading to activation and translocation of NF-kB to the nucleus. This results in a 
sequential chain o f events that link the NF-kB pathway to a defined extracellular 
signal and the transcription o f anti-apoptotic and neuroprotective genes (Yabe, et 
al. 2001). Second, under certain growth conditions, PEDF activates the mitogen- 
activated protein kinase (MAPK) pathway by regulating the phosphorylation of 
extracellular-signal-regulated kinase (ERK) 1 and 2 in endothelial cells 
(Hutchings, et al. 2002). Third, in the study by Volpert, et al. (2002), PEDF 
generates antiangiogenic signals by activating the Fas-Fas ligand (FasL) death 
cascade in endothelial cells. However, in mice that are deficient in Fas or FasL, 
PEDF still inhibits ocular angiogenesis, and hence it must have additional 
inhibitory actions in endothelial cells, independent of the Fas-FasL cascade 
(Barreiro, et al. 2003). Figure 1.8 summarises the reported (Yabe et al., 2001; 
Hutchings et al., 2002; Volpert et al., 2002) signalling pathways that PEDF may 
be involved.
1.5. Retinal pigment epithelium (RPE)
The RPE cells is thought to play a central role in the development of choroidal 
neovascularisation in AMD, which is the most common cause of severe visual 
loss in patients over age 60 years in the US alone (Friedman et al., 2004; Brown 
et al., 2005).
1.5.1 General features of the RPE
The RPE is a monolayer o f pigmented cells that lies between the retinal 
photoreceptors and the choroid, and forming a part of the barrier between the 
choroidal circulation and retina (Bok, 1993; Marmorstein, 2001; Rizzolo, 1997). 
The RPE gets its name from the melanin pigment that is present within 
cytoplasmic granules called melanosomes. The RPE is derived embryologically 
from the same neural tube tissue that forms the neurosensory retina, but is 
differentiated into a secretory epithelium (Marmor, 1998).
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Fig 1.8 A schematic representation of the reported signaling 
pathways that PEDF involved.
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RPE cells are small (about 10-14 gm in diameter) in the macular region, and 
become flatter and broader with diameter up to 60 pm toward the periphery. The 
RPE has two distinct membrane regions: the apical membrane that faces the 
photoreceptor outer segments and the basolateral membrane faces Bruch’s 
membrane, which separates the RPE from fenestrated endothelium of the 
choriocapillaris (Fig 1.9). These two regions show distinct membrane 
permeability properties due to the asymmetric distribution of various channels 
and transporters. The apical side has numerous long apical microvilli which 
surround the light-sensitive outer segments establishing a complex of close 
structural interaction. The apical cytoplasm contains microfilaments and 
microtubules, and the highest concentration of melanin granules. The midportion 
contains the nucleus, golgi apparatus, endoplasmic reticulum and lysosomes, etc. 
The basal membrane has small convoluted infoldings that increase the surface 
area for absorption and secretion (Marmor, 1998).
As a layer of pigmented cells the RPE absorbs the light energy focused by the 
lens on the retina (Bok, 1993; Boulton and Dayhaw-Barker, 2001). Like other 
epithelia, RPE also transports ions, water, and metabolic end products from the 
subretinal space to the blood (Domonville de la Cour M, 1993; Hamann, 2002; 
Marmor, 1999). The RPE takes up nutrients such as glucose, retinol, and fatty 
acids from the blood and delivers these nutrients to photoreceptors. Importantly, 
the RPE plays a key role in maintaining the photoreceptor excitability: a) via the 
visual cycle of retinal, i.e. takes up retinal from the photoreceptor and transports 
to the RPE, reisomerise all-trans- retinal to 11-cA-retinal, and transport back to 
photoreceptors; b) to stabilise ion composition in the subretinal space by RPE’s 
voltage-dependent ion conductance of the apical membrane (Hamann, 2002; 
Steinberg, 1985); c) via its macrophage-like properties, i.e. it functions to 
phagocytise and digest discarded portions of photoreceptor outer segments, and 
essential substances such as retinal are recycled and returned to photoreceptors to 
rebuild light-sensitive outer segments from the base of the photoreceptors (Bok, 
1993; Finnemann, 2003). In addition, the RPE is able to secrete a variety of
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growth factors helping to maintain the structural integrity of choriocapillaris 
endothelium and photoreceptors. Furthermore, the secretory activity of the RPE 
plays an important role in establishing the immune privilege of the eye by 
secreting immunosuppressive factors (Ishida et al., 2003; Streilein et al., 2002). 
Fig 1.9 summaries the RPE function (adapted from Strauss, 2005).
1.5.2 Secretary function of the RPE
The RPE is known to produce and to secrete a variety of growth factors 
(Tanihara et al., 1997) and factors that are essential for maintenance of the 
structural integrity of retina (Cao et al., 1999) and choriocapillaris (Witmer et 
al.2003), e.g., different types of tissue inhibitor of matrix metalloprotease 
(TIMP) (Alexander et al., 1990; Qi et al., 2002). Therefore, the RPE makes 
factors that support survival o f photoreceptors and ensure a structural basis for 
optimal circulation and supply o f nutrients. Table 1.4 lists the secreted factors by 
the RPE reported to date (reviewed by Strauss, 2005). Of particular interested 
for this study is the secretion of VEGF and PEDF by RPE.
Table 1.4 Reported factors that secreted by RPE (reviewed by Strauss, 2005)
Growth factors Others
VEGF; FGF-1,-2,-5; TGF-p, IGF-I,CNTF, PDGF; LEDGF, 
Interleukin family; PEDF
MMP-2
MMP-9
TIMPs
In the healthy eye, secreted PEDF from RPE helps to maintain the retinal as well 
as the choriocapillaris structure by protecting neurons against glutamate-induced 
or hypoxia-induced apoptosis (Cao et al., 2001; Ogata et al., 2001). PEDF also 
acts as an antiangiogenic factor to inhibit EC proliferation and stabilise the 
endothelium of the choriocapillaris (Dawson et al., 1999; Ogata et al., 2002a & 
b). Interestingly, VEGF is also secreted in low concentration by the RPE in the 
healthy eye where it prevents ECs apoptosis and is essential for an intact 
endothelium of the choriocapillaris (Bums and Hartz, 1992). VEGF also acts as a 
permeability factor stabilising the fenestrations of the endothelium (Roberts and 
Palade, 1995). In a healthy eye, PEDF and VEGF are secreted at opposite sides
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of the RPE: PEDF to the apical side where it acts on neurons and photoreceptors, 
whereas the majority of VEGF is secreted to the basal side where it acts on the 
choroidal endothelium (Becerra et al., 2004; Blaaugeers et al., 1999). Growth 
factor secretion changes in response to damage or injury, which stimulates the 
RPE to also secrete neuroprotective factors including bFGF or CNTF (Blanco et 
a l, 2000). In the relation between VEGF and PEDF, Ohno-Matsui et al. (2003) 
reported that VEGF upregulates PEDF via VEGFR-1 in HRPE cells in an 
autocrine manner.
Taken together, the complex functions of the RPE indicate that the RPE is 
essential for visual function; also an interesting cell model for study the 
regulation of VEGFR-1 /VEGFR-2 by VEGF /PEDF in paracrine/autocrine 
manners.
1.6. Hypothesis
To date, it is vital to understand the biochemical pathways by which PEDF exerts 
its actions and how they interact with the pathways that are activated by other 
factors. From the evidence reviewed above, the action of PEDF may occur 
through the following steps (Fig 1.10a and Fig 1.10b): PEDF inhibits VEGF 
induced angiogenesis by inhibiting the enzyme(s) activity of the first or second 
or both cleavages of VEGFR-1 or VEGFR-2 in the RIP signalling pathway. 
Consequently, the cleavage of VEGFR-1 (or VEGFR-2) is reduced and less of 
the cytosolic domain of VEGFR-1 (or VEGFR-2) is translocated into the nuclei, 
resulting in the inhibition of angiogenesis.
1.7. Project objectives
The overall aim of the project was to define the involvement of a new signalling 
pathway-PS-dependent RIP -  in relation to VEGF/PEDF, VEGFR-1 /VEGFR-2 
in in vitro models of bovine retinal microvascular endothelial cells (BRMECs) 
and human RPE (HRPE). Specific objectives to achieve this aim include:
1) To investigate the expression profiles of the elements that possibly 
involved in the RIP pathway in cultured BRMECs and HRPE cells;
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2) To define the interactions between the above members in RIP pathway in 
BRMECs and HRPE cells;
3) To further determine the biological functions of VEGF/PEDF in 
regulation of angiogenesis through inhibition of VEGF function.
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Fig 1.10a A schematic representation of the hypothesis -  the effect of VEGF 
on VEGFR-1 / VEGFR-2. Upon the ligand binding (e.g. VEGF), an enzyme 
(possibly one of the MMPs) cleaves a portion of the extracellular domain of the 
VEGFR-1; this 1st cleavage initiates y-secretase to cleave the cytosolic domain 
of the VEGFR-1, allowing this fragment to translocate to the nucleus of the 
endothelial cells to promote angiogenesis.
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Fig 1.10b. A schematic representation of the hypothesis -  the effect of 
VEGF/PEDF on VEGFR-l/VEGFR-2. PEDF inhibits VEGF induced 
angiogenesis by inhibiting the enzyme(s) activity of the first or second or both 
cleavages of VEGFR-1 in the RIP signalling pathway.
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2.1. Introduction
The retina has frequently been used as a source of microvascular endothelial cells 
(MEC) (Meezan et al., 1974; Frank et al., 1979; Bowman et al., 1982; 
Rymaszewski et al., 1992), partly because of its extensive microvascular network 
and partly because of the well-documented involvement of the retinal 
microvasculature in diabetic retinopathy (reviewed in Afzal et al., 2007). 
Cultured bovine retinal microvascular endothelial cells (BRMECs) has been used 
as an in vitro model for study o f angiogenesis by several groups (Schor, AM and 
Schor, SL, 1986; Simorre-Pinatel et al. 1994; Cai et al. 2003; Tombrain-Tink et 
al., 2004). Due to bovine eyes are easy to obtain; eyes are one of the targeted 
organs from pathological neovascularisation; the MECs are more representative 
than human umbilical vein endothelial cells (HUVECs) in regard to the 
functional study in angiogenesis, this project made use of cultured BRMECs as 
an in vitro model. The limitation is due to the variations between the species, the 
results from BRMECs may not accurately represent human cells.
The retinal pigment epithelium (RPE) is a monolayer of highly specialized cells 
located between the neural retina and vascular choroids that influences the 
structure and function of cells in both (Marmor, 1998; Strauss, 2005). The RPE 
cells may modulate activity of the choriocapillaries through diffusible 
angiogenesis factors (Henkind and Gartner, 1983; Eichhom et al., 1996). One of 
the candidates, vascular endothelial growth factor (VEGF), is secreted by RPE 
cells in physiological and pathological conditions (Adamis et al., 1993; Kvanta et 
al., 1996). However, some studies question the importance of VEGF alone in 
promoting choroidal neovascularisation (Okamoto et al., 1997). More 
interestingly, pigment epithelial-derived factor (PEDF), a potent antiangiogenic 
factor, is also secreted by RPE cells. Recent in vitro studies have demonstrated 
that a dynamic balance exits between VEGF and PEDF in physiological 
conditions that is critical in regulating the behaviour of choroidal endothelial 
cells (ECs) (Ohno-Matsui et al., 2001). A unique relationship between VEGF 
and PEDF in HRPE cells has been reported in that VEGF upregulates PEDF via 
VEGF receptor-1
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(VEGFR-1) in an autocrine manner (Ohno-Matsui et al., 2003). Apart from 
VEGFR-1, HRPE cells also express VEGFR-2. Therefore, cultured HRPE cells 
would be an ideal in vitro model for exploring the relationship further among 
VEGF, PEDF, VEGFR-1 and VEGFR-2. HRPE can also act as a non-angiogenic 
cell type to compare with the angiogenic cell type of ECs. It hopes that the 
differences between endothelial cells and RPE in response to the exogenous 
VEGF/PEDF would provide new insight about the mechanism of VEGF and 
PEDF action.
The aim of this study was to set up in vitro models using BRMECs, as an 
angiogenic cell type, and HRPE cells, as a non-angiogenic cell type to compare 
the interplay among PEDF, VEGF, VEGFR-1, VEGFR-2 and presenilin-1.
The objectives of this study were:
• To establish in vitro cultures by isolation of BRMECs from bovine eyes, 
and isolate HRPE cells from human eyes;
• To characterise the isolated cells by monitoring the purity, cellular 
markers and cell viability;
• To determine the expression of VEGFR-1 and VEGFR-2.
2.2 Experimental design
This study was designed to be carried out by 1) Isolation of BRMECs from 
bovine eyes; and isolation o f HRPE cells from human donor eyes. 2) Culture 
both cells using the protocols available in the group. 3) Cell purity monitoring by 
characterisation of the cells (morphology and specific cellular markers). 4) Cell 
viability monitoring. 5) Confirmation of expression of the targets of interest 
(VEGFR-1 and VEGFR-2). A flow chart for the experimental design is shown in 
Fig 2.1.
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Fig 2.1 Flow chart of experimental design for the chapter 2.
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2.3 Materials and methods
2.3.1 Cell culture
All the cell culture procedures were carried out in a Class II laminar flow 
cabinet.
2.3.1.1 Isolation of bovine retinal microvascular endothelial cells (BRMECs)
BRMECs were isolated from fresh bovine eyes by homogenisation and a series 
of filtration steps, as described previously (Cai et a l, 2003). In brief, bovine eyes 
were enucleated within 1 2  hours post-mortem and transported from the local 
abattoir to the laboratory and processed for ECs within 24 hours. The 
surrounding tissue of the eyes was cleaned off and the eyeballs were immersed in 
5% beta iodine for at least 5 minutes and subsequently washed with 1 x 
phosphate-buffered saline (PBS). The eyeball was cut open 5 mm posterior to the 
limbus, the contents removed and the retina separated from the RPE layer and 
placed in Eagle’s Minimum Essential medium (MEM) supplemented with 30 
mM hepes buffer at pH 7.4 (EARLE/HEPES) (GIBCO, UK). A pool of bovine 
retinas was isolated from 10 or 20 bovine eyes for each batch. The retinas were 
washed with lxPBS (autoclaved) 3 times then transferred to fresh MEM for 
homogenisation using a rotary Teflon-glass homogeniser. The resultant 
microvessels were trapped on an 85 pm nylon mesh and digested by an enzyme 
cocktail containing 0.5 mg/ml of collagenase (Sigma, USA), 0.2 mg/ml of 
protease (Sigma, USA) and 0.2 mg/ml deoxyribonuclease (Sigma, USA) in 
MEM in a standard incubator for 20 - 30 minutes. The ECs from digested 
micro vessels were trapped on a 53 pm mesh, and washed with cold MEM. The 
ECs were pelleted by centrifugation at 250 g for 10 minutes and the pellets were 
resuspended using human Microvascular Endothelial Cell Basal Medium with 
Growth Supplement (see growth medium for BRMECs in Appendix 1) into 2 
(from 10 eyes) or 4 (from 20 eyes) T25-flasks (25 cm2) (Orange Scientific) 
precoated with the Attachment Factor (ZHS-8949, TCS CellWorks, UK). Cells 
were incubated at 37°C, with a humidified atmosphere containing 5% CO2 and 
95% air and fed every 2 to 3 days. It was observed that the cell number started 
increasing within 4 days of initial seeding and reached confluence around 10-14
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days. Subculture was carried out at a split ratio of 1:2 or 1:3 when confluence 
reached 75-80% of the flask surface. The cells were used within 3 passages.
2.3.1.2 Isolation of human retinal pigment epithelial (HRPE) cells
Human donor eyes were obtained from the Bristol Eye bank with specific 
consent for research use. HRPE cells were isolated as described previously 
(Boulton et al. 1983). In brief, eyes were used within 48 hours post-mortem and 
cut open at 4mm posterior to the limbus. The vitreous and neural-retina were 
gently removed. The posterior eyecup was placed on the inverted lid of a 
universal (sterilised), and the RPE layer was fixed on the edge of the cup if it had 
detached to reduce the contamination by fibroblast cells. Both the eyecup and the 
lid were placed into a 60ml sterile pot. 0.25% (w/v) trypsin with 0.05% (w/v) 
EDTA (see Appendix 1 for more detail) was added to just below the edge of the 
RPE layer and incubated at 37°C, 5% CO2 and 95% air for 60 minutes. The 
digestion was stopped by adding foetal calf serum (FCS). A pellet was collected 
by centrifugation at 250g for 5 min. The pellet was resuspended in Ham’s F-10 
medium containing 10% (v/v) FCS (growth medium for HRPE cells, see 
Appendix 1), and then seeded into one T25-flask per eye. The flasks were kept in 
an incubator at 37°C with a humidified atmosphere containing 5% CO2 and 95% 
air. The cells were fed with Ham’s F-10 medium containing 10% FCS every 2 
days. It was observed that the cell number started increasing around 7 days after 
initial plating and reached confluence around 18 days.
2.3.1.3 Subculture and maintenance
Subculture was carried out at a split ratio of 1:2 / or 1:3 when confluence reached 
75-80% of the flask surface. In brief, the medium was removed and the cells 
rinsed in PBS. The addition of trypsin [0.25% (w/v)] • EDTA [0.05% (w/v)] 
solution was applied to completely cover the monolayer of cells. The flasks were 
placed in a 37°C incubator for approximately 2 minutes to allow the cells to 
detach. Proteolysis was stopped by adding the same volume of the medium that 
designated for the growth of BRMECs or HRPE cells as soon as the cells 
detached. The detach progress was checked by examination with an inverted
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microscope. The cells were pelleted at 250g for 5 minutes and resuspended in the 
growth medium that specific for BRMECs or HRPE cells, before seeding into 
new T25-flask for HRPE cells, or the T25-flask that precoated with Attachment 
Factor for BRMECs at a ratio of 1:2 /or 1:3. Cells were incubated at 37°C, with 
a humidified atmosphere containing 5% CO2 and 95% air and fed every 2 to 3 
days.
2.3.1.4 Preparation of cell stocks
In order to keep a continuous supply of HRPE cells, some of the HRPE cells 
were prepared as stocks and stored in liquid nitrogen. HRPE cells were 
trypsinised from culture vessels at 75 - 85% confluence as described in section 
2.3.1.3 and resuspended in FCS containing 10% (v/v) dimethylsulphoxide 
(DMSO) at a density o f l xlO6 - 1 x 107 cells/ml. Cells were transferred to a 
cryopreservation vial, frozen at -20°C in a container immersed in isopropanol for 
24 hours then transferred to -80°C for another 24 hours. The vials were then 
transferred to a designated liquid nitrogen tank for long term storage.
2.3.1.5 Recovery of cells from cell stocks
Stock of HRPE cells were recovered from liquid nitrogen storage by rapidly thaw 
the cryopreservation vial(s) at 37°C in a water bath then seeded into Ham’s F-10 
medium containing 10% FCS. Incubating at 37°C, with a humidified atmosphere 
containing 5% CO2 and 95% air for overnight. On the next day, the medium was 
removed and replaced with fresh Ham’s F-10 containing 10% FCS. Then cells 
were fed every 2-3 days.
2.3.2 Cell viability and purity
Cultures were examined daily using an inverted light microscope to monitor the 
morphological changes. Photomicrographs were taken at primary and subculture 
passages using the SPOT Advanced software (Version 3.2.4 for Windows) 
attached to an OLYMPUS, 1X70 inverted light microscope.
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In order to obtain BRMECs of good quality and purity, the morphology and 
Factor VIII expression of the cultured BRMECs were monitored throughout the 
whole process o f culture. Cytokeratin peptide 18 was monitored as cellular 
marker for cultured HRPE cells.
Trypan Blue staining was used to monitor cell viability during the subculture.
This method is based on the principle that a live (viable) cells do not take up 
certain dyes, whereas the dead (non-viable) cells do. Cells were trypsinised as 
described above and resuspended in lxPBS (0.5 ml). Trypan Blue solution [0.4%
(v/v), (0.5 ml)] was added to the cell suspension and mixed thoroughly. With the 
cover-slip in place, a small amount of Trypan Blue-cell suspension mixture was 
transferred to both chambers o f a haemocytometer. Cells were counted in the 
1mm centre square and four 1 mm comer squares. Cell viability was calculated 
using the equation:
, . total number o f  non -  stained cells
cell viability = --------------------------------------   x 1 0 0 %
total number o f  non -  stained cells + total number o f  stained cells
2.3.3 Immunofluorescence staining
2.3.3.1 Procedures for use with polyclonal antibodies
Subconfluent BRMECs/HRPE cells were subcultured on cover slips at a density 
of 5 x 104 cells/well overnight in a 24-well plate. The cells were fixed at room 
temperature using 4% (w/v) formaldehyde for 10 minutes, and then washed with 
lxPBS for 2 0  minutes with 3 changes. Cells were permeabilised using 0 .1 %
(v/v) Triton X-100 for 5 to 10 minutes at room temperature and washed with 
lxPBS three times. To suppress non-specific binding of immunoglobulin G 
(IgG), cells were incubated with 5% blocking serum (derived from the same 
species in which the secondary antibody is raised, in this case donkey serum was 
used) for 30 minutes. The blocking buffer was removed and cells were incubated 
with primary antibody (1:100 dilution, i.e. 0.5-5.0 pg/ml in lxPBS with 1.5% 
blocking serum) for 2 hours. Substitution of the primary antibodies with same 
species semm at the same concentration acted as a negative control. Cells were 
washed three times with 1 xPBS for 5 minutes each, and specific binding was
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detected with donkey antibody to rabbit IgG conjugated with Alex Fluor 488 for 
60 minutes (1:600 dilution in lxPBS). For nuclei staining, 3pl/ml of 1% (w/v) 
Hoechst (No.33342, Sigma-ALDRICH) was added and mixed with the buffer 
containing the secondary antibody. Cells were washed with three changes of PBS 
before mounting in Hydromount™ (National diagnostics). Slides were stored in 
a dark location at 4° C until examination using a fluorescence microscopy (Leica 
4000) with FITC/DAPI filters under UV light. Results were recorded using 
Leica Qfluoro software. Table 2.1 listed the primary antibodies used for the 
characterisation o f BRECs and HRPE cells.
Table 2.1 T he list o f  th e  p r im a ry  an tibod ies used in the im m unofluorescence sta in ing
Nam e S ource A gainst a pep tide a t D ilution used
VEGFR-1 
(F it-1) 
(C-17)
Rabbit polyclonal 
(sc-316)
Carboxy term inus o f human 
origin
1:100
VEGFR-1 
(Fit-1) 
(H-225)
Rabbit polyclonal 
(sc-9029)
Amino acids 23-247 within 
the extracellular domain o f 
human origin
1:100
VEGFR-2
(Flk-1)
(C-1158)
Rabbit polyclonal 
(sc-504)
Amino acids 1158-1345 at 
the carboxy term inus o f  
mouse
1:100
VWF
(H-300)
Rabbit polyclonal 
(sc -14014)
Amino acids 23-247 at the 
carboxy terminus o f 
human origin
1:100
2.3.3.2 Procedures for use with monoclonal antibody
FITC Monoclonal Anti-Cytokeratin peptide 18 is a purified mouse monoclonal 
antibody conjugated with fluorescein isothiocyanate (FITC) isomer 1 (Sigma, 
USA).
Cells were fixed and permeabilised as described in 2.3.3.1. Then cells were 
incubated with FITC Monoclonal anti-cytokeratin peptide 18 in 1:100 dilution in 
1 x PBS for two hours at room temperature (in dark). Substitution of the primary 
antibody with the serum of same species at the same concentration acted as a 
negative control. For nuclei staining, 3pl/ml of 1% (w/v) Hoechst was added 
with the buffer containing the antibody. Cells were washed with 1 x PBS for 15
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minutes with three changes, and then mounted with Hydromount™ (National 
diagnostics). Slides were stored in a dark location at 4° C and examined using a 
fluorescence microscope with FITC/DAPI filters under UV light. Results were 
recorded using Leica Qfluoro software.
2.4 Results
2.4.1 Characterisation of cultured BRMECs
The purity of cultured BRMECs was determined by morphology and expression 
of Von Willebrand Factor (VWF), one of the endothelial phenotype markers. It 
was observed that cell clusters started appearing approximately 2 to 4 days after 
the isolation; by day 5-6 an increased cell number and enlarged clusters were 
observed; by day 8-10 the cells had formed a confluent monolayer (Fig. 2.2 A- 
C). A typical cobblestone shape o f BRMEC morphology was constantly 
observed in this study [Fig. 2.2(A-C)] which is consistent with the description by 
Bachetti and Morbidelli (2000). Positive VWF staining (green, Fig 2.3 A) 
confirming endothelial phenotype and demonstrating that cultures consist of 
100% endothelial phenotype by co-immunostaining of the nuclei (blue, Fig 2.3 
B); Negative controls confirmed that there was no non-specific staining (Fig.2.3 
C&D). Only cells that met the criteria of ECs in morphology and cellular marker 
were used for this study.
2.4.2 Characterisation of cultured HRPE cells
The character and purity o f the cultured HRPE cells were assessed by 
morphology and immunolocalisation of one of the epithelial markers. A typical 
epithelioid morphology which is representative of cultured HRPE cells (Fig.2.4) 
was observed. Cells were observed to progressively depigment and change 
morphology during the primary culture (Fig.2.4 A-D). The morphology had little 
change in the subcultures from passage 1 to passage 6  (Figs 2.4 E&F). Fig.2.5 
shows phenotype immunostaining of the epithelial marker, cytokeratin peptide 
18, in the cultured HRPE cells. Co-immunostaining of the nuclei (Fig 2.5 B) 
demonstrated that cultures consist of 100% epithelial phenotype. Only cells that 
met the criteria of epithelial morphology and characters were used for the study.
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Fig 2.2 Characterisation of the morphology of cultured BRMECs. (A)
Approximately 2-4 days after the isolation, cell clusters were observed by 
Olympus 1x70 inverted microscope. (B) By day 5-6 an increased cell number 
and enlarged clusters were observed. (C) By day 8-10, the cells had formed a 
confluent monolayer.
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EaSI
Fig 2.3. Immunolocalisation of VWF in cultured BRMECs.
(A) VWF staining in BRMECs (green) (B) Merge of VWF 
staining with Hoechst nuclei staining (blue). (C) Negative control 
for VWF. (D) Negative control for VWF combined with Hoechst 
nuclei staining (blue).
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Fig.2.4. C haracterization of the morphology of cultured HRPE cells. (A-D) 
Primary cultures of HRPE cells with a progressive depigmentation and changes 
in morphology. (E-F) The representatives of passage 2-4 cultures demonstrating 
little change in the morphology.
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Fig 2.5 Im m unolocalisation of Cytokeretin 18 in cultured HRPE cells.
(A) Cytokeretin 18 staining in HRPE cells. (B) Merge of Cytokeratin 18 
(green) with Hoechst nuclei staining (blue). (C) Negative control. (D) 
Merge of negative control with Hoechst nuclei staining (blue).
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2.4.3 Expression of VEGFR-1 in BRMECs and HRPE cells
Immunostaining for the cytosolic domain and extracellular domain of VEGFR-1 
confirmed that VEGFR-1 was expressed in cultured BRMECs (Fig. 2.6). The 
cytosolic domain o f VEGFR-1 localised in both the nuclei and cytoplasm of the 
BRMECs (Fig 2.6A) while the extracellular domain localised on the membrane 
(Fig.2.6B). In HRPE cells the immunostaining shows VEGFR-1 cytosolic 
domain predominantly localised to the perinuclear area (Fig.2.7 A-B).
2.4.4 Expression of VEGFR-2 in BRMECs and HRPE cell
Immunolocalisation showed that VEGFR-2 was expressed in cultured BRMECs 
(Fig 2.8) and HRPE cells (Fig 2.9). In BRMECs, VEGFR-2 expression was 
predominantly localised to the perinuclear area (green) (Fig 2.8 A and B). In 
HRPE cells, VEGFR-2 predominantly localised to the cell membrane and the 
perinuclear area (Fig 2.9 A and B).
2.5 Discussion
It is essential to obtain highly purified primary cells from animal or human tissue 
in order to carry out the down-stream functional study using in vitro models. The 
present study confirmed that highly purified BRMECs can be obtained using the 
combination o f homogenisation, digestion by cocktail enzymes and series 
filtration as previously described (Cai et al. 2003). By enzyme digestion, highly 
purified HRPE also can be obtained as previously reported (Boulton et al. 1983).
It has been well documented that VEGFR-1 and VEGFR-2 are co-expressed in a 
wide range o f cells, particularly vascular ECs (Yang et al., 2004). Recently, 
Ohno-Matsui et al. (2003) reported that VEGFR-1 and VEGFR-2 are co­
expressed in HRPE cells. However, it was unclear how the VEGFR-1 or 
VEGFR-2 was distributed in HRPE cells. The result from this study showed that 
VEGFR-1 is expressed throughout the cell of the cultured BRMECs, which is in 
agreement with the report by Cai et al. (2006); and for the first time this study 
provides evidence that VEGFR-1 only expressed in the cytoplasm and membrane 
of cultured HRPE cells in the untreated condition. This study has also confirmed
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Fig 2.6 Immunolocalisation of VEGFR-1 in cultured BRMECs. (A)
The cytosolic domain of VEGFR1 was localised predominantly in the 
nuclei of BRECs with reduced intensity in cytoplasm, whereas very faint 
extracellular domain staining was observed in BRMECs by a 
fluorescence microscopy (B); C) and D) Negative control for the 
cytosolic domain and extracellular domain of VEGFR-1, respectively.
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Fig 2.7 Immunolocalisation of the cytosolic domain of 
VEGFR-1 in cultured HRPE cells. (A) The cytosolic domain of 
VEGFR-1 was localised mainly to the cytoplasm and membrane 
of HRPE cells (green). (B) Merge of the cytosolic domain of 
VEGFR-1 with Hoechst nuclei staining (blue, B). (C) Negative 
control for the cytosolic domain of VEGFR-1. (D) Merge of the 
negative staining with Hoechst nuclei staining (blue).
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Fig 2.8 Immunolocalisation of VEGFR-2 in cultured 
BRMECs. (A) VEGFR-2 was predominantly localised to the 
nuclei and perinuclei area (green). (B) Merge of VEGFR-2 
staining with Hoechst nuclei staining. (C) Negative control show 
no positive staining. (D) Merge of negative control with Hoechst 
nuclei staining.
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Fig 2.9 Imm unolocalisation of VEGFR-2 in cultured HRPE cells. (A)
VEGFR-2 expression was predominantly in the prinuclear area and 
membrane (green). (B) Merge of VEGFR-2 with Hoechst nuclei staining. 
(C) Negative control shows no positive staining, and combined with 
Hoechst nuclei staining (D).
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the expression of VEGFR-2 in BRMECs and HRPE cells. In BRMECs, VEGFR- 
2 predominantly localised in the perinuclei, while in HRPE cells VEGFR-2 
predominantly expressed on the membrane and perinuclei of the cells. The 
importance of these differential distributions is yet to be determined.
The confirmation o f co-expression of VEGFR-1 and VEGFR-2 in both BRMECs 
and HRPE cells under normal culture conditions suggests that they may play a 
role in the orchestration of retinal homeostasis.
2.6 Conclusions
• Highly purified BRMECs and HRPE cells have been isolated. Cultured 
BRMECs and HRPE cells have been well characterised.
• The interested target molecules, VEGFR-1 and VEGFR-2 are all 
expressed in the BRMECs and HRPE cells.
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The effects of VEGF and PEDF 
the expression of VEGFR-1 and VEGFR-2 
in BRMECs and HRPE cells
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3.1 Introduction
Terminal differentiation occurs through mechanisms that promote growth arrest 
and specialisation in cells (Tombran-Tink et al. 2004). These two processes are 
tightly and co-ordinately linked to the control of cell proliferation. Their 
disruption results in a variety o f pathological conditions including cancer and 
neovascular diseases, which are both characterised by increased cell 
proliferation. A number o f factors regulate these proliferative processes 
independently or through interdependent regulation of each other.
PEDF was first described as an ocular neurotrophic protein that induced 
differentiation in human Y79 retinoblastoma cells (Tombran-Tink and Johnson, 
1989; Tombran-Tink et al., 1991). It functions as a potent neurotrophic factor 
that protects neurons in many regions of the central nervous system (CNS) 
against a wide range o f neurodegenerative insults. PEDF is also a natural 
inhibitor of angiogenesis, targeting the growth of only new vessels (Dawson et 
al., 1999). Inhibition o f endothelial cell growth, blockade of endothelial cell 
migration, and prevention of new blood vessel are well documented biological 
features of PEDF in numerous models of retinal neovascular diseases (Mori et 
al., 2001, 2002; Raisler et al., 2002; Duh et al., 2002). The properties of PEDF 
make it a strong candidate as a pharmacological tool for slowing the progression 
of a range of neurodegenerative diseases and those pathologies associated with 
abnormal vessel growth in the eye and metastatic cancers of various tissues.
Understanding the mechanism of PEDF action is crucial for its clinical 
applications. There is increasing evidence showing that, at least in the eye, the 
balance between the pro-angiogenic factor, VEGF, and the anti-angiogenic 
factor, PEDF, appears to determine the formation of new vessels (Ohno-Matsui 
et al. 2001). An inverse relationship is noted between these two factors in the 
vitreous of patients with PDR and AMD, suggesting an underlying cooperative 
relationship between these proteins in maintaining vascular quiescence. The 
counterbalance o f VEGF and PEDF is supported by the previous demonstrations 
that either inhibition of the VEGF system or over expression of PEDF inhibits 
choroidal neovascularisation (Krzystolik et al., 2002; Mori et al., 2002).
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To further understand the direct and unique relationship between PEDF and 
VEGF may provide new insight in understanding the mechanism(s) of PEDF 
action.
To date, three signalling pathways for PEDF action have been proposed and 
studied intensively: the NF-kB pathway by Yabe et al. (2001); the MAPK 
pathway in ECs by Hutching et al. (2002) and the Fas-FasL death cascade in ECs 
by Volpert et al. (2002).
More recently, Cai et al. (2006) reported that PEDF inhibits VEGF induced 
angiogenesis in vitro, and this closely correlates to the cleavage of VEGFR-1 via 
y-secretase, suggesting a possible involvement of the regulated intramembrane 
proteolysis (RIP) pathway. It is hypothesised that VEGF, y-secretase and 
VEGFR-1 may be the key elements that are involved in this pathway in which 
PEDF acts as a regulator (see Fig 1.10a and Fig 1.10b for the illustrated 
hypothesis). Interestingly, three o f the above four elements, VEGF, VEGFR-1 
and PEDF have been linked together by Ohno-Matsui et al. (2003) in HRPE 
cells, with evidence that VEGF upregulats PEDF in HRPE cells via VEGFR-1 in 
an autocrine manner.
Based on the studies by Ohno-Matsui et al. (2003), Cai et al. (2006) and Ni et al. 
(2 0 0 1 ), the aim o f the project was to investigate the mechanism(s) in which 
PEDF regulates angiogenesis. This was approached by exploring the 
involvement o f the RIP signalling pathway in relation to VEGF/PEDF and 
VEGFR-1 /VEGFR-2 in in vitro models. As the first step, the goal of the current 
study was to determine whether PEDF functions as an antagonist of VEGF in 
regulating the expression of VEGFR-1 or VEGFR-2 in BRMECs and HRPE 
cells.
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3.2 Experimental design
To meet the goal of this study, the experiments were carried out from the 
following aspects: 1) Western blotting for the effect of VEGF/PEDF on the 
expression o f VEGFR-1 and VEGFR-2 in BRMECs and HRPE; 2) Evaluation of 
the specificity o f the antibodies used; 3) Verification of the linearity of the ECL 
Western blotting; and 4) Immunofluorescence staining for the effect of 
VEGF/PEDF on the distribution of VEGFR-1 and VEGFR-2 in BRMECs and 
HRPE. A flow chart for the experimental design is shown in the Fig.3.1.
3.3 Materials and methods
3.3.1 Cell culture
BRMECs and HRPE cells were cultured as described in section 2.3.1. Cells were 
used within passage 3.
3.3.2 Preparation of whole cell lysates
Cell lysates were obtained essentially as described previously (Cai et al., 2003) 
with some modifications. Briefly, the culture medium was removed and the cells 
were washed with ice cold 1 x PBS containing lx  protease inhibitor and 
phosphatase inhibitor cocktails (Santa Cruz, UK). Ice cold 
Radioimmunoprecipitation (RIPA) buffer (500 pi) containing lx  protease 
inhibitor and phosphatase inhibitor cocktails was added to the cell monolayer in a 
T25 flask and gently rocked for 15 minutes at 4°C. The lysed cells were scraped 
and transferred into a microcentrifuge tube. Further cell disruption was achieved 
by passing the lysate through a 21-gauge needle to shear the DNA and incubating 
the lysate on ice for 30 min. The supernatants were obtained by centrifugation at 
10,000 x g for 10 min at 4°C. The supernatant representing the total cell lysate 
was transferred to a new microcentrifuge tube. The protein concentration was 
estimated using BCA assay (see section 3.3.3) before being subjected to Western 
blotting.
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Fig 3.1 Flow chart of experimental design for chapter 3.
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3.3.3 Estimation of protein concentration -  BCA Protein Assay 
The BCA Protein Assay is a detergent-compatible formulation based on 
bicinchoninic acid (BCA) for the colorimetric detection and quantification of 
total protein. This method combines the well-known reduction of Cu+2 to Cu+1 
by protein in an alkaline medium (the biuret reaction) with the highly sensitive 
and selective colorimetric detection of the cuprous cation (Cu+1) using a unique 
reagent containing bicinchoninic acid (Smith et al., 1985).
A titration series o f protein standard was prepared alongside each set of test 
samples. Bovine serum albumin (BSA) at 2.0 mg /ml (provided in the kit) was 
used as the stock standard. The dilution series was prepared as shown in the 
Table 3.1.
Table 3.1. The dilution series o f the BSA standard for BCA Protein Assay
Volume o f  Diluents 
(PBS, nl)
Volume and Source o f  
BSA (nl)
Final BSA
Concentration (ng/ml)
A 0 20 |il o f  stock 2,000
B 20 20 nl o f stock 1,000
C 20 20 nl o f  vial B dilution 500
D 20 20 (il o f  vial C dilution 250
E 20 20 (il o f vial D dilution 125
F 20 20 |il o f  vial E dilution 62.5
G 20 20 nl o f  vial F dilution 31.25
H 20 0 0
The volume o f BCA Working Reagent (WR) was calculated using the following 
formula: number of duplicates of the standards plus number of triplicates of the 
test sample plus three (pipetting error) times the volume of WR for each sample.
Total volume o f WR = [(# standards) *2+ (# samples) *3 + 3] x volume of WR/sample
The WR was prepared by mixing 50 volumes of BCA Reagent A with 1 volume 
of BCA Reagent B (50:1, Reagent A: B). 10 pi of each standard in duplicate or
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test samples in triplicate were added into the wells of a 96-well microplate 
(Orange Scientific). 200 ^1 of the WR (sample: WR =1:20) was added to each 
well and incubated at 37°C for 30 minutes. The plate was cooled to room 
temperature before measuring the absorbance at 550nm and 570nm on a 
microplate reader (Multiskan Ascent ®, Labsystems, Finland).
The standard curve was prepared by plotting the average measurement of each 
dilution of BSA standard into a regression of linear fit (Microsoft Excel). 
Concentration of the total protein in each sample was determined by reference to 
the standard curve (Microsoft Excel).
3.3.4 Sodium Dodecyl Sulphate -  Polyacrylamide Gel Electrophoresis 
(SDS-PAGE)
3.3.4.1 Preparation o f SDS-PAGE
SDS-PAGE is a dissociating system that is designed to denature proteins into 
their constituent polypeptides and hence examines the polypeptide composition 
of samples (Shi and Jackowski, 1998). The anionic detergent SDS denatures the 
proteins and covers them with an overall negative charge. The sample is then 
fractionated by electrophoresis through a polyacrylamide gel. The proteins are 
separated on the basis o f their mass, since all of them have an identical charge to 
mass ratio. The smallest proteins move farthest. SDS-PAGE can be used to 
estimate the molecular mass o f a protein and the number of polypeptide subunits 
in a protein as well as the degree o f sample purity (Hames and Hooper, 2000).
A 10% (w/v) resolving gel with a 5% (w/v) stack gel (Table 3.2) was used to 
separate the peptides in the samples prepared for the target(s) of interested. 
Samples were mixed with an equal volume of 2xelectrophoresis sample buffer 
(sc-24945, Bio Rad Laboratories Ltd., Herts, UK) and incubated at 95° C for 5 
minutes. Equal amount of protein at a volume of 15-20 jal /well was loaded and 
the gel was run at 30 mA in lx  laemmli buffer (Bio-Rad Laboratories Ltd., 
Herts, UK) until the dye approached the bottom of the gel. The gel was analysed 
by Coomassie staining or silver staining for the protein profile depending on the
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protein concentration loaded; or further for western blotting. To ascertain the 
molecular weights o f protein species detected with Coomassie blue staining or 
silver staining, 5 |al o f a prestained molecular weight standard (Precision Plus 
Protein Standards, range 7.2-250 kDa; BioRad Laboratories, Herts, UK) was 
applied to the gel.
Table 3.2. Solutions for casting a 10% resolving and 5% stack gel for SDS-PAGE
(Cai et al., 2006).
Resolving Gel (10%) 
(10ml)
Stacking Gel(5% ) 
(3 ml)
Distilled H20 4.0 ml 2 . 1  ml
30%  acrylam ide mix 3.3 ml 500 [l\
1.5 M Tris/HCl pH 8.8 2.5 ml -
1.0 M Tris/H Cl pH 6.8 - 380 nl
10% SDS 1 0 0  nl 30 Hi
10% APS 1 0 0  nl 30 h1
TEM ED 4.0 yi\ 3.0 hI
3.3.4.2 Visualisation o f protein profile by Coomassie brilliant blue staining 
Coomassie brilliant blue staining is the most commonly used protein stain to 
visualise proteins following electrophoresis. After electrophoresis, the gels were 
immersed in an acidic alcoholic solution of the dye - Coomassie Staining buffer 
(methanol and acetic acid at a ration of 4.5:1, and Coomassie brilliant Blue R250
2.5 mg/ml). This denatures the proteins, fixes them in the gel and allows the dye 
to bind to them. Subsequently the gel was distained in 2:1 methanol and acetic 
acid solution for visualisation of the bands.
3.3.5 Western blotting
Western blotting can be used for detection of one or more antigens in a mixture 
(Hames and Hooper, 2000). ECL (Enhanced Chemiluminescence) Western 
blotting from Amersham Biosciences is a light emitting non-radioactive method 
for detection of immobilised specific antigens, directly or indirectly with 
Horseradish Peroxidase (HRP) labelled antibodies (Instructions of ECL Western
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blotting detection reagents and analysis system, Amersham Biosciences). A 
schematic representation of the principle of ECL Western Blotting is shown in 
Fig 3.2.
The procedures o f Western blotting can be divided into four major steps: 1) The 
separation o f proteins by SDS-PAGE; 2) the transfer of separated proteins onto a 
transfer membrane. 3) Immunological probing to detect specific protein antigens 
of interest. 4) Visualisation of the detection of the specific protein antigen(s) 
using ECL™.
3.3.5.1 Separation o f proteins by SDS-PAGE
Samples were loaded with equal amount of protein and run on a 10% (w/v) SDS- 
PAGE (5% stacking gel) at 30 mA in duplicate until the samples approached the 
bottom of the gel, as described in section 3.3.4.1.
3.3.5.2 Transfer o f separated proteins onto a transfer membrane
Proteins were transferred from the gel to a nitrocellulose membrane in 1 xtransfer 
buffer (Bio-Rad, see Appendix 2) at 005 V for 30 minutes on a semi-dry transfer 
apparatus (Biometra, Germany). The order of gel and membrane sandwich in the 
blotting apparatus was as follows: cathode (the top lid) —> one layer of saturated 
filter paper —► gel —» nitrocellulose membrane •—> two layers of saturated filter 
paper —► anode (bottom of the apparatus). To check the efficiency of the transfer, 
membranes were stained with Ponceau S staining buffer (see Appendix 2). 
Destaining was achieved using dELO.
3.3.5.3 Blocking non-specific binding
To minimise non-specific binding, blocking buffer (see the Appendix 2) was 
applied for 30 minutes at room temperature before incubation with the primary 
antibody. Alternatively, the membrane may be blocked at 4° C overnight in a 
container, using the above buffer without Tween-20.
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Oxidized
product
Peracid
Oxidized
fo rm
of enzyme
Hyperfilm 
ECL
+  Luminol +  enhancer
Secondary Ab-HRP
Primary Ab
Protein
Fig 3.2 Principles of ECL Western blotting. Ab: antibody. HRP: 
Horseradish Peroxidase. (Reproduced from Instructions of ECL Western 
blotting detection reagents and analysis system, Amersham Biosciences).
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3.3.5.4 Immunological probing to detect specific protein antigens of interest
The blocked membrane was incubated with primary antibody in blocking buffer 
for 2 hours on a roller at room temperature (an optimised dilution 1:125 was 
used). Corresponding negative controls were exposed to just blocking buffer for 
the same period o f time with agitation. On removal of the primary antibody, all 
the membranes were washed in the blocking buffer for 30 minutes with 3 
changes. Subsequently, all the membranes were exposed to a secondary 
antibody conjugated with horseradish peroxidase (HRP) (Santa Cruz 
Biotechnology, Inc.) for 60 minutes at room temperature. This secondary 
antibody was diluted in the blocking buffer at an optimised dilution. Membranes 
were washed with the washing buffer (see the Appendix 2) for 30 minutes with 3 
changes.
3.3.5.5 Visualisation o f the specific protein antigen(s) using ECL™
Before applying ECL™ reagent (Amersham, Amersham, UK) to the membranes, 
the entire washing buffer was removed. An equal volume of both ECL™ 
reagents A and B were mixed and added to the membranes. After incubation for 
1 minute, excess reagent was removed membranes sealed in individual bags and 
placed in an X ray film cassette. 2 sheets of Hyperfilm™ ECL™ (Kodak, UK) 
were placed on top o f the sealed membranes and exposed for an optimised time 
before being manually developed in the standard solutions (Sigma, USA).
In order to normalise the band detected, the same membrane was stripped and re­
probed with an antibody specific to one of the house-keeping proteins, p-actin 
(1:200 dilution) (Autogen o f Santa Cruze, UK) or GAPDH (lug/ml) (Ambion, 
UK). Bands of VEGFR-1 and VEGFR-2 were semi-quantified by densitometry 
using the Scanimage software and normalised with a-actin or GAPDH level.
3.3.6 Evaluation of linearity of ECL Western blotting detection
It has been demonstrated (Johnstone and Thorpe, 1982) that Hyperfilm ECL 
exhibits a linear response to the light produced from enhanced 
chemiluminescence. This relationship can be used for the accurate quantification
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of proteins of ECL Western blots, using densitometry (manual book, Amersham 
Biosciences). The sample containing the protein to be quantified plus a set of 
standards (known amounts o f the same antigen) should be used to prepare a 
Western blot. However, a standard for the targets of interest, VEGFR-1, 
VEGFR-2 and Presenilin-1, was not available. This study used semi­
quantification instead, i.e. percentage of the protein expression after treatment in 
comparison with control (set as 1 0 0 %) and normalised with a house keeping 
protein, such as a-actin or GAPDH. It is still important that the concentration of 
the protein to be semi-quantified lies within the linear range, therefore, a dilution 
series of a sample with highest concentration of protein were prepared for 
Western blotting.
3.3.7 Evaluation of antibody specificity
To determine the specificity o f antibody binding to antigen, VEGFR-1 or 
VEGFR-2 antibody was blocked by preincubation overnight at 4°C with 5-fold 
(by weight) excess (recommended by the manufacturer) of VEGFR-1 (Flt-1) or 
VEGFR-2 (Flk-1) peptide (Santa Cruz) in a small volume (500 pi) of PBS. 
Following blocking, the antibody/peptide mixture was diluted into appropriate 
blocking buffer. The immunoreactivity from the pre-incubated antibodies was 
compared with the immunoreactivity from antibodies incubated overnight in 
BSA at the same concentration and with membranes or cover-slips incubated 
with freshly diluted antibodies.
3.3.8 VEGF/PEDF treatment for Western blotting
As described by Cai et al. (2006), at passage 2 or 3, 80-90% confluent 
monolayers (7.5 xlO 6 cells/flask) in T25-culture flasks were washed with lxPBS. 
Then the cells were rendered quiescent in serum free medium for 45 min at 37°C, 
5% CO2 . The addition of 100 ng/ml of VEGF, or PEDF in 1% FCS medium 
respectively in duplicates was followed; flasks without growth factor treatment 
but 1% FCS medium was included as control. After one hour, lOOng/ml of PEDF 
was added to one VEGF flask, and 100 ng/ml of VEGF added to one PEDF 
flask, and further incubated for 24 hours at 37°C, 5% CO2 . The medium was
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collected and stored at -20°C. The cells were subjected to the protein extractions 
(section 3.3.2) and Western blotting (section 3.3.5).
3.3.9 VEGF/PEDF treatment for immunostaining
BRMECs/HRPE cells at 80-90% subconfluence on the cover slip were treated 
with serum-free medium for 45 minutes. Subsequently lOOng/ml of VEGF or 
PEDF was added to the wells o f 24-well plate containing medium with 1 % (v/v) 
serum respectively. Cells were incubated at 37°C, 5% C 0 2 and 95% humidity for 
1 hour before addition o f 1 OOng/ml of PEDF (to one of the wells treated with 
VEGF) or VEGF (to one o f the wells treated with PEDF) and further incubated 
for 24 hours prior to immunostaining. A control without any growth factor 
treatment was included.
3.3.10 Immunofluorescence staining
Immunofluorescence staining was carried out as previously described in section 
2.2.1. Controls, included omission of primary antibodies, substitution of the 
primary antibodies with the serum from same species and non-treatment wells. 
Controls for the specificity o f the antibodies were also prepared as described in 
section 3.3.7.
3.3.11 Statistical analysis
The results were given as the mean ± standard error (SEM) from 3 separate 
experiments. An unpaired Student’s t-test was performed to analyse the data with 
SPSS. A P value less than 0.05 (P<0.05) considered statistically significant.
3.4 Results
3.4.1 Differential protein profile of whole cell lysates of BRMECs and 
HRPE cells
Equivalent amounts of protein from samples were separated on 10% SDS-PAGE 
and stained with Coomassie blue. The pattern of the protein profile in BRMECs 
was different from the pattern in HRPE cells (Fig 3.3). In BRMECs, several
76
Chapter .3................................................................................................... Yadan .Zhang
bands were observed above 250 kDa while only two bands were seen in HRPE 
cells; a band at 250 kDa was seen in both BRMECs and HRPE cells; two bands 
between 250 kDa and 150 kDa were observed in BRMECs while no obvious 
band was observed in the same region in HRPE cells. At 75 kDa and under, the 
pattern of the bands were very similar in BRMECs and HRPE cells though the 
intensity of the band varies.
1 2 3 4 5
IWV BRMECsl BRMECs2 HRPE1 HRPE2
250 kDa 
150 kDa 
100 kDa 
75 kDa
50 kDa
37 kDa
25 kDa 
15 kDa
Fig 3.3 Protein profile in whole cell lysates from BRMECs and HRPE cells 
by Coomassie staining of 10% SDS-PAGE. Whole cell lysates were obtained 
using RIP A buffer. Lane 1: MW-the molecular weight marker; Lane 2 and 3: 
whole cell lysates from BRMECs; Lane 3 and 4: whole cell lysates from HRPE 
cells.
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3.4.2 The linearity of ECL western blotting detection
By plotting the peak area [(Optical Density - OD) unit] against quantity of the 
protein, it was observed that ECL exhibits a linear response (Fig 3.4). Calculated 
linear regression equation y = 0.0928X - 0.2418 where the correlation coefficient 
R2 = 0.9585.
3.4.3 The effects of VEGF and PEDF on VEGFR-1 expression in BRMECs
Western blotting showed that three bands of VEGFR-1, at approx. 250 kDa, 180 
kDa and 100 kDa were detected in the untreated BRMECs (Fig. 3.5 A). In 
comparison with the untreated control, the 250 kDa fragment increased when 
exposed to VEGF (p<0.05), PEDF (p<0.05), VEGF followed by PEDF (V+P) 
(p<0.0001), P+V (p<0.05) (Fig 3.5 B); the 180 kDa (full-length) increased when 
treated with V+P (p<0.05) or P+V (p<0.05) (Fig. 3.5 C); the combination of V+P 
significantly increased the 180 kDa full-length (p<0.05) compared with VEGF 
only (Fig. 3.5 C); the 100 kDa fragment was increased significantly when treated 
with PEDF (p<0.05) (Fig. 3.5 D).
3.4.4 The effects of VEGF and PEDF on VEGFR-1 expression in HRPE 
cells
In HRPE cells, four bands (at approximately 250 kDa, 180 kDa, 85 kDa and 75 
kDa) were detected in the untreated HRPE cell lysates by Western blotting (Fig
3.6 A). The 75 kDa and 85 kDa fragments of VEGFR1 decreased significantly 
when treated with VEGF (p<0.05), V+P (p<0.05) or P+V (p<0.05) for 24 hours 
(Fig 3.6 B and C); PEDF alone had no effect on the bands of 85 kDa or 75 kDa, 
but both fragments significantly decreased when pre-exposed or post-exposed to 
VEGF (p<0.05); VEGF decreased the 75 kDa VEGFR-1 fragment and this effect 
was enhanced by pre-treatment with PEDF (p<0.01).
These bands (either in BRMECs or HRPE cells) were not detected when the 
primary antibody was omitted or replaced by the IgG from same species. The 
specificity of the VEGFR-1 antibody was further confirmed by the blockade of 
the antibody binding with a peptide specific to VEGFR-1 (see the appendix 3).
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Loaded Protein 
(M9)
Peak area 
(Optical density unit)
2.8 0.03669
5.6 0.10767
11.2 1.0206
22.4 1.766
y = 0.0928X - 0 .2418  
R2 = 0 .9585
20
Protein loaded (ug)
Fig 3.4 The linearity of peak area (OD units) against amount of protein 
loaded on ECL Western blotting. A: Western blotting of VEGFR-1. B: 
densitometrical analysis o f peak area detected by ECL. C: A linear relation 
between peak area and amount o f protein loaded. Calculated linear regression 
equation y =0.0928x-0.2418 where the correlation coefficient R2 = 0.9585. The 
protein loaded ranged from 5-22.4 pg and produced a linear relationship between 
load (pg) and peak area (OD unit).
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Fig 3.5 The effects of VEGF/PEDF on VEGFR-1 expression in BRMECs by 
western blotting. (A) Western Blotting of VEGFR-1 in BRMECs; (B-D) 
Densitometric analysis o f immunoblots in (A). Data are normalised to a-actin 
from 4 separated experiments and presented as the relative ratio of VEGFR-1 to 
the control. (B) high molecular weight band of 250 kDa, (C) full-length (180 
kDa), (D) fragment o f 100 kDa. Data are presented as mean ± SEM. *p <0.05; 
*** pO.001.
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Fig 3.6 The effects of VEGF/PEDF on VEGFR-1 expression in HRPE cells 
by western blotting. (A) Western blotting of VEGFR-1 in HRPE cells. (B-C) 
Densitometric analysis o f the 85 and 75 kDa bands on immunoblot in (A). Data 
are normalised to a-actin and presented as the relative ratio of VEGFR-1 to the 
control from 4 separate experiments. Data are presented as mean ± SEM. *p 
<0.05; ** p<0.01.
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3.4.5 The effects of VEGF and PEDF on VEGFR-1 localisation in 
BRMECs
By confocal microscopy, it was observed that both the extracellular and cytosolic 
domains of VEGFR-1 were localised to the plasma membrane and the nuclei of 
BRMECs (Fig 3.7. Column 1 and 2). The fluorescence signal from the cytosolic 
domain of VEGFR-1 staining was reduced when cells were exposed to VEGF; 
the signal was increased, or at least no change when cells exposed to PEDF (Fig
3.7 Panel C); VEGF was not able to reverse this effect by either pre-treatment or 
post -treatment (Fig 3.7 Panel D and E).
3.4.6 The effects of VEGF and PEDF on VEGFR-1 localisation in HRPE 
cells
By fluorescence microscopy, it was observed that the cytosolic domain of 
VEGFR-1 was predominantly expressed in the membrane and perinuclear area in 
HRPE cells (Fig 3.8 Panel A). The fluorescence signal was increased in the 
perinuclear area when HRPE cells were exposed to VEGF for 24 hours (Fig 3.8 
Panel B). PEDF did not significantly change the localisation of VEGFR-1 when 
compared to the control (Fig 3.8 Panel C). PEDF did not reverse the effect of 
VEGF on VEGFR-1 by pre-treatment (Fig 3.8 Panel E) or post-treatment (Fig
3.8 Panel D).
3.4.7 The effects of VEGF and PEDF on VEGFR-2 expression in BRMECs
Western blotting showed that two bands (at approx. 180 and 170 kDa) were 
detected for VEGFR-2 in the untreated BRMECs (Fig.3.9A). Addition of VEGF 
alone reduced the expression o f VEGFR-2 (p < 0.05); addition of PEDF also 
reduced the expression o f VEGFR-2 (p < 0.05) (Fig 3.9 B). The combination of 
VEGF and PEDF (either VEGF followed by PEDF or vice versa) had similar 
effect as VEGF or PEDF alone.
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Fig 3.7 The effects of VEGF/PEDF on VEGFR-1 localisation in 
BRMECs by confocal microscopy. Column 1: VEGFR-1 (extracellular 
domain) staining (green) in BRMECs. A. control (without treatment); B. 
VEGF treatment; C. PEDF treatment; D. VEGF followed by PEDF; E. 
PEDF followed by VEGF. Column 2: VEGFR-1 (cytosolic domain) 
staining (red). Column 3: Merge of VEGFR-1 cytosolic domain and 
extracellular domain with nuclei staining.
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Fig 3.8 The effects of VEGF/PEDF on VEGFR-1 localisation in 
HRPE cells by fluorescence microscopy. Column 1: VEGFR1 
(cytosolic domain) staining (green) in HRPE: A. control (without 
treatment); B.VEGF treatment; C:PEDF treatment; D: VEGF followed by 
PEDF; E: PEDF followed by VEGF. Column 2: Merge of VEGFR1 
staining with nuclei staining. Scale bar = 50 pm.
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Fig 3.9 The effects of VEGF/PEDF on VEGFR-2 expression in BRMECs by 
western blotting. (A) Western blotting of VEGFR-2 in BRMECs. (B) 
Densitometric analysis of immunoblot in (A). Data are normalised to a-actin 
from 4 separated experiments and presented as the relative ratio of VEGFR-2 to 
the control. Data are presented as mean ± SEM. *p <0.05, **p <0.01.
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3.4.8 The effects of VEGF and PEDF on VEGFR-2 expression in HRPE 
cells
In HRPE cells, both full length and a fragment of VEGFR-2 were observed in 
untreated HRPE cells (Fig. 3.10 A). The combination of VEGF and PEDF (either 
VEGF followed by PEDF or vice versa) reduced the expression of VEGFR-2 
(Fig 3.10 B) (/>< 0.01).
The specificity o f the VEGFR-2 bands (in either BRMECs or HRPE cells) was 
monitored by enclosed negative controls, such as without primary antibody, or 
with the IgG of same species. The specificity of the bands was further confirmed 
by the blockade of the antibody binding with a peptide specific to VEGFR-2 (see 
the Appendix 3).
The results obtained from this study are summarised in Table 3.3.
Table 3.3 Summary of the results produced in this study
Treatment R l in BRMECs R2 in 
BRMECs
R l in HRPE R2 in 
HRPE
VEGF Overall
expression
increased
Overall
expression
decreased
Overall
expression
decreased
Overall
expression
decreased
Reduction in 
immunostaining of 
cytosolic domain
Reduction in 
immunostaining 
of cytosolic 
domain
PEDF Overall
expression
increased
Overall
expression
decreased
Overall
expression
sustained
Overall
expression
reduced
No change or 
increased
immunostaining
No change or 
increased
immunostaining
3.5 Discussion
Defining the cellular mechanisms responsible for the homeostasis of the retinal 
vasculature is a prerequisite to achieving a complete understanding of the process 
of angiogenesis. Despite various attempts aimed at defining the factors that 
regulate retina microvascular endothelial cells (MECs), the mechanisms involved
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Fig 3.10 The effect of V EGF/PEDF on VEGFR-2 expression in HRPE cells 
by western blotting. (A) Western blotting of VEGFR-2 in HRPE cells. (B) 
Densitometric analysis o f immunoblots in (A). Data are normalised to a-actin 
and presented as the relative ratio o f VEGFR-2 to the control from 4 separated 
experiments. Data are presented as mean ± SEM. ** p<0.01.
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in the determination o f MECs state during retinal vasculature homeostasis remain 
ambiguous.
Two counter-balancing systems: angiogenic stimulators and angiogenic 
inhibitors are believed to play an important role in regulating the homeostasis of 
angiogenesis (Miller et al., 1997; Bussolino et al., 1997). VEGF, a pro- 
angiogenic factor and PEDF, a potent anti-angiogenic factor have been reported 
as the representatives o f these two systems (Gao et a l, 2001; Eichler et al., 
2006).
It is now believed that a switch of angiogenic phenotype in a tissue is dependent 
upon the local balance between angiogenic factors and inhibitors. Although 
upregulation of angiogenic factors is necessary to stimulate angiogenesis, 
simultaneous downregulation o f angiogenic inhibitors is also required to 
sufficiently turn on angiogenesis. Therefore in theory, VEGF and PEDF should 
have opposite effects on angiogenesis; in practice, results from numerous 
investigations have supported this theory in the animal studies or in in vitro 
studies. In those studies, PEDF alone prevented EC migration or in the presence 
of the potent proangiogenic factors, such as VEGF, FGF1, FGF2 or interleukin-8 
(Dawson et al. 1999); using gene therapeutic strategy, PEDF inhibits the 
formation of both retinal and choroidal neovascularisation in mouse models of 
ocular angiogenesis. Even more importantly, PEDF causes regression of 
neovascularisation already underway (Mori et al. 2001; 2002); recently it also 
has been shown that PEDF cancels VEGF-induced increases in vascular 
permeability (Liu et al., 2004). However, some studies observed a dual role of 
PEDF, in that PEDF can exert opposite effects on EC proliferation dependent 
upon the maintenance o f their phenotype (Hutching et al. 2002); Apte et al. 
(2004) observed that low dose (90 pg/ml) of PEDF had significantly inhibitory 
effect on CNV in mice while a high dose (360 pg/ml) of PEDF can augment the 
development of the neovascularisation.
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Two receptor-tyrosine-kinases, VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1 or KDR) 
that specifically bind to VEGF, have also been studied intensively (Waltenberger 
et al., 1994). It has been well documented that VEGF provokes
neovascularisation by engaging multiple EC surface receptors, including 
VEGFR-1, VEGFR-2, neuropilin-1, and neuropilin-2, by generating potentially 
homologous and heterologous signalling networks. The activation of VEGFR-1 
and VEGFR-2 plays a critical role in neovascularisation. By using a chimeric 
system, Meyer and Rahini (2003) demonstrated that selective activation of 
chimeric VEGFR-2, but not chimeric VEGFR-1, stimulated ECs growth, 
migration, and differentiation. Stimulation of cells, co-expressing chimeric 
VEGFR-1 and VEGFR-2, suppressed VEGFR-2-mediated endothelial cell 
growth. Their results also indicate that VEGFR-1, unlike VEGFR-2, is unable to 
undergo ligand-dependent tyrosine phosphorylation and kinase activation. In 
HRPE cells (a non-angiognenic cell type), VEGF upregulates PEDF expression 
via VEGFR-1 (Ohno-Matsui et al. 2003). Very recently, Cai et a l (2006) 
reported that PEDF inhibits angiogenesis via RIP of VEGFR-1 in cultured 
BRMECs.
Based on the above arguments, the role of VEGF and PEDF in regulating the 
expression and distribution o f VEGFR-1 and VEGFR-2 was examined in 
BRMECs and HRPE cells, where BRMECs acted as an angiogenic cell type and 
HRPE cells as a regulatory cell type.
Upon the establishment o f the specificity of the antibody of VEGFR-1 and 
VEGFR-2 and the confirmation o f the linearity of ECL Western blotting, this 
study observed that in BRMECs, VEGF and PEDF (at 100 ng/ml) exert similar 
positive effects on VEGFR-1 and similar negative effects on VEGFR-2 
expression; while in HRPE cells, VEGFR-1 can be downregulated by VEGF but 
sustained by PEDF while VEGFR-2 can be downregulated by either VEGF or 
PEDF. As supportive evidence for the involvement of RIP, fragment(s) of the C- 
terminal of VEGFR-1 were detected in BRMECs (100 kDa) and in HRPE cells 
(75 kDa and 85 kDa). These fragments responded to the exogenous application
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of VEGF or PEDF. In addition, VEGFR-1 was localised to the nuclei of 
BRMECs and HRPE in the unstimulated states.
MECs have been well documented as a key type of cells in the initiation of 
angiogenesis (Hudlicka et al., 1992). In adulthood, MECs are quiescence in most 
organs and only proliferative in certain organs or under pathological conditions; 
and VEGF is a key growth factor in the induction o f ECs proliferation and 
migration (Hutchings et al., 2002). The upregulation of VEGFR-1 and 
downregulation o f VEGFR-2 expression by VEGF or PEDF in this study 
suggests that VEGF/PEDF is regulating VEGFR-1 in a paracrine manner (ECs- 
independent), and VEGFR-2 in an autocrine manner (ECs-dependent). Further 
more, since VEGF and PEDF can both be produced from BRMECs (Tombran- 
Tink, et al. 2004), and VEGFR-1 and VEGFR-2 are also expressed in BRMECs, 
the result from the present study suggest that there is an autocrine loop between 
VEGF, PEDF and VEGFR-2 in BRMECs. The stimulation of VEGFR-1 and 
inhibition of VEGFR-2 by exogenous VEGF/PEDF suggests that under 
physiological conditions, VEGFR-1 expression may be in a basal level while 
VEGFR-2 is in a higher level. If this is the case, it would be interesting in 
comparison with the autocrine loop among VEGF, PEDF and VEGFR-1 in 
HRPE cells. Further study by monitoring the production of VEGF/PEDF in 
BRMECs before the addition o f VEGF/PEDF would help to understand better 
the inter-relationship o f VEGF/PEDF and VEGFR-1 and VEGFR-2.
An antagonising relationship between VEGF and PEDF was not observed at the 
level of VEGFR-1 and VEGFR-2 in the present study. This is in agreement, at 
least in part, with the reports by Hutching et al. (2002) and Apte et al. (2004). On 
the other hand, it is possible that the antagonising relationship of VEGF and 
PEDF observed by other studies may come from the concert effect of multiple 
regulators on multiple receptors in vivo or in vitro. Further studies, such as knock 
down of VEGFR-1 /VEGFR-2 in BRMECs and observation of the effects of 
VEGF/PEDF on ECs proliferation/migration would help to clarify the role of 
VEGF and PEDF.
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HRPE cells have been well documented as a main source of VEGF and PEDF 
(Ohno-Matsui et al., 2001). In addition, it has been shown that VEGF 
upregulates PEDF via VEGFR-1 in an autocrine manner (Ohno-Matsui et al., 
2003). In the current study, the down regulation of VEGFR-1 fragments in HRPE 
by exogenous VEGF suggests that VEGFR-1 was in a predominantly active state 
under physiological conditions. The reduction of the expression of VEGFR-1 
fragments by the VEGF is a reflection of the autocrine mechanism in that VEGF 
production in HRPE is regulated by VEGFR-1; and consequently this regulation 
leads to the restoration o f a normal balance between angiogenic stimulators and 
inhibitors. This balance might have a key role in maintaining the homeostasis of 
the retinal vasculature.
To date, there are no reports regarding the state of VEGFR-1 /VEGFR-2 in 
BRMECs/HRPE cells under physiological conditions; and there is no standard 
marker for indicating if  VEGFR-1 or VEGFR-2 is active or inactive. Based on 
the classical pathway for a tyrosine kinase receptor, ligand-dependent 
autophosphorylation is considered to be an essential step in receptor activation 
and recruitment o f signalling molecules to the receptor (Heldin and Ericsson, 
2001; Meyer and Rahimi, 2003).
However, based on the report by Cai et al. (2006), VEGFR-1 may be involved in 
the RIP pathway, the pathway that has been well documented in ErbB4, Notch 
signalling pathway and the production of amyloid precursor protein (APP) as 
reviewed in Chapter 1. As hypothesised in Chapter 1.6, VEGFR-1 can be 
activated by the sequential cleavage of its ectodomain and cytosolic domain upon 
ligand binding, and the cleaved cytosolic domain is translocated to the nuclei to 
regulate genes related to angiogenesis. According to this hypothesis, full-length 
VEGFR-1 would be an inactive form which should exist only or predominantly 
in untreated BRMECs or HRPE cells; and the fragment of VEGFR-1 would be 
the active form and should be present or increased in VEGF-treated BRMECs or 
HRPE cells. As an antagonist o f VEGF in regulation of angiogenesis, PEDF
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should exert opposite effects on VEGFR-1 by keeping VEGFR-1 similar to the 
untreated state, i.e. PEDF has no effect on VEGFR-1 expression when compared 
with the control. In contrast to the hypothesis, this study demonstrated that PEDF 
alone significantly upregulated the expression of VEGFR-1 fragment.
The increased full-length and fragment of VEGFR-1 upon the exposure to the 
exogenous VEGF observed in this study seem not to fit the typical model for 
RIP, in that the full-length o f the receptor should be reduced while the fragment 
should be increased. However, since other signalling pathways that involved 
VEGFR-1 have not been eliminated in this study, it is possible that the current 
observation is the integrated result between the RIP and other signalling 
pathways, such as autophosphorylation and the activation of the downstream 
pathways; such a situation has been discussed by Heldin and Ericsson (2001), 
and a model which reflects the close relation between RIP and classical pathway 
in tyrosine kinase receptors had been proposed thereafter.
There are more debatable points in regarding the disagreement with the report by 
Cai et al. (2006). In this report an 80 kDa fragment of the C-terminal domain of 
VEGFR-1 was observed when cells were exposed to VEGF followed by PEDF. 
This has two implications that 1) instead of VEGF, PEDF may play a role as a 
ligand of VEGFR-1 and 2) PEDF’s ligand role only appears when the phenotype 
of BRMECs is under VEGF’s control and this may be transient when compared 
with other signalling pathways. However, it is plausible that the homeostasis of 
angiogenesis is strictly regulated by the dynamic balance between pro- 
angiogenic factors and anti-angiogenic factors. In the current study, the detection 
of the 100 kDa fragment in the control and the treatments may reflect the notion 
of basal expression o f VEGFR and VEGF activity. Exogenous PEDF alone 
seems also play a ‘ligand’ role based on its effect on the 100 kDa fragment of 
VEGFR-1. Therefore despite the variations between the experiments, it is 
possible that these two results may reflect the complex role of PEDF.
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By using immunofluorescence staining and confocal microscopy, this study 
observed that the cytosolic and extracellular domains of VEGFR-1 were 
localised in the nuclear o f untreated BRMECs; though a significant translocation 
of VEGFR-1 to the nuclei was not seen, the overall distribution of the cytosolic 
domain of VEGFR-1 was reduced by the addition of VEGF. PEDF alone or in 
combination with VEGF had no significant effect. The nuclei staining of 
VEGFR-1 in untreated cells suggests that VEGFR-1 is in a basal activation state. 
The absence of translocation may be due to the fact that a basal level of VEGFR- 
1, in untreated conditions, prevents a significant change from being detected by 
confocal microscopy. Quantitative analysis by live FRET may be a better means 
to observe the changes caused by the various treatments.
It is worth to noting the observed differences between BRMECs and HRPE cells 
in their response to exogenous VEGF/PEDF: 1) in response to exogenous VEGF, 
VEGFR-1 is upregulated in BRMECs while downregulated in HRPE cells; 2) in 
response to exogenous PEDF, VEGFR-1 is upregulated in BRMECs while 
sustained or decreased in HRPE; 3) in response to exogenous VEGF or PEDF, 
VEGFR-2 was downregulated in both BRMECs and HRPE cells. These results 
thus provide evidence, for the first time, that suggests that VEGF can exert 
opposite effect on VEGFR-1 depending on cell type; and similarly with PEDF. 
This may reflect the regulatory role of VEGF/PEDF via VEGFR-1 in angiogenic 
or no-angiogenic cell types. One limitation of the current study is the use of 
BRMECs and HRPE cells from different species. Therefore this study only 
compared the general trend in the hope of providing some new insight for further 
study. With the availability of human retinal MECs, further study would provide 
decisive evidence to understand the mechanism of angiogenesis regulation.
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4.1 Introduction
The y-secretase complex is an unusual, multimeric, aspartyl protease responsible 
for the intramembrane cleavage of a variety of type-I transmembrane proteins, 
including the amyloid-p (AP) precursor protein, Notch, ErbB4, CD44, p75NTR 
and N-cadherin (Lavoie et al., 2003; Ni et al., 2003). Very recently, VEGFR-1 
has been added to this list (Cai et al. 2006).
The intramembrane cleavage process and its implication in normal cell signalling 
have been termed Regulated Intramembrane Proteolysis (RIP) (Brown et al. 
2000). As one o f the three protease families (reviewed in more detail in chapter 
1), the main function o f Presenilin (PS)-dependent RIP seems to be the 
regulation of surface to nucleus signalling and gene expression by controlling 
production of peptides that act either as transcriptional stimulators or repressors 
(Landman and Kim, 2004). Recent findings for E-cadherin, syndecan-3 and the 
p75NTR suggest that PS-dependent RIP may also function in non-nuclear 
signalling pathways. An example of this is its involvement in regulating the 
formation/disassembly o f high-affinity heteromeric receptor complexes and/or 
adherens junctions, providing additional diversity to PS-dependent RIP-mediated 
signalling (Landman and Kim, 2004).
y-Secretase catalyses proteolysis within the transmembrane (TM) domains and 
has two unique characteristics: 1) There is a lack of requirement for specific 
amino acid target sequences immediately adjacent to the cleavage site within the 
TM domains due to a limited homology among the putative cleavage sites of the 
known y-secretase substrates; 2) There is a requirement for ectodomain shedding 
to produce membrane-tethered C-terminal substrate fragments (Struhl and 
Adachi, 2000; Sisodia et al., 2001; Li, 2001; Kimberly and Wolfe, 2003).
PS and three other multipass membrane proteins, nicastrin, Aph-1 and Pen-2, 
have been genetically linked to y-secretase activity (Yu et al. 2000a; Goutte et al. 
2002; Francis et al. 2002), and biochemical isolation has provided evidence that 
these proteins are indeed necessary members of the protease complex (Esler et
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al. 2002; Steiner et a l  2002; Gu et al. 2003). Co-expression of these four 
transmembrane proteins is sufficient to reconstitute y-secretase activity in yeast, 
which lacks these mammalian orthologs (Edbauer et al. 2003). It has also been 
observed that the biogenesis, maturation, stability, and the steady state levels of 
y-secretase components are co-dependent. Down regulation or targeted gene 
disruption of any one o f these components affects maturation and stability of 
other subunits, indicating that their assembly into a high molecular weight 
(HMW) complex is a highly regulated process that occurs during biosynthesis of 
these polypeptides (Leem et al. 2002).
PS is essential for y-secretase activity and is likely to serve as a catalytic 
component in the heteromultimeric y-secretase complex (Sisodia and George- 
Hyslop, 2002; Xu et al. 2002; Haass and Steiner, 2002; Iwatsubo, 2004). In 
mammals there are two PS homologues, PS-1 and PS-2, both contributing 
independently to y-secretase activity (Tandon and Fraser, 2002), and both 
expressed throughout most adult human tissues and brain regions (Rogaev et al 
1995; Berezovska et al. 1997, 1998).
It is unknown, at the molecular level, whether y-secretase possesses a 
homogeneous or a heterogeneous activity. Several factors or processes have 
been reported to affect the nature and degree o f y-secretase activity; these include 
y-secretase complex assembly and activation, the integral regulatory subunit 
CD 147 (Zhou et al. 2005), transient or weak binding partners (Takashima et al. 
1998; Chen et al. 2006), inflammatory cytokines (Liao et al. 2004; Blasko et al. 
2000; Gianni et al. 2003) and cholesterol and sphingolipid levels (Sparks et al. 
1990; Sjogren et al. 2006), which may affect the proteolytic microenvironment 
of the y-secretase complex (reviewed by Zhou et al. 2007).
In the study by Cai et al. (2006) PEDF was shown to have a positive effect on y- 
secretase activity in cultured BRMECs, while VEGF did not. In another study by 
Yoshida et al. (2005), they reported that Ap accumulation affects the balance 
between VEGF and PEDF in the RPE, and an accumulation of Ap reproduces
Chapter 4 Yadan Zhang
features characteristic o f human AMD. As one of the substrates, Ap has been 
tightly linked to y-secretase (Haass et al. 1992; Busciglio et al. 1993; Haass and 
Selkoe 1993).
As HRPE cells express VEGF, PEDF and VEGFR-1, it would be interesting to 
see 1) if PS-1 and PS-2 are expressed in HRPE cells; 2) if exogenous VEGF 
and/or PEDF have any effect on PS-1 expression in HRPE; 3) if there is any y- 
secretase activity in HRPE cells; and 4) if  exogenous VEGF and/or PEDF have 
any effect on y-secretase activity in HRPE cells.
The aim of this study was therefore to use BRMECs, as a control cell line, to 
investigate the association between VEGF and/or PEDF and PS-1 and the 
potential association between exogenous VEGF and PEDF and the y-secretase 
activity in HRPE cells.
4.2 Experimental design
To meet the goal o f this study, the experiment was designed to be approached 
from the following three aspects: 1) Enzyme activity assay for the effects of 
PEDF/VEGF on y-secretase activity in BRMECs and HRPE; 2) 
Immunocytochemistry for the confirmation of PS-1 localisation and the effect of 
PEDF/VEGF on PS-1 localisation; and 3) Western blotting for the confirmation 
of PS-1 expression and the effect o f PEDF/VEGF on the PS-1 expressions. A 
flow chart for the experimental design is shown in Fig.4.1.
4.3 Materials and methods
4.3.1 Cell culture
Isolation and growth o f BRMECs and HRPE cells were performed as described 
in section 2.3.1. Cells were used within passage 4.
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Fig 4.1 Flow chart of experimental design for chapter 4. PE
= PEDF, VE=VEG F.
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4.3.2 VEGF/PEDF treatment for y-Secretase Activity Assay and Western 
blotting
VEGF/PEDF treatment for y-Secretase Activity Assay was performed using cells 
within passage 4, 80-90% confluent monolayer (7.5 xlO6 cells/flask) in T25- 
culture flasks as described in section of 3.3.8.
4.3.3 Estimation of protein concentration -BCA protein assay
The protein concentration was estimated using the BCA assay kit as described in 
section 3.3.3.
4.3.4 y-Secretase Activity Assay
A y-Secretase Activity Assay Kit (R&D Systems, R&D Systems Inc. UK. Cat 
No.FP003) was used to determine if y-secretase is functional in BRMECs and 
HRPE cells. This kit uses a fluorometric reaction to detect enzymatic activity of 
the y-secretase class o f proteases associated with the cleavage of amyloid 
precursor protein (APP) from cell lysates.
Principally, cells are lysed to collect their intracellular contents. The cell lysates 
are tested for secretase activity by the addition of a secretase-specific peptide 
conjugated to the reporter molecules EDANS [5-(2-aminorthyl) 
aminonaphthalene-1-sulfonic acid] and DABCYL [4-(4-
dimethylaminophenylazo) benzoic acid]. In the uncleaved form the fluorescent 
emissions from EDANS are quenched by the physical proximity of the 
DABCYL moiety which exhibits maximal absorption at the same wavelength 
(495 nm). Cleavage o f the peptide by the secretase physically separates the 
EDANS and DABCYL allowing for the release of a fluorescent signal. The level 
of secretase enzymatic activity in the cell lysate is proportional to the 
fluorometric reaction (kit manual). Fig. 4.2 illustrates the principle of the assay.
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Secretase-specific peptide
EDANS DABCYL
+ y-secretase 
(samples)
Fig 4.2 Principle of the Y~secretase Activity Kit. A
secretase-specific peptide is conjugated to the reporter 
molecules EDANS and DABCYL. In the uncleaved form the 
fluorescent emissions from EDANS are quenched by the 
physical proximity of the DABCYL moiety which exhibits 
maximal absorption at the same wavelength (495 nm). 
Addition of y-secretase cleaves the peptide and physically 
separates the EDANS and DABCYL allowing for the release 
of a fluorescent signal. The level of secretase enzymatic 
activity in the cell lysate is proportional to the fluorometric 
reaction.
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The y-secretase activity assay was carried out according to the manufacturer’s 
instruction with some modification. In brief, cells from the T25-culture flasks 
harvested and stored at -20°C were thawed on ice. Cell Extraction Buffer (0.5 
ml) was added to each flask and incubated on ice for 30 minutes. The 
supernatants were collected and centrifuged at 10,000 xg for 1 minute at 4°C 
before transferring to new tubes on ice. The protein content of the cell lysate was 
estimated using the BCA Protein Assay Kit (Pierce Chemical Co., Cat No. 
23225). For the y-secretase activity reaction, lOOpl of the cell lysate was added 
to each well of the microplate (provided) in duplicates. 2x Reaction Buffer (100 
pi) and 10 pi of Substrate were added to each well. The plate was covered in the 
dark and incubated at 37°C for 1 hour. The following controls were included in 
each assay: a) Mix o f Extraction buffer and Reaction buffer; aa) Mix of 
Extraction buffer, Reaction buffer and substrate; b) Cell lysate (not receiving 
growth factor) in extraction buffer and Reaction buffer; bb) Cell lysate (not 
receiving growth factor) in extraction buffer, Reaction buffer and substrate. The 
plates were read using a Fluostar OPTIMA microplate reader (BMG) at 355 nm 
excitation wavelength and 520-p nm emission wavelength. The amount of y- 
secretase activity in each sample was reported as Mean of the arbitrary unit ± 
Standard Error (SEM) from three separated experiments. The effect of VEGF 
and PEDF on y-secretase activity in BRMECs and HRPE was expressed as the 
ratio of the y-secretase activity relative to the control [bb) Cell lysate (not 
receiving growth factor) in extraction buffer, Reaction buffer and substrate].
4.3.5 Preparation of a positive control for the y-secretase activity assay
Mouse brain is a tissue known to contain y-secretase activity and is 
recommended as a positive control by the manufacturer. However, this positive 
control is not included in the kit and is not available commercially. Therefore, a 
positive control from mouse brain was prepared as following: fresh normal mice 
brains were obtained from the animal house in the School of Biosciences (Cardiff 
University), and either stored at -20°C in lx  Cell Extraction Buffer, or 
homogenised in ice cold lx  Cell Extraction Buffer to yield a final protein 
concentration o f 0.5-2.0 mg/ml.
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A dilution series of 20, 30, 40, 50 pg /well of the mouse brain lysate were tested 
for y-secretase activity. Mouse brain lysate prepared by different procedures, 
such as frozen or fresh, homogenised or not, were tested for y-secretase activity. 
The preparation with the highest y-secretase activity was chosen as a positive 
control for this study.
4.3.6 Immunofluorescence staining
Cell preparation and immunofluorescence staining were performed as described 
in section 2.2.1. VEGF/PEDF treatment for immunostaining was performed as 
described in section 3.3.9.
4.3.7 Western blotting
The preparation o f whole cell lysate and Western blotting were performed as 
described in the section o f 3.3.5 and 3.3.8.
4.3.8 The primary antibodies used for immunofluorescence staining and 
western blot
Table 4.1 The list of primary antibodies used in the immunostaining
and western blot
N am e S ource A gainst a pep tide  a t D ilution used
Presenilin-1
(PS-1)
(H-70)
R abbit polyclonal 
(sc-7860)
A m ino acids 23-247 at the 
N -term inus o f  human origin
1:100
Presenilin-2
(PS-2)
(C-20)
G oat polyclonal 
(sc -1456)
A peptide m apping at the C- 
term inus o f  PS-2 o f  human 
origin
1:100
4.3.9 Statistical analysis
The results were given as the mean ± standard error (SEM) from 3 separate 
experiments. An unpaired Student’s t-test was performed to analyse the data 
using SPSS program. A P value less than 0.05 (P<0.05) was considered 
statistically significant.
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4.4 Results 
4.4.1 Estimation o f the sensitivity of the y-secretase activity kit
The sensitivity o f the y-secretase activity kit was assessed using the mouse brain 
preparation. The results showed that the addition of substrate increased the 
fluorescence signal > 1  fold in the background control (dark red) when compared 
with the background control without substrate [blue] (Fig.4.3). y-secretase 
activity was detected above background with statistical significance in the mouse 
brain preparation when the total protein concentration was>l mg/ml and extracted 
by fresh homogenisation. This preparation was used as a positive control for the 
study of y-secretase activity in BRMECs and HRPE cells.
4.4.2 The effect of VEGF/PEDF on y-secretase activity in BRMECs and 
HRPE cells
In BRMECs, the y-secretase activity assay revealed that cells that were pre­
exposed to PEDF had y-secretase activity increased 13.36 ± 5.4% than the 
control (p<0.05). The fluorescence signal did not significantly increase in the 
samples that were pre-exposed to VEGF alone, or the combination of VEGF and 
PEDF (Fig 4.4).
In HRPE cells (Fig 4.5), pre-exposed to VEGF, y-secretase activity was 14.65 ± 
5.8 higher than the control (p<0.05); the fluorescence signal did not significantly 
increase in the samples that were pre-exposed to PEDF alone, or the combination 
of VEGF and PEDF.
4.4.3 Localisation of PS-1 in BRMECs and HRPE cells
Immunostaining confirmed that PS-1 was expressed in BRMECs (Fig. 4.6) 
where it was predominantly localised to the cytoplasm and membrane. In HRPE 
cells, PS-1 was localised in the perinuclear and membrane area (Fig. 4.7).
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Fig. 4.3 Estimation of the sensitivity of the y-secretase kit. Mouse brain with 
total protein concentrations >1 mg/ml. y-secretase activity increased in mouse 
brain tissue that had been freshly extracted without homogenisation [fsh (w)], 
with homogenisation [fsh (h)], and extracted from frozen tissue without 
homogenisation [frz (w)]. The controls for background (blue: without substrate; 
red: with substrate) were included. The orange line indicates the level of 
fluorescence taken as baseline. *p <0.05.
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Fig 4.4 The effects of VEGF/PEDF on y-secretase activity in cultured 
BRMECs. VE: VEGF, PE: PEDF, VE+PE: VEGF + PEDF, PE+VE: 
PEDF+VEGF. C: control cell not exposed to growth factors; Pos: positive 
control made from mouse brain. Data are presented as the ratio of treatment 
relative to the control. Data are presented as mean ± SEM from 3 independent 
experiments.. * p  <0.05.
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Fig. 4.5 The effects of VEGF/PEDF on y-secretase activity in cultured 
HRPE cells. VE: VEGF, PE: PEDF, VE+PE: VEGF + PEDF, PE+VE: 
PEDF+VEGF. C: control cell not exposed to growth factors; Pos: positive 
control made from mouse brain. Data are presented as the ratio of treatment 
relative to the control. Data are presented as mean ± SEM from 3 independent 
experiments. * p  <0.05.
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Fig 4.6 Im m unolocalisation of Presenilin-1 (PS-1) in cultured 
BRMECs. A) Presenilin-1 staining was in the cytoplasm (predominantly 
perinuclear area) and membrane. B)PS-1 staining with Hoechst nuclei 
stain. C) Negative control shows no positive staining. D) Negative control 
with Hoechst nuclei stain.
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Fig 4.7 Im m unolocalisation of PS-1 in cultured HRPE cells. A)
Presenilin-1 (PS-1) staining was found predominantly in the cytoplasm 
(perinuclei) and membrane. B) PS-1 staining with Hoechst nuclei stain. 
C) Negative control shows no positive stain. D) Negative control with 
Hoechst nuclei stain.
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4.4.4 The effects of VEGF/PEDF on the localisation of PS-1 and PS-2 in 
HRPE cells
By dual immunolabeling, it was demonstrated that PS-1 and PS-2 were co­
expressed in HRPE cells (Fig. 4.8 A2). PS-1 was localised in the perinuclear and 
membrane area while PS-2 localised predominantly to the perinuclear and 
nuclear area, and in the nuclei area presented as ‘speckles’ (Fig 4.8 red).
The addition o f VEGF reduced the PS-1 distribution on the membrane of HRPE 
cells (Fig.4.8B) whereas PEDF alone (Fig. 4.8C) or the combination with VEGF 
(Fig. 4.8 D+E) had no significant effect on the distribution of PS-1.
The addition o f PEDF increased the distribution o f PS-2 in the perinuclear and 
nuclear area (Fig. 4.8 C l). Pre-exposure or post-exposure to VEGF could not 
reverse the effect o f PEDF on PS-2 distribution (Fig. 4.8. D l+E l).
4.4.5 The effects of VEGF/PEDF on the expression of PS-1 in BRMECs
By western blotting, three bands at approx. 120, 100 and 75 kDa were detected in 
the untreated BRMECs (Fig 4.9 Control), and specific to PS-1 when compared 
with the negative control (data not shown). A 47 kDa band representing PS-1 
was not detected in any o f the three experiments. The addition of PEDF 
increased the 120 kDa high molecular weight (HMW) band of PS-1 (p<0.01). 
The addition of VEGF had no significant effect on all the bands detected (Fig 4.9 
A, B, C). The addition o f VEGF followed by PEDF (V+P) significantly 
increased the 75 kDa HMW (p<0.001).
4.4.6 The effects o f VEGF/PEDF on the expression of PS-1 in HRPE cells
Western blotting o f HRPE cell extracts revealed the presence of two bands of 47 
kDa and 75 kDa specific to the anti-PS 1 antibody (Fig. 4.10A Control). The 75 
kDa HMW band significantly decreased in the samples exposed to VEGF 
followed by PEDF (p<0.05) or PEDF followed by VEGF (p<0.01). VEGF or 
PEDF alone had no significant effect on the expression of PS-1 in HRPE cells 
(Fig 4.1 OB, C).
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Control 
VEGF
PEDF  
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PE+VE
Fig. 4.8. The effects of VEGF and PEDF on PS-1 and PS-2 localisation in 
cultured HRPE cells by fluorescence microscopy. Column 1: PS-1 (green) 
with nuclei (blue) staining; A. control; B. VEGF treatment; C. PEDF treatment; 
D. VEGF followed by PEDF (VE+PE); E:PEDF followed by VEGF (PE+VE). 
Column 2: PS-2 (red) with nuclei (blue) staining; Column 3: Merge of PS-1 and 
PS-2 with nuclei staining. Scale bar = 5 pM.
109
Chapter 4 Yadan Zhang
p + v
Presenilin 1 
Actin
***** *M * 'mink **
-  »■ §m m m* hm k
120 kDa
100 kDa 
75 kDa
B
120 kDa 100 kDa
200 -
150-
c A l  i o o -
o Z
.2 - I
If
200-
(0 ^
150-
<h £  100-
'■§ <o 50-
V P V+P P+V 
Various treatment
Various treatment
75 kDa
200
“ s150
If
o f
100
5 ™U- <D 50
X
★ * *
III
V P V+P P+V 
Various treatment
Fig 4.9. The effects of VEGF/PEDF on presenilin-1 (PS-1) expression in 
BRMECs. (A) Western blotting of BRMECs extracts showing expression of PS- 
1. (B-D) Densitometric analysis of Western blotting from 4 independant 
experiments. (B) Data are normalised to a-actin and presented as the relative 
ratio of the 120 kDa band to the control. (C) Data are normalised to a-actin and 
presented as the relative ratio o f the 100 kDa band to the control. (D) Data are 
normalised to a-actin and presented as the relative ratio of the 75 kDa band to the 
control. Data is presented as mean ± SEM. **p <0.01, ***p<0.001. C=control; 
V=VEGF; P=PEDF; V+P=VEGF+PEDF; P+V= PEDF+VEGF.
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Fig 4.10. The effects of VEGF/PEDF on presenilin-1 (PS-1) expression in 
HRPE cells. (A) Western blotting of HRPE cell extracts showing the presence of 
a 75 kDa band as well as the full-length of PS-1 (47 kDa). Blots were stripped 
and reprobed with an antibody to actin to show equal loading of protein. (B-C) 
Densitometric analysis o f Western blotting from 4 independant experiments. (B) 
Data are normalised to a-actin and presented as the relative ratio of the 75 kDa 
band to the control. (C) Data are normalised to a-actin and presented as the 
relative ratio o f the 47 kDa band to the control. Data is presented as mean ± 
SEM. *p <0.05, **p<0.01. C=control; V=VEGF; P=PEDF; V+P=VEGF+PEDF; 
P+V= PEDF+VEGF.
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4.5 Discussion
The aim of this study was to determine whether VEGF and PEDF treatment 
altered y-secretase activity in BRMECs and HRPE cells. Normal mouse brain, a 
tissue known to have y-secretase activity, was prepared and used as a positive 
control to validate the assay.
It was noticed that the substrate (one o f the reagents included in the kit) induced 
very high background, the fluorescence signal only increased when the protein 
concentration (in mouse brain) was greater than 1 mg/ml.
In order to match the protein concentration of the positive control, the cell lysates 
were prepared by scaling up cell numbers while scaling down the extraction 
buffer. The same amount o f protein from control and samples was loaded for the 
assay. PEDF significantly increased y-secretase activity in BRMECs; whilst 
VEGF significantly increased y-secretase activity in HRPE cells. This provides 
evidence to suggest that y-secretase activity in BRMECs and HRPE cells is 
regulated differently by VEGF and PEDF. The upregulation of y-secretase 
activity by PEDF in BRMECs is consistent with the report by Cai et al. (2006). 
However, the combination o f VEGF and PEDF had not increased y-secretase 
activity as demonstrated by Cai et al. (2006). This may be due to the change of y- 
secretase activity was too small to be detected by the kit. Or VEGF can 
antagonise PEDF’s effect in this case.
The association between y-secretase and VEGF/PEDF was investigated further 
by exploring the expression o f PS following VEGF and PEDF stimulation, since 
PS has been regarded as the catalytic centre of y-secretase (Wolfe et a l 1999b; 
Li et al. 2000). It has been well documented that PS, as the core element of y- 
secretase, is endogenously expressed in every type of mammalian cell 
(Thinakaran et al., 1996; Iwatsubo, 2004), localized predominantly to the 
endoplasmic reticulum (ER) and Golgi compartments (Annaert, et al. 1999). A 
small percentage o f PS can be detectable at the cell surface in specific cell types 
(Ray et al. 1999; Schwarzman et al. 1999; Kaether et al. 2002). This study
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confirmed the expression o f PS-1 in cultured BRMECs and HRPE cells, and the 
localisation o f PS in both cell types is in agreement with the above reports. 
Further more, this study revealed, for the first time, that the distribution of PS-1 
was differentially regulated by exogenous VEGF and PEDF in HRPE cells, in 
that VEGF reduced the membrane distribution of PS-1 whilst PEDF sustained 
the distribution. Pre-exposure or post-exposure of VEGF to HRPE cells did not 
reverse the effect o f PEDF suggesting that VEGF and PEDF act on PS-1 in an 
antagonising manner. This evidence supports our hypothesis that VEGF and 
PEDF have oppositing effects on the PS-dependent RIP pathway.
‘Speckles’ have been considered as storage depots for inactive splicing 
components, and are less prominent in cells that transcribe RNA at high levels 
and strikingly prominent when RNA processing is inhibited (Pollard and 
Eamshaw, 2002). In response to the application of exogenous VEGF, PS-2 
distribution increased in the perinuclei and nuclei and decreased in the 
membrane, suggesting that VEGF promotes the translocation of PS-2 from 
membrane to perinuclei and nuclei area in HRPE cells. In contrast, PEDF 
increased the overall distribution o f PS-2 in HRPE.
It is not surprising that PS-1 in BRMECs was expressed as three higher 
molecular weight (HMW) bands of 120, 100 and 75 kDa rather than a 47 kDa 
band. Such phenomena have been observed by several groups in that PS was 
presented in HMW aggregates in a range from 100 to 250 kDa, and includes both 
the PS NTF and CTF (Thinakaran et al. 1996; De Strooper et al. 1997; Seeger et 
al. 1997). It has also been reported by several groups (Capell et al. 1998; Yu et 
al. 1998, 2000a & b) that full-length (FL-PS1) is present in lower molecular 
weight complexes while the NTF/CTF is present in HMW complexes in cell 
culture studies. Cai et al. (2006) detected FL-PS1 and CTF in BRMECs by 
immunoprecipitation and Western blotting. Therefore, the HMW bands detected 
in this study may be just the intermediate complex of y-secretase that is 
expressed specifically in the BRMECs. If this is the case, the increase of 120 kDa
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by PEDF suggests that PEDF upregulates PS processing into HMW complexes, 
towards the active form of y-secretase complex. The upregulation of y-secretase 
activity by PEDF from this study supports the above speculation. In contrast, in 
HRPE cells, the combination o f VEGF and PEDF down-regulated the 75 kDa 
HMW complex but had no significant effect on the band at 47 kDa, suggesting 
that the effect o f PEDF on PS-1 expression in HRPE cells is opposite to the one 
observed in BRMECs.
Taken together, this study provides evidence for the first time that exogenous 
VEGF and PEDF have opposite effects on 1) the y-secretase activity in BRMECs 
and HRPE cells; and 2) the distribution of PS-1 and PS-2 in HRPE cells. It would 
be interesting to carry out further work to study the relationship between A0, PS 
and exogenous VEGF/PEDF in HRPE cells, which may contribute to a new 
therapeutic approach in treatment of AMD by targeting PS or y-secretase.
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5.1 Introduction
y-Secretase has been implicated in many biological activities, such as the 
pathogenesis o f Alzheimer’s disease and developmental signalling by Notch 
receptor. Other activities involve ErbB4, CD44, VEGFR-1 and E-cadherin as 
reviewed in Chapters 1 and 4.
Involvement o f P-secretase and y-secretase in producing the p-amyloid 
component of plaques found in the brains of Alzheimer’s patients has led to the 
design of selective inhibitors o f these proteases that might be of therapeutic 
interest for Alzheimer’s disease. The use o f selective p and y-secretase inhibitors 
might also be important to reveal new functions of these proteases during other 
physiological processes opening the possibility of new applications for these 
drugs. Meanwhile, y-secretase inhibitors have also been used for identifying new 
substrates that are involved in the PS-dependent RIP pathway by interfering with 
the molecular interaction between the enzyme (y-secretase) and its target. For 
example, Ni et al. (2001) used a y-secretase inhibitor to clarify if the soluble 80 
kDa (s80) fragment detected was from y-secretase cleavage or from 
contamination.
As discussed previously (Chapters 3 and 4), evidence suggests that there is a 
relationship between VEGF/PEDF and VEGFR-1/VEGFR-2 (Chapter 3) and 
between VEGF/PEDF and PS-1 (Chapter 4). However, this evidence is not 
sufficient to confirm the association of y-secretase with VEGFR-1. y-secretase 
inhibitors provide a mean to examine the association of y-secretase and VEGFR- 
1/VEGFR-2.
The aim of this study was to investigate the association between: 1) y-secretase 
and VEGFR-1 and 2) y-secretase and VEGFR-2 in HRPE cells using a y- 
secretase inhibitor.
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Fig 5.1 Flow chart of experim ental design for chapter 5.
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plate in replicates o f six (from 0/well to 5400/well). A simple regression model 
was used to analyse the linearity of the crystal violet staining with cell number.
5.3.2.3 Preparation o f the y-secretase inhibitor stock
A y-secretase inhibitor (C33H 57N 5O9F2, molecular formula see the Appendix 4) 
(Sigma, Catalogue number S 2188), which has been used in BRMECs by Cai et 
al. (2006), was applied to determine if y-secretase is associated with VEGFR- 
1/VEGFR-2 in cultured HRPE cells.
This y-secretase inhibitor has been documented as a reversible y-secretase 
inhibitor (Wolfe et al., 1998; Wolfe et a l , 1999) selective for aspartyl protease. It 
inhibits amyloid p protein (AP) biosynthesis at the level of y-secretase. It is also a 
potent inhibitor o f Ap production in embryonic kidney (HEK) 293 cells and its 
IC50 for total inhibition o f Ap is 13.5 pM (Product Information, Sigma).
The y-secretase inhibitor (lm g) was dissolved in 90% (v/v) of dimethyl sulfoxide 
(DMSO) with 10% (v/v) water to form a 1350 pM stock solution and stored at - 
20°C in aliquots.
For assessing the cytotoxcity o f the y-secretase inhibitor, a dilution series of the 
inhibitor was prepared by further diluting the 1350 pM stock to 0.135, 1.35, 13.5 
and 27.0 pM with Ham’s F-10 medium containing 1% FCS. DMSO in 10% 
water in the corresponding dilutions with Ham’s F-10 containing 1% FCS was 
also prepared as the vehicle controls.
5.3.2.4 Evaluation o f the cytotoxic effect of the y-secretase inhibitor
To determine if the concentration of 13.5 pM was a usable concentration in 
HRPE cells with minimum cytotoxicity, HRPE cells were subcultured in a 96- 
well plate at 3000 cells/well and maintained in Ham’s F-10 medium containing 
10% FCS for 24 hours. Prior to the treatment, serum-free medium was replaced 
and incubated for 45 min. The y-secretase inhibitor was added at concentrations
118
Chapter 5 Yadan Zhang
ranging from 0.135, 1.35, 13.5 and 27pM in (1000 pl/well of) Ham’s F-10 
medium containing 1% FCS respectively, so that each well containing a specified 
concentration o f y-secretase inhibitor and DMSO. Medium without any addition 
and medium containing DMSO only (in correspondent concentrations) were 
included as controls. Each treatment and control was prepared in triplicates. 
Initially, cells were incubated with a given y-secretase inhibitor concentration for 
26 hours at 37 °C. The cytotoxicity of y-secretase inhibitor was assessed by the 
Crystal Violet assay.
5.3.3 y-secretase inhibitor and PEDF / VEGF treatment
Once the optimal concentration o f the y-secretase inhibitor was identified, HRPE 
cells were subcultured in T25 flasks with consistent cell numbers in each flask. 
At near confluence, the cells were washed with PBS three times, and incubated 
with serum-free Ham’s F-10 medium for 45 min. Cells were treated with 13.5 
pM y-secretase inhibitor in Ham’s F-10 medium containing 1% FCS (2 ml/flask) 
and incubated at 37°C for 2 hours. The addition of PEDF (100 ng/ml) or VEGF 
(100 ng/ml) was followed respectively. One hour after incubation at 37°C 
another dose o f VEGF (100 ng/ml) was added to one of the flasks that had been 
treated with PEDF, and same dose o f PEDF to one of the flasks that had been 
treated with VEGF. Cells without any treatment, and cells treated with just the y- 
secretase inhibitor were included as controls. Cultures were incubated for a 
further 24 hours in a 37°C standard incubator. At the end of the time course cells 
were harvested and subjected to protein extraction.
5.3.4 Preparation of whole cell lysate
The whole cell lysate was prepared as described in section 3.3.2.
5.3.5 Preparation of subcellular fractions
5.3.5.1 Preparation o f  four subcellular fractions
In order to analyse the localisation of the target of interest, the ProteoExtract™ 
Subcellular Proteome Extraction Kit (S-PEK) was used in an attempt to obtain 
four subcellular fractions. The S-PEK uses special reagent mixtures to solubilise
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different subcellular compartments while the structural integrity of the 
subcellular structures is preserved before and during the extraction. It enables 
the differential extraction o f proteins according to their subcellular localisation. 
The S-PEK procedure yields proteins in their native state (manual of the S-PEK) 
(Fig 5.2).
Subcellular Proteome Extraction was carried out according to the manufacturer’s 
instruction [ProteoExtract™ Subcellular Proteome Extraction Kit (S-PEK) (Cat. 
No. 539790, EMD Biosciences, Inc.UK)] with some modification. In brief, the 
cells in a T25-flask  were washed with PBS, and any remaining liquid removed. 
Ice-cold Extraction buffer I (500pl) containing Protease Inhibitor Cocktail (5pl) 
was added to each flask and incubated at 4°C for 10 min under gentle agitation. 
The supernatant (fraction 1 - cytosolic) was collected and stored at -20°C in 
aliquots for further analysis. A mixture o f ice-cold Extraction buffer II (500pl) 
and Protease Inhibitor Cocktail (5 pi) was added to each flask and incubated for 
30 min at 4°C under gentle agitation. The supernatant (fraction 2 -  organelle / 
membrane) was collected and a mixture o f ice-cold Extraction buffer III (500pl) 
with Protease Inhibitor Cocktail (5pl) and Benzonase® (1.5pl ) was added to 
each flask and incubated for 10 min at 4°C under gentle agitation. The 
supernatant (fraction 3 -nucleic) was collected and a mixture of Extraction 
buffer IV (500pl) with Protease Inhibitor Cocktail (5pl) at room temperature was 
added to each flask. Cell particles were suspended by vigorously pipetting, and 
transferred into a new eppendorf (fraction 4 - cytoskeleton). The protein 
concentration o f the subcellular protein extracts was determined by BCA Protein 
Assay as described in section 3.3.3 before being subjected to SDS-PAGE or 
Western blotting.
5.3.5.2 Preparation o f  two subcellular fractions
In an attempt to extract subcellular fractions o f cells in their native state with a 
higher protein concentration, extraction o f two subcellular fractions was 
undertaken using Triton X-100 soluble (Tx-sol) (containing the cytosol fraction) 
and Triton X-100 insoluble (Tx-insol) (containing the cytoskeleton and nuclei
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fraction) as previously described (Stolz et al. 1992; Lampugnani et al. 1995; Cai 
et al. 1999; Cai et al. 2006).
In brief, at near confluence, HRPE cells were washed twice with lxPBS after 
removal of Ham ’s F-10 medium. T riton X-100 soluble buffer (500 pi) (see 
Appendix 2) was added to the cells in T25 flasks and incubated on ice for 30 
minutes with gentle agitation. The extraction buffer was collected and 
centrifuged at 14,000g for 5 minutes at 4°C. The supernatant was defined as the 
Tx soluble (Tx-sol) fraction. After this step, the cells appeared homogenously 
adherent to the culture vessel with well preserved nuclei and cytoskeleton fibres 
under phase contrast microscopy. They were then extracted with 1% SDS buffer 
containing protease inhibitors (see the Appendix 2) (500 pi) for 10 minutes on 
ice. The mixture o f 1% SDS buffer and cell cytoskeleton were collected into 
eppendorfs using a cell-scraper and further disrupted by vigorously pipetting 
before centrifugation at 14,000g for 5 minutes. This supernatant was defined as 
the Tx-insoluble (Tx-ins) fraction. The protein concentration from both fractions 
was estimated using the BCA protein assay (as described in section 3.3.3.). 
Equal amounts o f protein from each sample were used for SDS-PAGE or 
Western blotting.
5.3.6 Estimation o f protein concentration -  BCA protein assay
The BCA protein assay was performed as described in the section of 3.3.3.
5.3.7 SDS-PAGE
5.3.7.1 Preparation o f SDS-PAGE
SDS-PAGE was prepared as described in the section o f 3.3.4.1.
5.3.7.2 Visualisation o f protein by Coomassie brilliant blue staining 
Coomassie brilliant blue staining was performed to visualise the protein profile 
in the preparation o f four subcellular fractions and two fractions as described in 
section 3.3.4.2.
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5.3.7.3 Visualisation o f protein by silver staining
All silver staining methods depend on the reduction of ionic to metallic silver to 
provide metallic silver images (Hames and Hooper, 2000). Silver staining is 
much more sensitive than Coomassie Blue staining and is usually carried out 
when the protein concentration is too low to be detected by Coomassie Blue 
staining.
The procedure o f silver staining was undertaken according to the manufacturer’s 
instruction (Pierec, UK) using the GelCode® Colour Silver Stain Kit. On 
completion o f running, SDS -PA G E gels were fixed with the mixture of ethanol 
and acetic acid (10:1) (v/v) overnight on an agitator. Next day gels were washed 
with deionised water (dH20) for 30 minutes with 4 changes, and incubated with 
the Silver Working Solution (WS) (Silver Concentrate: Water = 1:14) for 30 
minutes at room temperature. Gels were rinsed in dH20 for 10 seconds and 
incubated with Reducer WS (equal volumes of Reducer Aldehyde WS and 
Reducer Base WS, prepared immediately before use) for 5 minutes. Gels were 
again rinsed with dH20 very briefly and incubated in Stabilizer WS (1:44 
dilution o f Stabilizer Concentrate in dH20) for up to 2 hours. The bands of each 
sample were analysed using EPSON scan (EPSON EXPRESSION 1680 Pro).
5.3.8 Western blotting
Western blotting was performed on whole cell lysates (as described in section 
3.3.2), two subcellular fractions (section 5.3.5.2) and four subcellular fractions 
(section 5.3.5.1).
5.3.9 Statistical analysis
The results were given as the mean ± standard error (SEM) from 3 independent 
experiments. An unpaired Student’s t-test was performed to analyse the data 
(SPSS). A probability value less than 0.05 (P<0.05) was considered statistically 
significant.
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5.4 Results
5.4.1 Selection of a usable concentration of y-secretase inhibitor for 
treatment with cultured HRPE cells
By crystal violet staining it was observed that the doses of y-secretase inhibitor 
applied to the HRPE had no significant effect on HRPE cell growth when 
compared with the controls as indicated by the orange colour line in Fig. 5.3. 
Thus, no toxic effect was observed in the concentration range 0.135 pM to 27.0 
pM. The 13.5 pM concentration o f y-secretase inhibitor was chosen for the 
following studies in HRPE cells since it has been previously used in BRMECs by 
Cai et al. (2006).
5.4.2 The crystal violet staining exhibits a linear response to the number of 
HRPE cells
To confirm the validity o f crystal violet staining for monitoring the proliferation 
of cultured HRPE cells, the staining was performed on cells cultured at different 
density for 24 hours. By plotting the Optical Density (OD) against the number of 
the cells used, it was demonstrated that there is a linear relationship between the
'y
OD and cell number with a very high coefficient o f determination (R =0.984) 
(Fig 5.4). This indicates that the variance in one variable (OD) would predict 
almost all the variance in the other variable (number of cells). Therefore, the 
crystal violet staining method is a valid approach to quantify HRPE cell 
proliferation (Calculated linear regression equation y = 4E-05X + 0.0834 where 
the correlation coefficient R = 0.984).
5.4.3 Protein profile from 4 subcellular fractions of BRMECs
Coomassie Blue staining o f protein showed no visible band from the samples 
prepared in four subcellular fractions. With silver staining, it was observed that 
each fraction has its own pattern. Bands were observed above and around 250 
kDa position in fraction 1 (FI- the cytosolic) and fraction 2 (F2 - membrane and 
organelle) whereas in fraction 3 (F3 - nuclei) the bands were weaker and were 
ambiguous in fraction 4 (F4 - cytoskeleton). See Fig 5.5.
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Fig 5.3 Evaluation of a usable concentration of y-secretase inhibitor in 
cultured HRPE cells. A dilution series o f the y-secretase inhibitor ranging from 
0.135, 1.35, 13.5 and 27 jiM were added to the cells and incubated for 26 hours. 
Medium only and cells without treatment were included as controls; cells 
exposed to DMSO (vehicle control) in correspondent concentrations (dark red) 
were also included. Vertical bars are mean ± SEM (n=3). The orange line 
indicats the level o f proliferation taken as baseline. rS-in = y-secretase inhibitor.
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Fig 5.5 Protein profile in four subcellular fractions from 
BRM ECs by silver staining of 10% SDS-PAGE gels. The
fractions were obtained using the ProteoExtractTM Subcellular 
Proteome Extraction Kit. FI: cytosolic fraction. F2: membrane/ 
organelle fraction. F3: nuclei fraction and F4: cytoskeleton 
fraction. M: molecular weight marker.
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5.4.4 Protein profile from 2 subcellular fractions of HRPE cells
Coomassie Blue staining o f 10% SDS-PAGE gels show that the protein profile 
from the Tx-sol fraction (containing cytosol) differs from the Tx-insol fraction 
(containing cytoskeleton and nuclei). There are more bands from the range of 75 
to 250 kDa in the Tx-sol than in Tx-insol (Fig. 5.6).
5.4.5 The effects o f y-secretase inhibitor on the expression of VEGFR-1 in 
HRPE cells
Western blot analysis was performed on total cell lysates of HRPE cells exposed 
to y-secretase inhibitor (13.5 pM) followed by the addition of VEGF/PEDF. The 
results revealed that y-secretase inhibitor alone decreased the 75 and 85 kDa 
fragments o f VEGFR-1 (p<0.05). Addition of VEGF alone had no statistically 
significant effect whereas the combination o f VEGF and PEDF sustained the 
effect o f the y-secretase inhibitor (p<0.01, p<0.05, respectively) (Fig. 5.7).
5.4.6 The effects of y-secretase inhibitor on the distribution of VEGFR-1 in 
HRPE cells
Western blotting analysis failed to detect VEGFR-1 /VEGFR-2 expression in any 
of the four subcellular fractions. In an attempt to increase the concentration of 
the total protein in each fraction, cells were fractionated into two fractions 
instead (Tx-sol and Tx-insol). Western blot analysis showed that treatment with 
the y-secretase inhibitor increased the 75 kDa and 85 kDa fragments of VEGFR- 
1 in the insoluble fraction o f HRPE cells (containing cytoskeleton and nuclei) 
(p<0.05); addition o f VEGF or PEDF or a combination of these did not reverse 
this effect (Fig 5.8).
5.4.7 The effects of y-secretase inhibitor on the expression of VEGFR-2 in 
HRPE cells
Western blot analysis demonstrated that the y-secretase inhibitor reduced the 
expression of VEGFR-2 (p<0.05), addition o f VEGF or PEDF alone, or the 
combination o f these reversed the effect o f y-secretase inhibitor and restored the 
expression of VEGFR-2 (Fig. 5.9).
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Fig 5.6 Protein profile in two subcellular fractions from HRPE cells 
by Coomassie staining of 10% SDS-PAGE gels. The two subcellular 
fractions were obtained using Triton X-100 buffer. Lanel: molecular 
weight marker; Lane 2 and 3: Triton x-100 soluble fractions. Lane 4 and 
5: Triton x -100 insoluble fractions.
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Fig 5.7 The effects of y-secretase inhibitor on VEGFR-1 expression in 
HRPE cells by W estern blotting. (A) Western blot of VEGFR-1 in HRPE cells. 
(B&C) Densitometric analysis o f immunoblots depicted in (A). Data are 
normalised with GAPDH from 3 separated experiments and presented as the 
relative ratio of VEGFR-1 to the control. Data are presented as mean ± SEM. *p 
<0.05; ** p<0.01. C: non-treatment control. C-rS in: control-y-secretase 
inhibitor only. rS-in + V : y-secretase inhibitor treatment followed by VEGF. rS- 
in + P: y-secretase inhibitor treatment followed by PEDF. rS-in + V+P: y- 
secretase inhibitor treatment followed by VEGF then PEDF.
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Fig 5.8 The effects of y-secretase inhibitor on VEGFR-1 distribution in the 
Tx-s/Tx-ins fractions of HRPE by western blotting. (A) Western blot of 
VEGFR-1 in Tx-s/Tx-ins fractions. (B & C) Densitometric analysis of 
immunoblots depicted in (A). Data are presented as the relative ratio of VEGFR- 
1 to the control from 3 separate experiments. Data are presented as mean ± SEM. 
*p <0.05; ** p<0.01. C: non-treatment control. C-rS in: control-y-secretase 
inhibitor only. rS-in + V : y-secretase inhibitor treatment followed by VEGF. rS- 
in + P: y-secretase inhibitor treatment followed by PEDF. rS-in + V+P: y- 
secretase inhibitor treatment followed by VEGF then PEDF.
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Fig 5.9 The effects of y-secretase inhibitor on VEGFR-2 expression in 
HRPE cells by western blotting analysis. (A) Western blot of VEGFR-2 
expression in HRPE cells. (B) Densitometric analysis of immunoblots depicted 
in (A). Data are normalised with GAPDH from 3 separate experiments and 
presented as the relative ratio o f VEGFR-2 to the control. Data are presented as 
mean ± SEM. *p <0.05. C: non-treatment control. C-rS in: controPy-secretase 
inhibitor only. rS-in + V: y-secretase inhibitor treatment followed by VEGF. rS- 
in + P: y-secretase inhibitor treatment followed by PEDF. rS-in + V+P: y- 
secretase inhibitor treatment followed by VEGF then PEDF.
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5.4.8 The effects of y-secretase inhibitor on the distribution of VEGFR-2 in 
HRPE cells
By fractionation of the cells into two subcellular fractions, Western blot analysis 
revealed that treatment with the y-secretase inhibitor had no significant effect on 
the distribution o f VEGFR-2 in Tx-sol and Tx-insol fractions of HRPE cells 
(p>0.05) (Fig 5.10).
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Fig 5.10 The effects of y-secretase inhibitor on VEGFR-2 distribution in the 
Tx-s/Tx-ins fractions of H RPE by western blot analysis. (A) Western blot of 
VEGFR-2 in the Txs/Tx-ins fractions. (B) Densitometric analysis of 
immunoblots depicted in (A). Data are presented as the relative ratio of VEGFR- 
2 to the control from 3 separate experiments. Data are presented as mean ± SEM. 
C: non-treatment control. C-rS in: control^-secretase inhibitor only. rS-in + V: 
y-secretase inhibitor treatment followed by VEGF. rS-in + P: y-secretase 
inhibitor treatment followed by PEDF. rS-in + V+P: y-secretase inhibitor 
treatment followed by VEGF then PEDF.
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5.5 Discussion
A well defined model for the RIP signalling pathway that y-secretase is involved 
in has been applied to Notch receptor and ErbB4 as reviewed in chapter 1. In this 
pathway the signalling is initiated upon the ligand binding. A metalloprotease 
cleaves the ectodomain o f the receptor. Subsequently, a second cleavage 
mediated by y-secretase is initiated and results in the release of the intracellular 
domain from the membrane and facilitates its translocation to the nucleus. In the 
case of ErbB4 receptor, the ectodomain and cytosolic domain of ErbB4 is 
cleaved sequentially by two enzymes, and the cytosolic domain translocated into 
the nucleus to regulate cell proliferation and differentiation (Ni, et al., 2001; Lee 
et al., 2002). In cultured BRMECs, VEGFR-1 has been reported to be cleaved by 
y-secretase (Cai et al., 2006).
To define the association between y-secretase and VEGFR-1 and/or VEGFR-2, 
one would expect to see the reduction/or the disappearance of the receptor 
fragment(s) from the ectodomain and intracellular domain when treated with an 
inhibitor of the metalloprotease or y-secretase; and /or to see the inhibition of the 
translocation o f the fragment(s) to the nucleus or other compartment within the 
cells.
To date, the relationship o f VEGFR-1 or VEGFR-2 with y-secretase activity and 
the cleavage o f VEGFR-1 or VEGFR-2 in HRPE cells has not been studied. In 
this study, two fragments smaller than the full-length VEGFR-1, were detected 
(as described in chapter 3) and predominantly expressed in HRPE cells, y- 
secretase inhibition resulted in the reduction o f the 75 kDa and 85 kDa fragments 
in the whole cell lysate suggesting that the production of the VEGFR-1 
fragments is associated with y-secretase in cultured HRPE cells. Restoration of 
the expression o f these fragments following the addition of VEGF further 
supports this relationship. More interestingly is the phenomenon that the 
inhibitory effect o f the y-secretase inhibitor can be sustained by the combined 
effect of VEGF and PEDF. These have two implications: 1) VEGF and PEDF
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have opposite effects on the y-secretase inhibitor and 2) PEDF exerts its effect 
with the presence o f VEGF.
Regarding the effects o f y-secretase inhibition on the distribution of VEGFR-1 
fragments, the reduction o f the fragments in Tx-soluble fraction by the y- 
secretase inhibitor suggests that y-secretase is related to the release of C-terminal 
fragments of VEGFR-1. It is interesting to note that addition of VEGF or PEDF, 
or the combination o f  both cannot reverse the effect o f y-secretase inhibition on 
the VEGFR-1 distribution. Since the Tx-soluble fraction contains the cytosol 
whereas the Tx-insoluble fraction contains cytoskeleton and nuclei, these data 
suggest that y-secretase regulates VEGFR-1 cleavage and the distribution in 
HRPE cells.
Similar to the effect on the expression of total VEGFR-1, y-secretase inhibition 
resulted in the reduction o f VEGFR-2 expression at the total protein level. The 
addition o f VEGF followed by PEDF restored VEGFR-2 expression. This 
evidence suggest that y-secretase also regulates VEGFR-2 but the subsequent 
response to VEGF and PEDF treatment is different from that of VEGFR-1. 
Another difference is that y-secretase inhibition had no significant effect on the 
distribution o f VEGFR-2 in Tx-sol/Tx-insol fraction.
Taken together, these results have two implications 1) y-secretase exists in HRPE 
cells and is involved in the fragment production o f VEGFR-1 and 2) y-secretase 
is involved in the VEGFR-2 signalling in a way that is different from VEGFR-1. 
Further studies are required to clarify the role o f soluble fragments of VEGFR-1 
in the regulation of angiogenesis.
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6.1 Introduction
VEGF plays a central role in vascular homeostasis. It is also a potent angiogenic 
stimulator and plays an important role in pathological angiogenesis (Shibuya, 
2001), such as diabetic retinopathy, choroidal neovascularisation (CNV) (Adamis 
et al., 1994; Aiello et al. 1994; Husain et al, 2002; Witmer et al. 2003) and 
tumour angiogenesis (Moreira et al., 2007). As reviewed in chapter 1, VEGF 
increases vascular permeability which might facilitate tumour dissemination via 
the circulation causing a greater delivery o f oxygen and nutrients. It recruits 
circulating endothelial precursor cells and acts as a survival factor for immature 
tumour blood vessels. The endotheliotropic activities of VEGF are mediated 
through the VEGF-specific tyrosine-kinase receptors: VEGFR-1 and VEGFR-2. 
VEGF and its receptors play a central role in ocular and tumour angiogenesis 
and, therefore, the blockade o f this pathway has been regarded as a promising 
therapeutic strategy for inhibiting angiogenesis and tumour growth.
Conversely, accumulating evidence has shown that the balance between VEGF 
and PEDF is crucial for the regulation o f vascular permeability and angiogenesis 
(Zhang et al. 2006). Under normal conditions, there is a balance between these 
two systems which is essential for maintaining the quiescence o f retinal 
vasculature and integrity o f the blood-retinal barrier (BRB) (Bussolino et al. 1997; 
Miller et al. 1997).
In certain pathological conditions, such as diabetic retinopathy, this balance is 
disturbed due to the over-production o f angiogenic stimulators and the decreased 
production o f angiogenic inhibitors. This will subsequently lead to the BRB 
breakdown and the over-proliferation o f capillary endothelial cells, resulting in 
retinal neovascularisation (Forsythe et al. 1996; Miller et al. 1997; Gao et al. 
2001; Gao & Ma 2002). In animal studies, Gao et al. (2001) demonstrated that in 
rats with oxygen-induced retinopathy, PEDF levels in the retina are significantly 
decreased in contrast to the increased VEGF levels leading to an increased retinal 
VEGF/PEDF ratio. This disturbed balance correlates with the formation and 
progression o f neovascularisation. Such evidence suggests an inverse correlation
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between VEGF and PEDF levels and that a reciprocal regulation exists between 
these two major angiogenic regulators (Gao et a l 2001; Ohno-Matsui et a l  2001; 
Ohno-Matsui et a l  2003; Doll et a l  2003).
In contrast, Ogata et a l  (2002) observed that in rats with experimental CNV, the 
levels o f expression o f VEGF and PEDF vary with the severity of CNV. When 
CNV was active VEGF and PEDF were both strongly expressed in the CNV 
lesions. However, after the CNV had developed, the expression of both VEGF 
and PEDF decreased. In another study, Matsuoka et a l  (2004) reported that 
VEGF and PEDF were strongly expressed in human active subretinal 
fibrovascular membranes from age-related macular degeneration (AMD) and 
polypoidal choroidal vasculopathy (PCV). This evidence suggests that VEGF- 
induces PEDF gene upregulation and a feedback mechanism may be present in 
CNV (Tong and Yao, 2006). A similar phenomenon has also been observed in 
cultured HRPE cells by Ohno-Matsui and colleagues (2003). They demonstrated 
that VEGF secreted by RPE cells upregulates PEDF expression via VEGFR-1 in 
an autocrine manner.
Interestingly, it has been demonstrated that VEGF and PEDF both can be 
produced from the same cells in primary cultures o f various cell types, such as 
cultured HRPE cells (Tombran-Tink et a l  1996; Ohno-Matsui et a l 2001; Ohno- 
Matsui et a l  2003), cultured primary retinal capillary endothelial cells (Simorre- 
Pinatel et a l  1994; Tombran-Tink et a l , 2004), and retinal glial (Muller) cells 
(Yafai et a l, 2007). Understanding the relationship between VEGF and PEDF 
production in the same cell type may lay the foundation for a different therapeutic 
approach for the treatment o f various angiogenesis related conditions. In chapters 
3, 4 and 5, the effect o f VEGF and PEDF, on the expression of VEGFR-1, 
VEGFR-2 and presenilin-1 (PS-1) were investigated in HRPE cells under 
overlapping o f autocrine (HRPE cell dependent) and paracrine (HRPE cell 
independent) pathways. However, further investigation was needed to define the 
responsibility o f VEGF and PEDF in autocrine and paracrine pathways. 
Techniques such as neutralising anti-VEGFR-1 or anti-VEGFR-2 antibodies have
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been used to study the relationship between VEGF and PEDF in HRPE cells 
(Ohno-Matsui et al. 2003).
RNA interference (RNAi), is the method of choice for studying loss-of-function 
study and has been applied to silence VEGF expression in various in vitro models 
(Reich et al., 2003; Li et a l ,  2005; Murata et al., 2006). RNAi has also been used 
in an attempt to inhibit ocular angiogenesis (Reich et a l,  2003; Kim et al., 2004; 
Murata et al., 2006) or to inhibit the growth of malignant melanoma (Tao et al., 
2005) in vivo. Despite the above attempts, the effect(s) of the altered expression 
of specific gene(s) on various downstream signalling and the expression of many 
other genes remain largely uninvestigated. In the hope of applying small 
interfering RNA (siRNA) technology to inhibit the expression of VEGF in HRPE 
cells, this study aimed to dissect the autocrine/paracrine effects of VEGF on 
PEDF, VEGFR-1, VEGFR-2 and PS-1 expression in HRPE cells.
The principal mechanisms o f  RNA interference (RNAi)
RNA interference is a normal, endogenous system for regulating gene expression 
in which short RNA segments, approximately 22 bases in length, form double­
stranded structures with an mRNA and either target it for destruction or block its 
translation. By use o f exogenously supplied RNAi sequences, scientists have 
taken advantage o f this system to design new and powerful technologies for gene 
silencing (Nussbaum et al., 2007; Sandy et al. 2005). This enables scientists to 
analyse the effect o f a gene on cellular function in a quick and easy way.
Long double-stranded RNAs (dsRNAs; typically >200 nt) can be used to silence 
the expression o f target genes in many non-mammalian systems, such as worms 
fruit flies and plants (reviewed in Bantounas et al., 2004). Upon introduction, the 
long dsRNAs enter a cellular pathway that is commonly referred to as the RNAi 
pathway. First, an RNase Ill-like enzyme called Dicer cleaves the dsRNAs into 
20-25 nt small interfering RNAs (siRNAs). Next the siRNAs assemble into 
endoribonuclease-containing complexes known as RNA-induced silencing
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complexes (RISCs), unwinding in the process. The antisense siRNA strand 
subsequently guides the RISCs to complementary RNA molecules, where they 
cleave and destroy the cognate RNA (effect step). Cleavage of cognate RNA 
takes place near the middle o f the region bound by the siRNA strand, leading to 
specific gene silencing (Fig 6.1, A).
Upon introduction o f long dsRNA (>30 nt), most mammalian cells initiate a 
potent antiviral response, exemplified by non-specific inhibition of protein 
synthesis and RNA degradation. To bypass the antiviral response in mammalian 
cells, RNAi is induced to these systems by either transfecting cells with siRNA 
(typically 21 bp RNA molecules with 3’ dinucleotide overhangs) or by using 
DNA based vectors to express short hairpin RNA (shRNA) that are processed by 
Dicer into siRNA molecules (Elbashir et al.2001, Caplen et al. 2001, Caplen & 
Mousses, 2003; Hutvagner et al. 2001; Hutvagner, 2005) (Fig 6.1, B and C, 
respectively).
Aims
The aims of this study were to investigate
1) The autocrine effect o f VEGF on PEDF, VEGFR-1, VEGFR-2 and PS-1 
expression in cultured HRPE cells by knockdown o f the VEGF gene using VEGF- 
siRNA.
2) The paracrine effect o f VEGF/PEDF on VEGFR-1, VEGFR-2 and PS-1 
expression in cultured HRPE cells by knockdown of the VEGF gene prior to the 
addition of exogenous VEGF /PEDF.
6.2 Project design
In order to meet the goals o f this study, the experiment was designed to be 
carried out in four stages: 1) preparation of VEGF-siRNA, 2) evaluation of the 
specificity and efficiency o f the VEGF-siRNA, 3) establishment of analytical 
methods for analysis o f the effect of VEGF-siRNA and 4) correlating silencing 
with biological effect. A flow chart for the experimental design is shown in 
Fig.6.2.1. & Fig 6.2.2.
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Fig 6.1 The RNAi Pathw ay. (A) In non-mammalian systems, the RNAi 
pathway commences when dsRNA (>30bp) is introduced into cells. In 
mammalian systems RNAi can be triggered by DNA based expression vectors 
designed to express (B) short hairpin RNA (C) or synthetic siRNA molecules .
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Stage 1 Preparation of VEGF-siRNA
Design siRNA sequence(s) (targeted 
/  non targeted)
Purchase oligonucleotides
I
siRNA synthesis by in vitro transcription
I
Estimation of siRNA concentration / integrity
Stage 2 Evaluation of the specificity and efficiency 
of the VEGF-siRNA
Plate out cells at the recommended density
siRNA transfection with HRPE cells 
at defined concentrations 
for defined time course
I
Harvest cells for RNA / protein extraction 
and
collect medium for protein level analysis
Fig 6.2.1 Flow chart of experimental design for chapter 6.
141
Chapter.6. Yadan Zhang
Stage 3 Downstream analysis method(s) for 
analysis of the effects of VEGF-siRNA
Design primers 
( V E G F / P E D F / V E G F R 1A /E G F R 2 / G APDH) for RT-PCR
Purchase primers
I
Optimise annealing temperature and program  
for each pair of primers
Stage 4 Correlating silencing with biological effect
Silencing V E G F  using optimised concentration and time-point
r
Monitoring 
the efficiency of the siRNA
Harvest cells 
for RNA /  protein extractions 
and
Collection of medium
4
R T -P C R  
W estern blotting 
ELISA
T  reatment 
with various growth factors 
for a defined time course
\
Harvest cells 
(RNA /  protejn extraction)
Analysing the effect of VEG F-siRNA  
On PEDF/R1/R 2/PS1  
at m RNA / protein level 
By R T-P C R  / W estern blotting
Fig 6.2.2 Flow chart o f experimental design for chapter 6.
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6.3 Materials & Methods
6.3.1 HRPE cell culture
The isolation, culture and characterisation of HRPE cells were performed as described 
in 2.2.1. Cells were used within passage 3.
6.3.2 Preparation o f siRNA
By in vitro transcription, siRNAs were constructed using the Silencer siRNA 
Construction Kit (Ambion, Inc.USA). This kit overcomes the sequence 
requirements o f traditional in vitro transcription strategies by using siRNA 
template oligonucleotides containing a ‘leader’ sequence that is complementary to 
the T7 promoter Primer included in the kit. The procedures fo r constructing 
siRNA were as recommended by the manufacture and shown in Fig 6.3.
6.3.2.1 siRNA Design
siRNA specific for human VEGF was designed in two steps according to the 
instruction of “siRNA Design” that is recommended by Ambion 
(www.ambion.com/techlib/misc/siRNA design.html).
The first step was to find 21 nt sequences in the target mRNA that begin with an 
AA dinucleotide, based on the observation by Elbashir et al. (2001) that siRNA 
with 3’ overhanging UU dinucleotides are the most effective. The potential 
siRNA target sites were selected with 21 nt sequences in the target mRNA that 
begin with an AA dinucleotide. In order to avoid the cleavage by RNase at 
single-stranded G residues, the sequence within G residues in the overhang were 
excluded; the siRNA with 30-50% G/C content was selected rather than those 
with a higher G/C content.
The second step was to convert the designed siRNA sequence into 
oligonucleotides based on the following guidelines: 1) The DNA counterpart 
(antisense template oligonucleotide) o f the target mRNA sequence should have 
the same sequence as the target RNA but U residues are replaced with T’s. 2)
The sense template oligonucleotide should start with an AA dinucleotide at the 5’
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Fig 6.3 Silence siRNA Construction Kit Procedure (Adapted from 
the Silencer®  siRNA Construction Kit manual)
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end followed by 19 nt that are complementary to the target sequence. 3) The 8 nt 
at the 3’ end o f both oligonucleotides should have the following sequence: 5’- 
CCTGTCTC-3’ (which is complementary to the T7 promoter Primer provided 
with the Silencer siRNA Construction Kit). Table 6.1 shows the sequences of 
the DNA oligonucleotides that were ordered from Sigma-Aldrich.
Table 6.1 Sequences o f the oligonucleotides for VEGF-siRNA and scrambled 
siRNA.
Sequence (5’-3’)
siVEGFant AAACCTCACCAAGGCCAGCACCCTGTCTC
siVEGFsen AAGTGCTGGCCTTGGTGAGGTCCTGTCTC
cVEGFant AAACTACCGTTGTTATAGGTGCCTGTCTC
cVEGFsen AACACCTATAACAACGGTAGTCCTGTCTC
6.3.2.2 Construction o f siRNA
6.3.2.2.1 Preparation o f  transcription template
The sense and antisense template oligonucleotides (DNA) for each siRNA must 
be converted to dsDNA with a T7 promoter at the 5’ end to make an efficient 
transcription template. This is accomplished by hybridising the 2 
oligonucleotides to the T7 Promoter Primer provided with the Silencer siRNA 
Construction Kit and extending the T7 promoter Primer and template 
oligonucleotides using a DNA polymerisation reaction.
Purchased DNA-oligonucleotides were resuspended in nuclease-free water to a 
final concentration o f 200 pM.
To hybridise each template oligonucleotide to the T7 Promoter Primer. 2 pi of T7 
Promoter Primer, 6 jllI o f  DNA Hyb Buffer and 2 pi o f either sense or antisense 
template oligonucleotide were mixed together in separate tubes and heated to 
70°C for 5 minutes, then left at room temperature for 5 minutes. Then the 
following were added: 2 pi o f lOx Klenow Reaction Buffer, 2 pi o f lOx dNTP
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Mix, 4 pi o f Nuclease-free water and 2 pi o f Exo-Klenow and incubated at 37°C 
for 30 minutes.
6.3.2.2.2 Synthesis o f  dsRNA
Transcription was performed in 20 pi o f transcription mix: 2 pi of sense or 
antisense siRNA template, 4 pi o f Nuclease-free water, 10 pi of 2x NTP Mix, 2 
pi of lOx T7 Reaction Buffer and 2 pi o f T7 Enzyme Mix. This was incubated at 
37°C for 2 hours, and then the sense and antisense transcription reaction were 
combined into a single tube and incubated overnight at 37°C.
6.3.2.2.3 Preparation and Purification o f  siRNA
The dsRNA made by in vitro transcription has a 5’ overhanging leader sequences 
that must be removed prior to transfection. The leader sequence is digested by a 
single-strand specific ribonuclease, RNase and DNase. This was achieved by 
adding 6 pi o f Digestion Buffer, 48.5 pi o f Nuclease-free water, 3 pi of RNase 
and 2.5 ul o f DNase to the tube o f dsRNA from 6.3.2.2.2., and incubating at 
37°C for 2 hours. The siRNA was eluted by adding 400 pi siRNA Binding 
Buffer to the nuclease digestion reaction and incubated at room temperature for 
2-5 minutes. The resulting siRNA was purified by glass fiber filter binding and 
elution which removes excess nucleotides, short oligomers, proteins, and salts in 
the reaction. The end product was a double-stranded 21-mer siRNA with 3’ 
terminal uridine dimers that can effectively reduce the expression of target 
mRNA when transfected into mammalian cells.
6.3.2.3 siRNA quantification
The concentration o f the siRNA synthesised was measured by diluting a small 
sample of the siRNA 1:25 into TE (10 mM Tris-HCl pH8, ImM EDTA) and 
reading the absorbance at 260 nm in a spectrophotometer.
The concentration o f the purified siRNA in pg/ml was determined by multiply 
the absorbance reading by 1,000 (1,000 = 25-fold dilution x 40 pg siRNA/ml per 
absorbance unit).
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The molar concentration o f the siRNA in p,M was determined by dividing the 
pg/ml concentration o f the siRNA by 14 (there are 14 pg o f RNA in 1 nmole of 
an average 21-mer dsRNA: 21nt x 2 strands = 42 nt x 0.333 pg/nmol for each nt 
= 14 pg/nmol).
6.3.2.4 Estimation o f siRNA integrity
The integrity o f the siRNA was determined by analysis o f 4ul o f siRNA sample, 
which was mixed with gel loading buffer at 5:1 (sample: buffer), on a 2 % 
agarose gel (0.05 ug/ml ethidium bromide) in TBE buffer at 80 volts. 
Electrophoresis was stopped when the bromophenol blue dye front had migrated 
two-thirds o f the way down the gel.
6.3.3 siRNA Transfection
The choice o f siRNA concentration for transfection is critical to the success of 
gene silencing experiments. Transfecting too much siRNA caused non-specific 
reductions in gene expression and toxicity to the transfected cells. Transfecting 
too little siRNA does not change the expression o f the target gene.
The choice o f a transfection agent for delivery o f siRNA is critical for gene 
silencing experiments. Without efficient transfection siRNA will fail to elicit a 
cellular response. The Silencer® siRNA Transfection II Kit (Ambion, Inc.USA) 
provides two different transfection agents, siPORT NeoFX  and siPORT Amine. 
siPORT NeoFX  is a proprietary mixture o f lipids and is compatible with a wide 
range of cell lines and experimental designs. siPORT Amine is a proprietary 
blend of polyamines that delivers siRNA into mammalian cells with minimal 
cytotoxicity. Both transfection reagents function by complexing with siRNAs 
and facilitating their transfer into cells. In this study, siPORT Amine was chosen 
to deliver siRNA into cells, as it has been used successfully in HRPE cells by 
other users (Li et al., 2005).
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In order to provide good gene knockdown while maintaining an acceptable level 
of cell viability for the particular cell type, optimisation had to be carried out to 
determine the conditions that produced the best results.
VEGF-siRNA (0, 5, 10, 20, and 30nM) was transfected into HRPE cells for a 
defined time course o f 24, 48 and 72 hours. Scrambled siRNA, at the 
correspondent concentration to the siRNA, was transfected into HRPE cells as a 
control (detailed in section 6.3.4).
Approximately 24 hours before transfection, RPE cells were plated in normal 
growth medium at a cell density o f 2x105 ( lx l0 5cell /ml) in 6-well plates, to give 
50% to 70% confluency after 24 hours. In sterile polystyrene tubes, siPORT 
Amine was diluted into Ham ’s F-10 medium to the concentration recommended 
by the manufacturer and incubated at room temperature for 30 minutes. Next 
siRNA was added to the diluted siPORT Amine Transfection Agent and 
incubated at room temperature for 20 minutes. After renewing the normal growth 
medium in each well, the Transfection Agent and siRNA complex was overlaid 
onto the cells. Following incubation o f cells under normal cell culture conditions 
for 24 hours, 1 ml/well o f fresh 10% FCS Ham’s F-10 was added. The cells 
were harvested at 24, 48 and 72 hours post transfection for analysis. The 
medium from each time point also collected for assays.
6.3.4 siRNA controls (Whither RNAi? 2003)
In order to monitor the efficiency, non-targeting effect or cytotoxicity effect of 
the siRNA, the following controls were included in each assay: 1) a negative 
control siRNA (also called scrambled siRNA or non-targeting siRNA). This was 
designed by scrambling the nucleotide sequence o f the gene-specific siRNA and 
lacked significant sequence homology to the genome. This scrambled siRNA 
was included in each assay in order to identify non-specific effects such as non- 
sequence-specific siRNA effects, cytotoxicity o f the transfection agent and/or the 
siRNA, or suboptimal transfection conditions; 2) a transfection reagent-only 
control was included for any nontransfection related phenomena; 3) a non­
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treatment control which only has normal medium was included. 4) GAPDH 
(glyceraldehyde-3-phosphate dehydrogenase) was included to monitor the 
efficiency o f the siRNA, and the effect on the targets involved in the down­
stream biological function.
Apart from the controls listed above, the efficiency of the siRNA was monitored 
at the mRNA level using semi-quantitative and protein level using quantitative 
approaches. In order to reduce the chance of side effects as well as providing 
grade readout o f the effect the siRNA was titrated to the lowest possible level.
6.3.5 RNA extraction
6.3.5.1 Homogenisation o f HRPE cells
(R)Cells were lysed directly in a well o f a 6-well plate by adding 1 ml of TRIzol 
Reagent (Invitrogen) and passing the cell lysate several times through a pipette. 
The lysate was collected into an eppendorf tube and stored at -80°C until further 
steps were carried out.
6.3.5.2 Phase separation
The homogenised samples were incubated for 5 minutes at room temperature to 
permit the complete dissociation o f nucleoprotein complexes. Chloroform (0.2 
ml /sample) was added to the RNA-containing TRIzol, mixed by inverting the 
tube several times and allowed to stand for 5 minutes at ambient temperature. 
The whole contents were transferred into a phase lock gel tube and centrifuged at 
12,000g for 15 minutes at 4°C. The upper RNA-containing aqueous phase was 
separated and transferred to a new eppendorf tube. All reagents and plasticware 
used for RNA extraction were RNase free.
6.3.5.3 RNA precipitation
The RNA in the aqueous phase was precipitated by mixing with an equivalent 
volume o f isopropanol (Sigma, USA). Samples were incubated at room 
temperature for 10 minutes and centrifuged at 12,000g for 10 minutes at 4°C. 
The RNA precipitate, a gel-like pellet was located on the side/bottom of the tube.
149
Chapter 6 Yadan Zhang
6.3.5.4 RNA wash
The supernatant was removed and the RNA pellet washed once with 1 volume of 
75% ethanol. The sample was mixed by vortexing and centrifuged at 7,500g for 
5 minutes at 4°C.
6.3.5.5 Redissolving the RNA
The supernatant was removed and the RNA pellet was briefly air-dried for 5-10 
minutes. The RNA pellet was dissolved in 40 ul of RNase free water and 
incubated at 60°C for 10 minutes.
6.3.5.6 Estimation o f RNA concentration and integrity
RNA concentration was determined by spectrophometric analysis at a 
wavelength o f 260 nm and 280 nm (GeneQuant II, Pharmacy); an A260/A280 ratio 
of 1.8-2.0 is expected. The integrity o f the RNA was determined by analysis of 
lug on a 1.5% agarose gel (containing 0.05 ug/ml ethidium bromide) in TBE 
buffer at 100V for 45 -60 minutes. The ribosomal RNA bands (28S and 18S) 
were visualised by an UV transilluminator (UVIDOC, version 99.01).
6.3.6 RT-PCR (Revrse Transcription -Polymerase Chain Reaction)
6.3.6.1 Primer design and optimisation
Primers were designed, using Primer3, to the mRNA sequences of genes of interest 
for semi-quantifying cDNA samples and generating amplicons of <200bp. The 
sequences o f forward and reverse primer pairs are shown in Table 6.2.
Table 6.2 Oligonucleotide primer sequences.
Gene Primer sequence ^Anneal
(°C)
Product
size(bp)
VEGF F. 5 ’ - GGG CA G  A A T CA T CAC GAA G T 
R. 5 ’ -  TGG TG A  TG T TGG A CT CCT CA
58 211
PEDF F .5 ’-G TG  GCA C C T CTG GAA AAG TC 
R .5 ’-ACC GAG A A G  GAG A A T GCT GA
58 165
VEGFR1 F .5 ’- TG T  CAA TG T GAA A CC CCA GA 
R .5 ’- GTC A C A  CC T TGC TTC GGA AT
58 175
VEGFR2 F .5 ’-AG C G A T GG C CTC TTC TG T AA 
R .5 ’-A C A  CGA CTC C A T G TT G G T CA
58 172
GAPDH F .5 ’-TG A  TGA C A T CAA CAA G G T G GT GAA 
R .5’-TC C TTG  GAG GCC ATG TGG GCC AT
58 235
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The annealing temperature for each primer pair was optimised using the 
programme shown in the Table 6.3 with a gradient annealing temperature from 
50°C to 62°C. The temperature that produced a single band with strongest signal 
was chosen as the annealing temperature for each pair of the primer. The 
optimised associated annealing temperature for each pair of primers used in this 
study is shown in the Table 6.3.
Table 6.3 Program used for PCR reaction.
Programme Cycle Numbers
Initial denaturation 94°C, 5 min 1 cycle
Denaturation 94°C, 30 sec
Annealing 58°C, 30 sec I 35 cycles
Extension 72°C, 1 min J
Final extension 72°C, 7 min 1 cycle
6.3.6.2 Reverse transcription
cDNA was produced by priming lug RNA (~11 pi) with 1 pi (500 ng/pl) of 
anchored oligo dT (Abgene, UK) at 70°C for 5 minutes to remove any secondary 
structure then placed on ice immediately. Addition o f 4 pi of 5x First Strand 
Synthesis buffer, 2 pi dNTP mix (5mM each), l pi Reverse-iT™ RNase Blend 
and 1 pi 100 mM DTT were added. Samples were incubated at 47°C for 30 
minutes. The reaction was terminated by incubation o f the samples at 75°C for 
10 minutes. cDNA samples were stored at -20°C. All the reagents were from 
Reverse-iT™ 1st Strand Synthesis Kit purchased from Abgene (UK).
6.3.6.3 Polymerase chain reaction (PCR)
A standard PCR reaction was used to selectively amplify the gene products of 
interest. 2 pi o f cDNA and 0.5 pi combined forward and reverse primers (mix of
TM
0.25 pi forward and 0.25 pi reverse) were added to 22.5 pi of ReddyMix PCR 
Master Mix (Abgene, UK) resulted in a final reaction volume of 25 pi, 
containing 0.625 units Thermoprime Plus DNA Polymerase, 75 mM Tris-HCl,
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20 mM (NH4)2S 0 4, MgCl2 and 0.01% (v/v) Tween® 20 and dNTPs (0.2mM 
each).
Reactions were performed using the program shown in Table 6.3. on a PCR 
mechine (PTC-220 DNA Engine Dyad™ Peltier Thermal Cycler —MJ Research 
Inc. USA).
6.3.6.4 Detection o f RT-PCR product
The RT-PCR products were detected by gel electrophoresis. 1.5% Agarose gel 
was prepared by dissolving 1.5 g o f Agarose powder (Sigma-Aldren, USA) in 
100 ml of lx  Tris-Borate-EDTA (TBE) buffer (Sigma-Aldren, USA) containing 
0.05 ng/ml o f Ethidium Bromide (Sigma).
6.3.7 Quantification of VEGF/PEDF by Enzyme-Linked Immunosorbent 
Assay (ELISA)
The total amount o f VEGF or PEDF in the cell culture medium was quantified 
using an ELISA kit specific for VEGF 165 (R&D Systems, Minneapolis, MN, 
USA) and PEDF (Chemicon Inc.) according to the manufacturers’ instructions.
6.3.7.1 Principle o f the assay
This assay employs the quantitative sandwich enzyme immunoassay technique. 
A monoclonal antibody specific for VEGF has been pre-coated onto a 
microplate. Standards and samples are pipetted into the wells and any VEGF 
present is bound by the immobilised antibody. After washing away any unbound 
substances, an enzyme-linked polyclonal antibody specific for VEGF is added to 
the wells. Following a wash to remove any unbound antibody-enzyme reagent, a 
substrate solution was added to the wells and colour develops in proportion to the 
amount of VEGF bound in the initial step. The colour development is stopped 
and the intensity o f the colour is measured (Fig 6.4).
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Figure 6.4 Schematic representation of the Enzyme- Linked 
Im m unosorbent Assay (ELISA) (Modified from Emma Blain, PhD Thesis, 
2002).
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6 3 .1 2  Procedures o f the assay
The recombinant VEGF standard was reconstituted with 1 ml of Calibrator 
Diluent RD5K to a stock solution of 2000 pg/ml, and a serial 2-fold dilution was 
prepared to produce a standard curve ranging from 31.2 pg/ml to 1000 pg/ml. 
All other reagents were reconstituted according to manufacturer’s instructions.
Standards, samples and buffer blanks (200 pi) were pippeted into the wells in 
triplicates and incubated at room temperature for 2 hours. Wells were aspirated 
and rinsed 4 times in wash buffer to remove unbounded VEGF containing 
sample. 200 pi o f recombinant anti-VEGFi65 polyclonal antibody conjugated to 
horseradish peroxidase (HRP) was added to the wells. The HRP-conjugated 
antibody binds the captured VEGF moiety. After additional 2 hours incubation at 
room temperature, the wells were again rinsed 3 times and 200 pi of hydrogen 
peroxide and tetramethylbenzidine were added. The reaction was stopped by the 
addition of 50 pi o f 2N sulphuric acid (Stop Solution). The absorbance o f each 
well was measured spectrophotometrically at 450 nm and plotted against a 
standard curve with VEGF levels expressed as ng/ml. The lower detection limit 
of the ELISA assay is 5.0 pg/ml. Each sample was analysed in triplicate.
6.3.8 Western Blotting
Western blotting was used to analyse the effect o f VEGF-siRNA on VEGFR-1, 
VEGFR-2 and PS-1 expression in HRPE cells with or without additional growth 
factor treatment. The procedures o f western blotting were the same as described 
in section 4.2.6.
6.3.9 Statistical analysis
The results are given as the mean ± standard error (SEM). Students T-test was 
performed to analyse the data (SPSS). A p  value less than 0.05 (p<0.05) was 
considered statistically significant.
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6.4 Results
6.4.1 The efficiency and specificity of the VEGF-siRNA
6.4.1.1 siRNA concentration and integrity
The concentration and purity o f the siRNAs were estimated by 
spectrophotometer, and the result revealed that approximately 100-130 ug (in 
100 pi volume) o f siRNA was synthesised by in vitro transcription using the kit. 
The integrity o f the siRNA was confirmed by gel electrophoresis (Figure 6.5).
The siRNAs synthesised show similar size and density when compared with the 
GAPDH-siRNA (Fig.6.5 column 5) which was provided within the Kit.
6.4.1.2 RNA concentration and integrity
The concentration and purity o f the RNA was estimated by spectrophotometer. 
The results revealed that approximately 7-15 pg (in 30 pi o f volume) o f total 
RNA was extracted from a 6-well plate when cells were at 50-95% confluence. 
Mean A260/A280 ratios o f 1.805 ± 0.156 (n=3) were obtained. The integrity of 
the RNA was confirmed by gel electrophoresis using lug/sample, and the 
intensity of the band from siRNA treatment /scrambled siRNA / non-treatment 
were similar: sharp, clear 28S and 18S rRNA bands were observed in the 
samples with VEGF-siRNA treatment and the samples with the scrambled 
siRNA or no treatment. The 28S rRNA band is approximately twice as intense as 
the 18S rRNA band; and this 2:1 ratio (28S:18S) is a good indication that the 
RNA is intact (Figure 6.6).
6.4.1.3 siRNA effectively and specifically suppressed VEGF mRNA in HRPE 
cells
In a time course o f 24, 48 and 72 hours, the efficacy and potency of the siRNA 
targeting VEGF was assessed by monitoring VEGF mRNA levels in cells that 
had received a range of siRNA concentrations (0, 5, 10, 20 and 30 nM), and 
compared to that in cells treated with a nontargeting negative control siRNA 
(scrambled siRNA) at the corresponding concentration, and in cells without any 
treatment (Fig. 6.7)
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1 2 3 4 5
CVE-C1 siVE-C1 CVE-C3 siVE-C3 Pos control
Fig 6.5 The intergrity and quality of VEGF-siRNA synthesed by in vitro 
transcription (2% Agarose gel). Lanel and 3 are scrambled siRNA synthesed 
at separated times (cVE-Cl and cVE-C3); lane 2 and 4 are VEGF-siRNAs 
(siVE-Cl and siVE-C3); lane 5 is GAPDH-siRNA provided with the 
Transfection kit (Positive control).
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24h
VEGF-siRNA Control
Scrambled
-siRNA Control
s30  s20  s10  s5 c30 c20 c10 c5
28S
rRNA
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rRNA
B 48 h
VEGF-siRNA
_____sK_____
Lad s30  s20  s10  s5
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-siRNA
_____A_____
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Scrambled
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ControlVEGF-siRNA Control
Fig 6.6 The integrity and quality of total RNA extracted by Trizol Reagent 
and analysed by 1.5% Agarose gel. A: total RNA extracted from cells 24 
hours post transfection with various concentration o f VEGF-siRNA (5-30 nM) 
and correspondent scrambled siRNA and controls; B: total RNA extracted from 
cells 48 hours post transfection; C: total RNA from 72 hours post transfection. 
Lad = DNA ladder; s30 = 30 nM of VEGF-siRNA; c30 = scrambled siRNA 30 
nM; 0-r = control o f transfection reagents only and 0 = non-treatment control.
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24 h
48h
72h
siRNA
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Fig 6.7 Time course of VEGF mRNA reduction by various concentrations 
of VEGF-siRNA analysed by RT-PCR on 1.5% Agarose gel. s30 = 30 nM of
VEGF-siRNA; c30 = scrambled siRNA 30 nM; 0-r = control of transfection 
reagents only and 0 = non-treatment control.
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By densitometric analysis, RT-PCR results showed that at 24 hours post 
transfection, the maximum silencing effect was 23.5 ± 3.65% of the control 
(76.41±3.56% remained) (n=3, p=0.0282) with 30 nM of VEGF-siRNA 
[Fig.6.7.1. A (VEGF) and B], whereas GAPDH mRNA from the corresponding 
samples had no change [Fig 6.7.1. A (GAPDH) and C].
At 48 hours post transfection, the maximum silencing effect 67.384 ± 2.295% 
(32.616 ± 2.295% remained) (n=3, p=0.0013) was observed with 30 nM VEGF- 
siRNA [Fig 6.7.2 A(VEGF) and B] whereas GAPDH mRNA from the 
corresponding samples had no change [Fig 6.7.2. A (GAPDH) and C].
At 72 hours post transfection, the maximum silencing effect was 67.688 ± 7.59 
% (32.312 ± 7.585 % remained) (n=3, p=0.013) with 30 nM of VEGF-siRNA 
[Fig 6.7.3.A (VEGF) and B], whereas GAPDH mRNA from the corresponding 
samples had no change [Fig 6.7.3. A (GAPDH) and C].
In summary, the densitometric analysis revealed that the maximum silencing 
effect on VEGF mRNA was observed at 48 hours post transfection with 30 nM 
of VEGF-siRNA (Fig 6.7.4).
6.4.1.4 siRNA effectively and specifically suppressed VEGF protein in HRPE 
cells
The efficacy and potency o f the siRNA targeting VEGF were also tested by 
monitoring VEGF at protein levels in the medium from the cells that had 
received a range o f siRNA concentrations, and compared to that in cells treated 
with a nontargeting negative control siRNA and in cells without any treatment. 
To correspond with the time points for mRNA analysis, the medium was 
collected at 24, 48 and 72hours. VEGF protein was determined by ELISA in 
triplicates.
The VEGF ELISA result revealed that the standard curve generated using VEGF 
standards showed a linear regression between the Optical Density (OD) unit and
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Controls Scrambled siRNA Controls
VEG F
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B
siRNA
S30 s20
— u -
30nM 20nM CnM 5nM 0-r
■ VEGF-siRNA 76.406 85.271 00.238 99.502 01654
■ scrambled siRNA 99.767 C0.017 03  042 00.684 02.291
□ Non-treatment CO CO CO CO CO
siRNA concentration (nM)
M
it 100 -
30nM 20nM OnM 5nM 0-r
■ VEGF-siRNA 00.893 01382 00.596 00.03 00.544
■ Scrambled siRNA 00.726 00.447 02.732 00.692 00.978
O Non-treatment CO 00 00 CO 00
siRNA concentration (nM)
Fig 6.7.1 Efficiency of VEGF-siRNA on VEGF mRNA expression at 24 hrs 
post-transfection by RT-PCR. (A) RT-PCR analysis of VEGF/GAPDH 
expression on 1.5% Agarose gel. (B & C) are densitometric analysis o f RT-PCR 
depicted in (A-VEGF) and (A-GAPDH), and are presented as the relative ratio of 
VEGF or GAPDH to the control from 3 separate experiments, respectively. 
Vertical bars are mean ±  SEM. *p <0.05. At 24 hours post transfection, the 
maximum silencing effect was 23.5 ± 3.65% (75.4 ± 3.65% remaining) with 30 
nM of siRNA-VEGF.
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Fig 6.7.2 Efficiency of VEGF-siRNA on VEGF mRNA expression at 48 hrs 
post-transfection by RT-PCR. (A) RT-PCR analysis of VEGF and GAPDH 
expression on 1.5% Agarose gel. (B  & C) are densitometric analysis of RT-PCR 
depicted in (A-VEGF) and (A-GAPDH), and are presented as the relative ratio of 
VEGF or GAPDH to the control from 3 separate experiments, respectively. 
Vertical bars are mean ± SEM. *p <0.05; ** p<0.01. At 48 hours post 
transfection, the maximum silencing effect was 67.38 ± 2.295% (32.62 ± 2.295% 
remaining) with 30 nM of siRNA-VEGF.
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Fig 6.7.3 Efficiency of VEGF-siRNA on VEGF mRNA expression a t 72 hrs 
post-transfection by RT-PCR. (A) RT-PCR analysis of VEGF and GAPDH 
expression on 1.5% Agarose gel. (B & C) are densitometric analysis of RT-PCR 
depicted in (A-VEGF) and (A-GAPDH), and are presented as the relative ratio of 
VEGF or GAPDH to the control from 3 separate experiments, respectively. 
Vertical bars are mean ± SEM. *p <0.05. At 72 hours post transfection, the 
maximum silencing effect was 67.688 ± 7.59% (32.31 ± 7.59% remaining) with 
30 nM of siRNA-VEGF.
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Fig 6.7.4 Summ ary of the maxim um  silencing effect on VEGF mRNA 
expression. VEGF-siRNA at 20 nM and 30 nM decreased VEGF mRNA 
expression by 48 hours. This was sustained at 72 hrs using the higher 
concentration of VEGF-siRNA (30 nM).
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a series titrations o f loaded VEGF (y =0.0015X+0.0211, R2 = 0.9998) (Fig.6.8. 
A). This allowed the amount o f VEGF to be calculated in experimental samples.
At 24 hours post transfection, the reduction o f VEGF protein was 11.54 ± 3.05% 
(88.46 ± 3.05% remained) (n=3, p=0.0307) with 30nM of VEGF-siRNA; at 48 
hours post transfection, the reduction o f VEGF protein was 43.12 ± 1.952% 
(56.89 ± 1.952% remaining) (n=3, p=0.0168) with 30 nM of VEGF-siRNA; at 
72hours post transfection, the reduction of VEGF protein was 17.51 ± 4.509% 
(82.49 ± 4.509% remaining)(n=3, p=0.1127) (Fig 6.8.B). The VEGF protein in 
the samples that were transfected with scrambled siRNA-VEGF showed no 
reduction in the correspondent time points (Fig 6.8.B dark-red bar).
In summary, the VEGF ELISA analysis revealed that the maximum silencing 
effect on VEGF protein was observed at 48 hour post-transfection with 30nM of 
VEGF-siRNA (Fig 6.8.C). The 30nM concentration o f VEGF-siRNA and the 
time-point o f 48 hours were chosen for the down-stream study.
6.4.2 The effects of VEGF-siRNA on PEDF, VEGFR-1, VEGFR-2 and PS- 
1 expression and the autocrine loop
To assess the biological effects o f VEGF silencing, it is critical to perform these 
assays during the time frame in which silencing is most profound. Based on the 
optimisation results described in section of 6.4.1.3 and 6.4.1.4, the time point of 
48 hours post transfection with 30nM VEGF-siRNA was chosen to analyse the 
effect of VEGF-siRNA on PEDF/VEGFR-1 /VEGFR-2 and PS-1.
6.4.2.1 The effects o f VEGF-siRNA on PEDF mRNA and protein expression 
The effects o f VEGF-siRNA on PEDF expression were assessed by monitoring 
PEDF mRNA levels in cells /or PEDF proteins in the medium of the cells that 
had received a range o f siRNA concentrations for 48 hours compared to that in 
cells treated with scrambled siRNA or cells without any treatment (Control).
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Fig 6.8 The effects of VEGF-siRNAs on VEGF protein. (A) Standard curve 
for quantifying VEGF protein in the culture media by ELISA. (B) The remaining 
VEGF protein is presented as the relative ratio o f VEGF to the control from 3 
separate experiments. Vertical bars are mean ± SEM. *p <0.05. (C) Summary of 
the silencing effect on VEGF protein with 30 nM of VEGF-siRNA at 24, 48 and 
72 hrs post-transfection. The maximum silencing effect was 43.12% at 48 hour 
post transfection.
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RT-PCR results show that at 48 hours post transfection, the reduction of PEDF 
mRNA was 43.36 ± 5.779% (56.63±5.779% remaining) (n=3, p=0.0166) with 30 
nM VEGF-siRNA, whereas the correspondent scrambled siRNA has no 
significant effect on PEDF mRNA expression when compared with the control 
(Fig. 6.9 A & B).
At the protein level, the PEDF ELISA result revealed that the standard curve, 
generated using PEDF standards, showed a linear regression between the Optical 
Density (OD) unit and a titration series o f loaded PEDF (y =0.1171X+0.9946, R2 
= 0.9864) (Fig.6.10. A). This allowed the amount of PEDF to be calculated in 
experimental samples. At 48 hours post transfection, the reduction of PEDF 
protein was 55.96 ± 1.607% (44.05 ± 1.607% remaining) (n=3, p=0.0468) with 
30 nM of VEGF-siRNA (Fig 6.10 B).
6.4.2.2 The effect o f VEGF-siRNA on VEGFR-1 mRNA and protein expression 
The effects o f VEGF-siRNA on VEGFR-1 expression were tested by monitoring 
VEGFR-1 at mRNA and protein levels in the cells that had received 30nM of 
VEGF-siRNA for 48 hours, and compared to that in cells treated with the 
scrambled siRNA or cells without any treatment.
RT-PCR showed that VEGF-siRNA at 30 nM had no significant effect on the 
mRNA expression o f VEGFR-1, which is similar to the effect on the samples 
with scrambled siRNA and the samples without any treatment (Fig 6.11 .A).
Western blot analysis showed that VEGF-siRNA (30 nM) reduced the 75 and 85 
kDa fragments (p=0.0453) o f VEGFR-1 (n=3) (Fig. 6.11. B&C).
6.4.2.3 The effect o f VEGF-siRNA on VEGFR2 mRNA and protein expression 
RT-PCR results show that VEGF-siRNA at 30 nM had no significant effect on 
the mRNA expression o f VEGFR-2, which is similar to the effect on the samples 
with scrambled siRNA and the samples without any treatment (Fig 6.12 A)
166
Chapter 6 Yadan Zhang
Controls Scrambled siRNA ControlssiRNA
GAPDH
B 150
_  100
5 0 -
-
30 nM 20 nM 10 nM 5nM . 0-r
■ VEGF-siRsA 56.63635 52.608 99.559 85.03916 88.46899
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Fig 6.9 The effects of VEGF-siRNA on PEDF mRNA expression in cultured 
HRPE cells 48 hours post transfection. (A) RT-PCR analysis of PEDF mRNA 
expression. (B) Densitometric analysis o f RT-PCR depicted in (A). Data are 
presented as the relative ratio o f PEDF/GAPDH to the control from 3 separated 
experiment. *p<0.05.
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Fig 6.10 The effects of VEGF-siRNA on PEDF protein expression in the 
medium of cultured H RPE cells at 48 hours post transfection. (A) Standard 
curve for quantifying VEGF protein in the culture media by ELISA. (B) The 
remaining VEGF protein is presented as the relative ratio of VEGF to the control 
from 3 separate experiments. Vertical bars are mean ± SEM. *p <0.05.
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Fig 6.11 The effects of VEGF-siRNA on VEGFR-1 expression in cultured 
HRPE cells 48 hours post transfection. (A) RT-PCR analysis of VEGFR-1 and 
GAPDH mRNA expression. Data shown is representative o f 3 separate 
experiments. (B) Western blot o f VEGFR-1 protein. Data is representative of 3 
separate experiments. Blots were stripped and reprobled for GAPDH. (C) 
Densitometric analysis o f Western blotting depicted in (B). Data is presented as 
the relative ratio o f VEGFR1 fragments/GAPDH to the control from 3 separated 
experiment. *p<0.05. **p<0.01.
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Fig 6.12 The effects of VEGF-siRNA on VEGFR-2 expression in cultured 
HRPE cells 48 hours post transfection. (A) RT-PCR analysis o f  VEGFR-2 and 
GAPDH mRNA expression. Data shown is representative of 3 separate 
experiments. (B) Western blot o f VEGFR-2 protein. Data is representative of 3 
separate experiments. Blots were stripped and reprobed for GAPDH. (C) 
Densitometric analysis o f Western blotting depicted in (B). Data is presented as 
the relative ratio o f VEGFR2/GAPDH to the control from 3 separate 
experiments.
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Western blot analysis showed that expression of VEGFR2 was not significantly 
reduced by VEGF-si RNA treatment. (Fig 6.12 B & C).
6.4.2.4 The effect o f siRNA-VEGF on PS-1 protein expression
Western blot analysis showed that VEGF-siRNA did not alter PS-1 expression (p
= 0.0788) (Fig 6.13).
6.4.3 The effects o f exogenous VEGF/PEDF on VEGFR-l/VEGFR-2/PS-l 
expression after transfection with VEGF-siRNA for 48 hours
6.4.3.1 The effects o f exogenous VEGF/PEDF on VEGFR-1
In order to elucidate the paracrine effect o f VEGF/ PEDF on VEGFR-1 
expression, HRPE cells were transfected with 30 nM of VEGF-siRNA in an 
attempt to knockdown the endogenous VEGF. Post transfection (48 hours) cells 
were treated with exogenous VEGF /PEDF /V+P /P+V respectively and a control 
without treatment was included. In addition cells that had only been exposed to 
the siRNA or cells that had only been exposed to growth factors were also 
included for comparison.
Western blot analysis showed that VEGF-siRNA reduced both the 75 & 85 kDa 
fragments o f VEGFR-1, but only the 75 kDa reduction was statistically 
significant (p<0.05); addition o f VEGF (100 ng/ml) overcame the effect of 
siRNA and increased the fragments to the level o f control, and was similar to the 
one without VEGF-siRNA that received exogenous VEGF treatment. In 
contrast, addition o f PEDF increased both fragments, but only the 75 kDa 
increased with statistical significance (p=0.0117). The combination of 
VEGF+PEDF /or PEDF+VEGF has a similar effect on the VEGFR-1 fragments 
to that of PEDF alone (p <0.05) (Fig. 6.14)
6.4.3.2 The effects o f exogenous VEGF / PEDF on VEGFR-2
The effect of VEGF /PEDF on the expression o f VEGFR-2 at post-transfection 
with VEGF-siRNA was analysed using the aliquots o f the same samples for
171
Chapter6 Yadan Zhang
ControlS cram bled
s iR N A
s iR N A
4 7 k D a
G A P D H
1 5 0 -.
B
TO
T reatm ent
Fig 6.13 The effect of VEGF-siRNA on PS-1 expression in cultured HRPE 
cells 48 hours post transfection. (A) Western blot of PS-1 protein. Data is 
representative of 3 separated experiments. Blots were stripped and reprobed for 
GAPDH. (B) Densitometric analysis o f Western blot depicted in (A). Data is 
presented as the relative ratio o f PS 1/GAPDH to the control.
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Fig 6.14 The effects of exogenous VEGF/PEDF on VEGFR-1 expression. (A)
Representative o f western blot o f VEGFR-1 expression. (B & C) Densitometric 
analysis of the 75 and 85 kDa bands in (A). Data are presented as the relative 
ratio of VEGFR-1/GAPDH to the control from 3 separate experiments. Vertical 
bars are mean ± SEM. *p <0.05; ** p<0.01 (treatment vs control).
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VEGFR-1 analysis. Western blotting showed that VEGF-siRNA did not 
significantly reduce VEGFR-2. The addition of VEGF followed by PEDF or vice 
versa significantly reduced VEGFR-2. Interestingly, exogenous VEGF, PEDF, 
VEGF+PEDF or PEDF+VEGF significantly reduced VEGFR-2 expression 
(p<0.05) (Fig. 6.15).
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Fig 6.15 The effects of exogenous VEGF/PEDF on VEGFR-2 expression.
(A) Representative of western blot o f VEGFR-2 expression. (B) Densitometric 
analysis of VEGFR-2 in (A). Data is presented as the relative ratio of VEGFR- 
2/GAPDH to the control from 3 separate experiments. Vertical bars are mean ± 
SEM. *p <0.05; ** p<0.01 (various treatment vs control).
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6.4.3.3 The effects o f exogenous VEGF / PEDF on PS-1 
Western blot analysis showed that VEGF-siRNA (30nM) has no significant 
effect on PS-1 expression; a similar result was observed following the addition of 
VEGF, PEDF, VEGF+PEDF or PEDF + VEGF (Fig 6.16).
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Fig 6.16 The effect of exogenous V EGF/PEDF on PS-1 protein expression.
(A) Representative o f western blot o f PS-1 expression. (B) Densitometric 
analysis of PS-1 bands in (A). Data is presented as the relative ratio o f PS- 
1/GAPDH to the control from 3 separate experiments. Vertical bars are mean ± 
SEM.
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6.5 Discussion
It has been demonstrated that RNAi mediated by siRNAs can specifically target 
the sequence(s) o f interest in either in vitro or in vivo models (Bantounas et al., 
2004). However, some concern has also arisen due to the observations of non­
specific inhibition o f protein synthesis and RNA degradation following the use of 
some siRNA and delivery vector combinations (Jackson et al., 2003).
In this study, VEGF-siRNA was used to address the role o f VEGF in relation to 
PEDF, VEGFR-1, VEGFR-2 and PS-1 in cultured HRPE cells. In order to 
ensure that the effect o f VEGF-siRNA on the down-stream signalling is the 
biological response rather than non-specific inhibition, the VEGF-siRNA used in 
this study was first tested for its specificity, efficiency and efficacy. A series of 
controls were set up alongside the experiments, such as scrambled siRNA, non­
treatment controls and house-keeping gene, GAPDH.
By monitoring total RNA quality, VEGF mRNA and protein level in cells that 
had received a range o f siRNA concentrations compared to that in cells treated 
with a scrambled siRNA, it was shown that the VEGF-siRNA had no effect on 
the total RNA level but reduced VEGF at both mRNA and protein levels in 
cultured HRPE cells in a dose and time-dependent manner. The specificity and 
efficiency of the VEGF-siRNA silencing was further confirmed by comparison 
with the house-keeping gene GAPDH and non-treatment controls. Hence, it was 
confirmed that the VEGF-siRNA used in this study was specifically silencing 
VEGF. In addition, the effectiveness and specificity o f the siRNA, constructed 
by in vitro transcription, in the suppression of VEGF expression in HRPE cells, 
suggests a promising approach towards the treatment o f CNV. This adds to a 
number of existing strategies to inhibit VEGF signal transduction, such as the 
development o f humanised neutralising anti-VEGF monoclonal antibodies, 
receptor antagonists, soluble receptors, antagonistic VEGF mutants, and 
inhibitors of VEGF receptor function (Moreira et al., 2007).
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Further more, a major finding o f this study is that VEGF has a close relationship 
with VEGFR-1, VEGFR-2 and PEDF in cultured HRPE cells. The time course of 
siRNA silencing o f VEGF mRNA and protein correlated well with decreased 
PEDF at transcript and protein level. This suggests that VEGF is up-regulating 
PEDF from the transcriptional level which is in agreement with published reports 
stating that VEGF up-regulated PEDF through VEGFR-1 in an autocrine manner 
(Ohno-Matsui et al. 2003).
The siRNA silencing o f VEGF mRNA and protein also correlated well with 
decreased VEGFR-1 at the protein level, but not at the mRNA level, suggesting 
that endogenous VEGF in HRPE cells upregulates VEGFR-1 post- 
transcriptionally. The consequence o f this kind o f regulation needs to be further 
investigated but could involve decreased degradation o f the receptors. The 
VEGF-siRNA has no significant effect on the expression of VEGFR-2 and the 75 
kDa high molecular weight (HMW) form of PS-1.
It was observed that the expression o f VEGFR-1 fragments in responding to 
exogenous VEGF/PEDF (when VEGF was inhibited by siRNA) was different 
from that when VEGF was not inhibited.
In response to exogenous PEDF or PEDF followed by VEGF, after about 68% of 
endogenous VEGF was silenced, the 75 kDa fragment o f VEGFR-1 increased.
This was in contrast to VEGFR-2 expression which was decreased, to a level 
similar to samples that had been exposed to VEGF and PEDF without inhibition 
of endogenous VEGF. These observations suggest that the autocrine and 
paracrine effects o f VEGF may need to be considered in the therapeutic strategic 
designing.
Dias et al., (2000) has reported that certain leukemic cells not only produce 
VEGF, but also acquire the capacity to express functional VEGFRs, which
177
Chapter 6 Yadan Zhang
results in the generation o f an endothelial-independent autocrine loop that 
supports leukemic survival and migration in vivo. Therefore, in VEGF- 
producing, VEGFR-expressing leukemias, generation of VEGF/VEGFR 
autocrine (endothelial-independent) and paracrine (endothelial-dependent) loops, 
may contribute toward leukemic growth. In assessing the relative contribution 
of paracrine and autocrine VEGF/VEGFR signalling pathways to the growth of 
human leukaemia in vivo , Dias et al., (2001) observed that targeting the paracrine 
or autocrine VEGF/VEGFR-2 signalling pathway delays leukemic growth, but it 
is not sufficient to cure inoculated mice. To achieve remission, both autocrine 
and paracrine pathways were targeted.
Furthermore, the effect o f VEGF-siRNA on the expression of PEDF observed in 
this study not only supports the data showing about the autocrine loop between 
VEGF and PEDF, but it also challenges the concept o f a reciprocal relation 
between VEGF and PEDF. This suggests that a single-targeted inhibition 
strategy may need to be replaced by a double- or multi-targeted inhibition.
In summary, this study demonstrates that siRNA, constructed using in vitro 
transcription methods, is efficient to silence the gene o f target with minimum of 
toxicity as reported by Li et al., (2005). This study demonstrates for the first 
time, the effects o f VEGF-siRNA on VEGFR-1, VEGFR-2, PEDF and PS-1 
expression in cultured HRPE cells, in that VEGF-siRNA down-regulates PEDF 
expression at both the transcriptional and protein level, while down-regulation of 
VEGFR-1 only occurs at the post-transcription level. Future work such as to 
examine the effects o f PEDF-siRNA on the expression o f VEGF, VEGFR-1, 
VEGFR-2 and PS-1 will provide insight into the relationship among these 
elements in HRPE cells.
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7.1 Introduction
Neovascularisation is one o f  the most vital biological processes required for the 
formation and physiological function of virtually all organs in both normal and 
disease states (Visconti et a l., 2002; Schmid and Varner, 2007).
An underlying common aetiology in pathological conditions, such as tumour 
growth and neovascular ocular diseases, is the proliferation o f aberrant blood 
vessels. Conversely, an inadequate blood supply can be seen in conditions, such 
as myocardial infarction and stroke. The importance o f neovascularisation in the 
above conditions has led to intensive research into viable therapies that target 
new blood vessel formation. Anti-angiogenic therapies, such as an anti-VEGF 
monoclonal antibody, soluble VEGF receptor chimeric proteins and VEGF 
antisense oligonucleotides, have been the focus o f the management of tumour 
growth and neovascular ocular disease with reasonable success. However, 
although reduction in tum our growth has been demonstrated, some side effects 
were also noted, including the inhibition o f local endothelial precursor cell (EPC) 
function in the retina and choroid. VEGF is a survival factor for all endothelial 
cells. Loss of VEGF may result in the inability o f resident vasculature to 
proliferate in response to injury and to maintain normal endothelial morphology. 
Examples of this include the fenestration observed in the choriocapillaris and the 
kidney glomerulae.
PEDF, a natural inhibitor o f  angiogenesis with neurotrophic and neuroprotective 
properties, has been identified in a wide variety o f tissues (Tombran-Tink et al., 
2003). The finding that PEDF is essential for maintaining avascularity (Dawson 
et al., 1999) and plays a critical role in preventing aberrant neovascularisation 
(Stell-mach et al., 2001) suggests that PEDF does not appear to harm the existing 
vasculature (Bouck, 2002). The inhibitory effect o f PEDF on vessel formation 
appears to be reversible when regulated, transient angiogenesis occurs in 
situations including tissue repair after injury (Tonnesen et al., 2000). PEDF has 
been shown to act by inhibition o f the angiogenic response to factors such as 
VEGF and fibroblast growth factor. These features make PEDF an attractive 
angiogenic inhibitory agent which may avoid the side effect o f anti-VEGF
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agents. However, controversy exists over the role o f PEDF. There is compelling 
evidence to suggest that PEDF has a dual role in the regulation of 
neovascularisation as reported by Hutching et a l ,  (2002) and Apte et a l, (2004). 
Depending on the maintenance o f endothelial cells (EC)’s phenotype, PEDF can 
exert opposing effects on EC proliferation (Hutching et a l  2002) in cultured 
BRMECs. In an animal study, Apte et a l  (2004) observed that low doses (90 
pg/ml) of PEDF had a significant inhibitory effect on CNV in mice, while a high 
dose (360 fig/ml) o f PEDF augmented the development o f neovascularisation. 
Therefore an understanding o f the mechanism of PEDF’s action is central to 
achieving a therapy with maximal effect.
Three research groups (Yabe et a l, 2001; Hutchings et a l, 2002; Volpert et a l, 
2002) have suggested different signalling pathways that PEDF may be involved 
in, though none o f these fully explains the role o f PEDF. Recently a fourth 
signalling pathway has been suggested by Cai et a l (2006). They demonstrated 
that the inhibitory effect o f PEDF on VEGF-induced angiogenesis results from 
the inhibition o f VEGFR-2 in BRMECs. This inhibitory effect was achieved by 
enhancing y-secretase-dependent cleavage o f the C-terminus of VEGFR-1. This 
suggests that PEDF may be involved in the Regulated Intramembrane Proteolysis 
(RIP) signalling pathway, which has been well documented to play a very 
important role in Notch (Struhl and Greenwald, 1999; Handler et a l ,  2000; 
Kimberly et a l ,  2003) and ErbB4 signalling (Ni et a l ,  2001; Lee et a l ,  2002) 
and Ap production (McLoughlin & Miller et a l ,  1996). Therefore, understanding 
the role of VEGF and PEDF in relation to RIP may contribute to a new strategy 
for treating not only neovascular disease but also a wider range o f clinical 
conditions.
The aim of the project was to investigate the mechanism(s) in which PEDF 
regulates angiogenesis by exploring the involvement of Presenilin (PS)- 
dependent RIP in relation to VEGF/PEDF and VEGFR-1 /VEGFR-2 in cultured 
BRMECs and HRPE cells. BRMECs were used as an example o f an angiogenic- 
type cell, whilst HRPE cells act as regulatory cells. The relationship between
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VEGF and PEDF in the regulation o f VEGFR-1/VEGFR-2 expression was also 
investigated by the inhibition o f VEGF function in HRPE cells.
The hypothesis that VEGF and VEGFR-1 are involved in PS-dependent RIP 
signalling pathway and PEDF acts as a regulator was examined using 
immunoblotting techniques and immunocytochemistry. The relationship between 
VEGF and PEDF in the regulation o f VEGFR-1 /VEGFR-2 expression was 
examined using siRNA assays.
Several fundamental objectives were undertaken to address the hypothesis. These 
included identification of:
1) The role o f VEGF and PEDF in the regulation of the expression and 
localisation o f VEGFR-1 and VEGFR-2
2) The role o f VEGF/PEDF on the activity o f y-secretase and the expression of 
PS-1
3) The association between VEGFR-1 and/ or VEGFR-2 and y-secretase in both 
BRMECs and HRPE cells. The overall project has led to novel findings and 
addresses the need for continued research which is detailed in the future work 
section (section 7.8).
7.2 Summary of findings:
7.2.1 The effects of VEGF and PEDF on VEGFR-1, VEGFR-2 and PS-1 
expression and y-secretase activity in BRMECs and HRPE cells
BRMECs (bovine retina microvascular endothelial cells):
As summarised in Fig 7.1, the results obtained in this thesis indicate that in 
BRMECs, under normal culture conditions, the expression o f VEGFR-1 and 
VEGFR-2 is counterbalanced. The overall expression o f VEGFR-1 can be 
upregulated by exogenous VEGF or PEDF at 100 ng/ml whereas the overall 
expression of VEGFR-2 can be downregulated by exogenous VEGF or PEDF at 
100 ng/ml. In addition, PEDF can augment VEGF’s effect on VEGFR-1 and 
VEGFR-2 in BRMECs.
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Fig 7.1 Effects of VEGF & PEDF on cell signalling. The effects of VEGF and 
PEDF on VEGFR-1 (R l), VEGFR-2 (R2) and presenilin-1 (PS-1) expression and 
y-secretase (rS) activity in (A) BRMECs and (B) HRPE cells, red arrow: VEGF’s 
effect; blue arrow: PEDF’s effect and dark red arrow: combined effects o f VEGF 
and PEDF.
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HRPE (human retina pigm ent epithelial) cells:
The evidence obtained in the study o f HRPE cells suggests that VEGFR-1 (the 
75 and 85 kDa fragments) and VEGFR-2 are highly expressed under 
physiological conditions. The expression of VEGFR-1 fragments can be 
downregulated by 100 ng/ml o f exogenous VEGF, and instead o f antagonising 
VEGF’s effect, addition o f PEDF synergistically inhibited the expression of 
VEGFR-1 and VEGFR-2 in HRPE cells
The differential regulatory roles for VEGF on VEGFR-1 in BRMECs and HRPE 
cells suggest that the effect o f VEGF on the expression of VEGFR-1 is cell-type 
dependent. This may be one o f the distinguishable differences between 
angiogenic and non-angiogenic cells, although this needs to be confirmed on 
cells from the same species.
Differential regulatory roles for VEGF and PEDF on the activity o f y-secretase 
and the expression o f PS-1 observed in this thesis suggest that VEGF and PEDF 
have a regulatory effect on the activity of y-secretase and the expression o f PS-1 
in BRMECs and HRPE cells. The role o f VEGF and PEDF on the activity of y- 
secretase and the expression o f PS-1 is cell-type dependent. In addition, y- 
secretase is involved in the expression of VEGFR-1 fragments and VEGFR-2 as 
well as the distribution of VEGFR-1 fragments in HRPE cells.
7.2.2 The effects of VEGF-siRNA on VEGF, PEDF, VEGFR-1 and 
VEGFR-2 expression in HRPE cells
The VEGF-siRNA used in this study efficiently reduced the expression o f VEGF 
and PEDF at both the transcript and protein level in HRPE cells, as well as 
VEGFR-1 at the protein level (Fig 7.2). The downregulation o f VEGF, as well as 
PEDF, by VEGF-siRNA supports the existence o f an autocrine loop between 
VEGF and PEDF and indicates that other anti-VEGF agents are likely to have 
similar effects on PEDF in cells secreting both VEGF and PEDF.
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Fig 7.2 Effects of VEGF-siRNA on VEGF cell signalling in HRPE cells.
VEGF-siRNA reduced VEGF and PEDF expression at transcript and protein 
level. VEGF-siRNA reduced VEGFR-1 expression at protein level while had no 
significant effect on VEGFR-2 and PS-1.
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It is likely that the differential role o f VEGF and PEDF, on VEGFR-1 and 
VEGFR-2, in BRMECs and HRPE cells contribute either directly or indirectly to 
the regulation o f neovascularisation. The implications o f these roles in the 
regulation of neovascularisation are discussed below.
Questions have been asked as to how PEDF intercepts growth-promoting signals, 
accelerates cell death cascades and prolongs cellular life span. It remains 
unknown whether the different activities o f PEDF are based on different 
receptors or if cellular diversity or variations in the cellular environment account 
for the variations in response to PEDF. A lipase-linked cell membrane receptor 
for PEDF has been identified by Notari et al. (2006). And there is a possibility 
that some activities o f PEDF may not be receptor mediated -  a phenomenon that 
has been seen with many other proteins (Tombran-Tink, 2005).
7.3 PEDF exerts its antiangiogenic role by modulating the 
counterbalance of VEGFR-1 and VEGFR-2 in BRMECs
An antiangiogenic role for PEDF in the retina emerged when Dawson et al. 
(1999) showed that PEDF inhibited angiogenic processes. The inhibitory effect 
of PEDF was more effective than the well studied angiogenesis inhibitor, 
angiostatin. In those studies, PEDF prevented EC migration alone, or in the 
presence of the potent proangiogenic factors: FGF-1, FGF-2, VEGF, interleukin- 
8 and lysophosphatic acid. In animal studies, ocular injection o f an adenoviral 
construct containing the PEDF gene not only inhibited the formation o f both 
retinal and choroidal neovascularisation in mouse models o f ocular angiogenesis 
but also caused the regression of neovascularisation that was already present 
(Mori et al., 2001; Mori et al., 2002). These studies are convincing and indicate 
that PEDF establishes specific mechanisms of interference that mitigate vascular 
growth propelling signals. Furthermore, PEDF was shown to be able to negate 
the increased vascular permeability induced by VEGF in an animal model (Liu et 
al., 2004). At the molecular level, Tombran-Tink (2005) has reported that PEDF 
reduced VEGFR-2 transcription in the adult monkey retina, as well as the human
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A-RPE-19 cell line. PEDF also inhibited phosphorylation of VEGFR-2 in 
HUVECs in the presence o f  its ligand, VEGF.
VEGFR-2 has been regarded as the major transducer o f VEGF signals in ECs, 
which result in cell proliferation, migration, differentiation, tube formation, 
increased vascular permeability and maintenance of vascular integrity (Ziche et 
al. 1997). VEGFR-1, on the other hand, has been proposed to play a negative 
role in the regulation o f the levels o f endogenous VEGF. This is achieved by 
absorbing the ligand with its extracellular domain (Shibuya, 2001). A 
considerable “cross-talk” between VEGFR-1 and VEGFR-2 has been observed 
by several groups (Rahimi et a l , 2000; Burkhardt and Zacharias, 2001; Zeng et 
a l 2001). They reported that the “cross-talk” between VEGFR-1 and VEGFR-2 
played a critical role in regulating VEGFR-2-mediated signalling and that 
dependent on conditions, VEGFR-1 can act as a pro- or anti-angiogenic regulator 
of VEGFR-2.
The findings of this study, that PEDF upregulates VEGFR-1 and downregulates 
VEGFR-2 in BRMECs is in agreement with the above report and supports the 
proposal that PEDF intercepts growth-promoting signals by modulating the 
expression of VEGFR-1 and VEGFR-2 in BRMECs, rather than solely 
downregulating VEGFR-2.
Of most interest is the antagonist effect between VEGF and PEDF was not 
observed but the synergistic effect on either VEGFR-1 or VEGFR-2 that results 
from the combined effects o f VEGF and PEDF. This suggests that PEDF’s 
maximal effect is dependent upon VEGF. This finding is consistent with 
previous reports and, furthermore it indicates a regulatory relationship between 
VEGF and PEDF. Further study is necessary to prove any potential impact on 
the design of anti-angiogenic strategies.
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Based on the accumulating evidence that the role of PEDF is dose-dependent and 
cell phenotype dependent (Apte et al. 2004; Hutching et al. 2002), caution has 
been taken when interpreting the data obtained from the present study. The data 
may represent only part of a mechanism since the data was produced from the 
treatment of a single dose of VEGF/PEDF. To further our understanding o f the 
relationship between VEGF/PEDF and VEGFR-1/VEGFR-2 future work is 
required (see section 7.8).
7.4 PEDF exerts its neurotrophic and neuroprotective role by regulating 
the activity of y-secretase and the expression of PS-1 in HRPE cells
PEDF was first identified in the conditioned-medium of fetal human RPE cells 
which had a differentiating effect on retinoblastoma cells (Tombran-Tink and 
Johnson, 1989; Tombran-Tink, et al. 1991). PEDF exerts its neurotrophic and 
neuroprotective function by protecting various types of cells, including neuronal 
cells, against oxidative stress or glutamate-induced injury through its anti- 
oxidative properties (Cao et al. 1999; Bilak et al. 1999; DeCoster et al. 1999; 
Yamagishi et al. 2002; Yamagishi et al. 2003; Inagaki et al. 2003). Increase in 
oxidative stress has been related to the hyperactivity o f glutamate receptors 
which results in the disturbance of glutamatergic neurotransmission. Oxidative 
stress has also been associated with the deposition o f Ap peptides in the brain 
and therefore implicated in the pathogenesis o f Alzheimer’s disease (AD) 
(Butterfield and Pocemich, 2003).
The involvement o f y-secretase in Notch, ErbB4 and VEGFR-1 signalling, and 
the production of Ap has been well documented. The implication o f y-secretase 
in the development, signal transduction, protease biochemistry,
neovascularisation and the pathogenesis o f AD suggests that the activity of y- 
secretase can be beneficial or harmful dependent upon the nature o f its targets. A 
fine line appears to exist between protective and damaging roles.
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Several factors or processes have been reported to affect the nature and degree of 
y-secretase activity, as reviewed in Chapter 4. PEDF overexpression has been 
found in cortical neurons and astrocytes in the brains of AD patients (Yamagishi 
et al. 2004), and the distribution of PEDF protein was in concordance with 
RAGE protein, one of the receptors for Ap peptide. PEDF overexpression has 
been suggested as a compensation mechanism in an attempt to prevent neuronal 
cell injury in AD.
Recently PEDF was also shown to upregulate y-secretase activity which resulted 
in the inhibition of angiogenesis in cultured BRMECs (Cai et al., 2006).
Conversely, a product of y-secretase activity, Ap, has been reported to have a 
regulatory role on the endogenous production of VEGF and PEDF in HRPE cells 
(Yoshida et al., 2005). It was reported that AP accumulation induced an increase 
in VEGF and decrease in PEDF in cultured HRPE cells. Taken together, these 
studies suggest a regulatory loop between VEGF/PEDF, y-secretase and the 
substrate(s) of y-secretase.
The finding from the present study that PEDF upregulates the activity of y- 
secretase in BRMECs is in agreement with Cai et al. (2006), in part, and suggests 
that the activity o f y-secretase in ECs may be beneficial with respect to the 
regulation of angiogenesis. Furthermore, the upregulation o f y-secretase activity 
by VEGF and the fact that PEDF can negate VEGF’s effect in HRPE cells, 
increases our understanding o f the relationship between VEGF/PEDF and y- 
secretase. It also suggests that, in HRPE cells, y-secretase activity may be 
harmful rather than beneficial. In addition PEDF may protect HRPE cells by 
negating the activation of y-secretase induced by VEGF. Collectively, these 
findings suggest that the role o f VEGF/PEDF on y-secretase activity is cell-type 
dependent.
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Another finding from the current study that y-secretase exerts differential 
regulatory effect on VEGFR-1 and VEGFR-2 in HRPE cells suggests that y- 
secretase involved in the VEGFR-1 and VEGFR-2 signalling. Future study is 
required to further our understanding of the role o f y-secretase on VEGFR-1 and 
VEGFR-2.
7.5 The role of an autocrine loop between VEGF and PEDF in HRPE 
cells
A precise balance between stimulators and inhibitors o f angiogenesis, such as 
VEGF and PEDF, respectively, is essential for angiogenic homeostasis, at least, 
in ocular tissues.
VEGF and PEDF are expressed in a wide variety of tissues and by many cell 
types as reviewed in the section 1.2.1 and section 1.4.1. More interestingly, 
VEGF and PEDF can be produced by the same cell, for example HRPE cells 
(Ohno-Matsui et al., 2001), BRMECs (Tombran-Tink, et al. 2004) and glial 
Muller cells (Eichler, et al. 2004). In HRPE cells, VEGF upregulates PEDF 
expression through VEGFR-1 in an autocrine manner (Ohno-Matsui et al., 
2003). On the other hand, VEGF produced by RPE cells may be involved in 
paracrine signalling between the RPE and choriocapillaris to induce endothelial 
fenestration (Roberts and Palade, 1995). Therefore, it is possible that 
VEGF/PEDF regulates endothelial proliferation and migration using both 
autocrine (EC-dependent) and paracrine (EC-independent) mechanisms. While 
the roles of VEGF and PEDF in neovascularisation are complicated, VEGF 
overexpression/and or PEDF under-expression is believed to be a main cause in 
the initiation of neovascularisation.
Due to its role in tumour neovascularisation, VEGF has been chosen as a 
therapeutic target to manage pathological neovascularisation. VEGF inhibitors, 
such as anti-VEGF monoclonal antibody and antisense oligonucleotides have 
shown partial success and most clinical trials have shown modest effects so far 
(Afzal et al. 2007).
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The demonstration that VEGF-siRNA downregulates VEGF, as well as PEDF, in 
this study suggests that the downregulation o f PEDF may be one o f the side- 
effects of anti-VEGF therapy. Such a side-effect has not been considered in any 
literature. It also challenges the therapeutic approach o f targeting a single 
molecule. This same concern has been raised by Afzal et al. (2007).
7.6 Are VEGF, VEGFR-1 and PEDF involved in the RIP signalling 
pathway?
Regulated Intramembrane Proteolysis (RIP) has been suggested as an non- 
classical signalling pathway for PEDF’s action by Cai et al. (2006) who showed 
that the inhibitory effect o f PEDF on VEGF-induced angiogenesis was a result o f 
the inhibition of VEGFR-2 in BRMECs. This inhibitory effect was achieved by 
enhancing y-secretase-dependent cleavage of the C-terminus of VEGFR-1.
A model for regulated intramembrane proteolysis o f a tyrosine kinase receptor 
has had been previously suggested by Heldin and Ericsson (2001), when Ni et al. 
(2001) showed that ErbB-4 undergoes proteolysis within its plasma membrane 
domain. In this model, binding o f a ligand to its tyrosine kinase receptor induces 
activation and autophosphorylation o f the receptor and created docking sites for 
signalling proteins containing SH2 domains. In this way, different signalling 
pathways, such as those containing mitogen-activated protein (MAP) kinase, are 
activated. In a separate signalling pathway, PLC-y activates PKC, which then 
activates the metalloprotease TACE (tumour necrosis factor-alpha-converting 
enzyme). This enzyme cleaves off the ectodomain of the receptor and allows 
intramembrane cleavage of the remaining part by y-secretase. The cleaved 
cytoplasmic region o f the receptor then moves to the nucleus, where it may affect 
the transcription of target genes (Heldin and Ericsson (2001) (Fig 7.3).
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Nucleus
Fig 7 3  Regulated intramembrane proteolysis of a tyrosine kinase receptor.
Binding o f a ligand to its tyrosine kinase receptor induces activation and 
autophosphorylation o f the receptor and the creation of docking sites for 
signaling proteins containing SH2 domains. In this way, different signaling 
pathways, such as that containing mitogen-activated protein (MAP) kinase, are 
activated. In a separate signaling pathway, PLC-y activates PKC, which then 
activates the metalloprotease TACE. This enzyme cleaves off the ectodomain of 
the receptor and allows intramembrane cleavage o f the remaining part by y- 
secretase. The cleaved cytoplasmic region o f the receptor then moves to the 
nucleus, where it may affect the transcription o f target genes (Copied from 
Heldin and Ericsson, 2001).
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By applying this model to VEGFR-1 /VEGFR-2, this thesis hypothesised that 
upon VEGF binding, an enzyme (possibly one of the MMPs) cleaves a portion of 
the extracellular domain o f the VEGFR-1. This first cleavage triggers y-secretase 
to cleave the cytosolic domain o f the VEGFR-1, allowing this fragment to 
translocate to the nucleus o f ECs to promote angiogenesis. As an inhibitor of 
neovascularisation, PEDF inhibits VEGF-induced angiogenesis by inhibiting one 
of the MMPs or y-secretase cleavage at the first, second or both sites in the RIP 
signalling pathway. Consequently, the cleavage of VEGFR-1 is reduced and less 
of the cytosolic domain o f VEGFR-1 is translocated into the nuclei, resulting in 
the inhibition o f angiogenesis (Fig 7.4a copied from Figl.lOb).
In contrast to this hypothesis, data in this thesis demonstrated that coincident 
with the upregulation o f VEGFR-1 fragment and downregulation of VEGFR-2, 
PEDF upregulated y-secretase activity and the expression of the high molecular 
weight (HMW) complex o f PS-1. The negligible effect of the combined VEGF 
and PEDF on the VEGFR-1 fragment is also consistent with the effect on the 
activity o f y-secretase. This is an indication that PEDF acts as a ‘ligand’ of 
VEGFR-1 to initiate the RIP signalling pathway in BRMECs, whilst VEGF 
seems to act as a regulator (Fig 7.4b).
Increased y-secretase activity in BRMECs by PEDF at 100 ng/ml has been 
reported by Cai et al. (2006). In their report the release o f an 80 kDa fragment of 
the C-terminal domain o f VEGFR-1 due to exposure o f BRMECs to VEGF, 
followed by PEDF, suggests that instead o f VEGF, PEDF may play a role as a 
ligand o f VEGFR-1. In addition, PEDF’s ligand role only appears when 
BRMECs are under the influence o f VEGF. The result obtained from the current 
study is in agreement, in part, with the above report. The disagreement on 
fragment size and the condition o f fragment release may be due to the 
involvement o f complicated pathways and interactive effects o f growth factors 
As well as the variables between experimental conditions. The variation o f the 
time for initiation o f the treatment may also be an important factor since ‘near 
confluent cells’ (Cai et al. 2006) and ‘80-90% of confluency’ (current study) can
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Fig 7.4-1 (= Fig 1.10b). A schematic representation of the hypothesis -  the 
effects of VEGF & PEDF on VEGFR-1/ VEGFR-2. Upon the ligand binding 
(e.g. VEGF), an enzyme (possibly one of the MMPs) cleaves a portion of the 
extracellular domain of the VEGFR-1; this 1st cleavage initiates y-secretase to 
cleave the cytosolic domain o f the VEGFR-1, allowing this fragment to 
translocate to the nucleus o f the endothelial cells to promote angiogenesis. PEDF 
inhibits VEGF induced angiogenesis by inhibiting the enzyme(s) activity of the 
first or second or both cleavages o f VEGFR-1 in the RIP signalling pathway.
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Fig 7.4-2 Amended hypothesis. In contrast to the hypothesis, data in this 
thesis suggested that exogenous PEDF increased the expression of VEGFR-1 
fragment by upregulating y-secretase activity and the high molecular weight 
(HMW) complex ofPS-1.
194
Chapter 7 Yadan Zhang
vary dependent upon an individual’s standard, whereas an elucidated response 
varies dependent upon the stage o f cell growth.
The relationship observed between VEGF, VEGFR-1 and PEDF in HRPE cells 
seems more difficult to fit into the RIP model, since VEGF downregulated the 
expression o f the VEGFR-1 fragments, while upregulating the activity of y- 
secretase. This may be the result o f the activation o f an autocrine loop in order 
to compensate for the high concentration o f VEGF, sensed by RPE cells.
7.7 Concluding remarks
> PEDF regulates the counterbalance o f VEGFR-1 and VEGFR-2 
expression in cultured BRMECs.
>  PEDF regulates the activity o f y-secretase and the expression of PS-1 in 
BRMECs. VEGF is an antagonist o f the effect of PEDF on y-secretase.
>  VEGF regulates the activity o f y-secretase in HRPE cells and PEDF acts 
as an antagonist o f VEGF.
>  y-secretase regulates the expression of VEGFR-1 fragments and VEGFR- 
2, as well as the distribution o f VEGFR-1 fragments in HRPE cells.
>  The VEGF gene silencing strategy induces a reduction of PEDF at both 
the transcript and protein level and VEGFR-1 at the protein level.
>  The effect o f VEGF and PEDF on VEGFR-1 and VEGFR-2 is cell type 
dependent.
7.8 Future work
7.8.1 To examine the effect o f VEGF/PEDF on VEGFR-1 and VEGFR-2 
expression. A titration series o f VEGF concentrations against a single 
dose o f PEDF or vice versa may give a more complete understanding of 
the relationship between VEGF and PEDF and VEGFR-1/VEGFR-2 
expression.
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7.8.2 To gain a better understanding about the production of VEGF/PEDF from 
ECs and RPE cells: measure the production of VEGF/PEDF under 
various conditions, such as serum free medium versus media containing 
1-2% or 10% FCS.
7.8.3 To use the ECs and RPE cells from same species, to compare the 
difference o f VEGFR-1/VEGFR-2 in response to VEGF/PEDF.
7.8.4 To use PEDF-siRNA to determine its effect on the expression of VEGF, 
VEGFR-1 and VEGFR-2 in HRPE cells.
7.8.5 Sequence analysis o f the fragments detected in BRMECs and HRPE 
cells.
7.8.6 The effects o f VEGF/PEDF on VEGFR-1 /VEGFR-2 signalling in 
cultured ECs when co-culturing with RPE cells.
7.8.7 The role o f VEGF/PEDF on the progenitors of endothelial and RPE cells.
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A P P E N D IC E S
A p p en d ix  1 
R eagents for Cell culture
Growth medium fo r  BRECs (TCS CellWorks, UK)
Microvascular Endothelial Cell Growth Supplement (ZHS-8947): 25ml 
[containing: heparin,
hydrocortisone,
human epidermal growth factor, 
human fibroblast growth factor, 
dibutyryl cyclic AMP 
5% (v/v) FCS (final concentration)]
Antibiotic Supplement (ZHR-9939): 0.5 ml 
[containing: 25 mg/ml gentamicin
50 pg /ml amphotericin B (1000 x concentrate)]
Make up in 500 ml o f Microvascular Endothelial Cell Basal Medium (ZHM- 
2946).
Growth medium fo r  H RPE cells (final concentration):
10% (v/v) FCS
0.06% (w/v) Penicillin-G
0.1% (w/v) Streptomycin
0 .1 % (w/v) Kanamycin
Make up in Ham’s F-10 (Gibco, Life Technologies, Scotland)
Trypsin - EDTA solution
0.25% (m/v) trypsin 
0.05% (m/v) EDTA
Disolve in 1 x PBS, mix thoroughly, filtered using 0.2 pm filter, store at -20°C in 
aliquots.
Antibiotics cocktail
1.0 g Streptomycin Sulphate (Sigma # S-913)
1.0 g Kanamycin (Sigma # K-4000)
0.6 g Penicilin-G (Sigma # PEN-NA)
Disolve in 100 ml o f ddH20 , mix thoroughly, filtered using 0.2 pm filter, store at 
-20°C in aliquots.
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A p p en d ix  2
Reagents for proteom ic analysis 
Buffers for protein extraction
Extraction buffers for the preparation of two-subcellular fraction (Cai et al. 
2006)
Buffer 1: l% Triton X-100 soluble buffer
25 mM Tris/HCl
150 mM NaCl
0.25% Sodium deoxycholate
1 mM NaF
1 mM Na3V 0 4
1 mM EDTA
1 mM phenylmethylsulfonyl fluoride
1 pg/ml aprotinin
1 pg/ml leupeptin
1 pg/ml pepstatin
1 % Nonidet P-40
1 % Triton X-100
Buffer 2: 1% SDS buffer
25 mM Tris/HCl
150 mM NaCl
0.25% Sodium deoxycholate
1 mM NaF
1 mM N a3V 0 4
1 mM EDTA
1 mM phenylmethylsulfonyl fluoride
1 pg/ml aprotinin
1 pg/ml leupeptin
1 pg/ml pepstatin
1 % Nonidet P-40
1 % SDS
Extraction buffer for the preparation of whole-cell lysate: RIPA Lysis 
Buffer (sc-24948, Santa Cruz)
RIPA - containing: lx  PBS
1% NonidetP-40 
0 .5 % sodium deoxycholate 
0.1% SDS
PMSF 50 pi for 10ml of lxRIPA
Protease inhibitor cocktail 50 pi for 10ml of lxRIPA
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Buffers for the w estern  blotting
Running  B u ffer  -1 x Tris /  Glycine /S D S  Buffer
25 mM Tris 
192 mM Glycine 
0.1% (w/v) SDS 
pH 8.3
To make 1 liter o f above buffer, add 100 ml of 10 xTris / Glycine / SDS Buffer 
(BIO-RAD, Cat# 161-0732) to 900 ml of dH20 . Mix thoroughly.
Transfer B u ffer  - 1 x Tris /  C APS B uffer
60 mM Tris 
40 mM CAPS 
15% (v/v) methonal 
pH 9.6
To make 100 ml o f above buffer, add 10 ml 10 xTris / CAPS Buffer (BIO-RAD, 
Cat# 161-0778) and 15 ml Methanol to 75 ml of dH2 0  just before use. Mix 
thoroughly.
Ponceau S  staining buffer (Sigma, U.S.A.)
2% Ponceau S 
30% trichloroacetic acid 
30% sulfosalicylic acid 
diluted in ddH 20 in 1:10 for use
Blocking B uffer
3-5% (w/v) skimmed milk powder (Sigma)
50 mM of Sodium Fluoride (NaF) (lg/500ml PBS)
0.05% (v/v) Tween 20™  (250 ul/500 ml PBS)
Make up in 1 x PBS for use.
Washing B uffer
50 mM of Sodium Fluoride (NaF)
0.05% (v/v) Tween 20™
Make up in 1 x PBS for use.
10 x PB S (1000 ml)
80.Og NaCl (Sodium Chloride):
2.0g KC1 (Potassium Chloride):
14.4g Na2P 0 4 (di-Sodium Hydrogen Orthophosphate anhydrous)
2.4g KH2PO4 (Potassium dihydrogen orthophosphate)
Disolves in 800 ml dH20 , adjusts pH to 7.4 (using HC1), add up to 1000 ml of 
dH20, mix well for use. To make l x PBS: dilute 10x PBS 1:10 in dH20 , mix 
well for use.
235
Appendices .Yadan.Zhang
10 x Lam ili B u ffer  (10L)
303.Og Tris
1441.4g Glycine
lOO.Og SDS
Dissolves in ddH 20 up to the volume of 10 litre.
1.5 M  Tris/HCl (100ml)
18.17 g Tris Base
HC1 to pH 8 . 8  
4ml 10% SDS
1.0 M  Tris/HCl (100ml)
12.1 Og Tris Base
HC1 to pH 6 . 8  
4 ml 10% SDS
Stripping B u ffer (500 ml)
3.75 g Tris Base
HC1 to pH 6.7 
3.52 ml (3-mecoptoethanol
10.0 g SDS
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A ppendix 3
Evaluation o f the specificity o f the VEGFR-1 and VEGFR-2 
antibody
The specificity of the VEGFR-1 antibody -  the blockade of the antibody 
binding with a peptide specific to VEGFR-1.
Fantibody
+
IFantibody
Blocking peptide 
+
> Fantibody 
+
IFantibody
Stripping reprobing
A1
IFantibody <
B1
sic ..
m  -
Fantibody
+
IFantibody
Neutralisation of the VEGFR-1 antibody binding in BRM ECs and HRPE 
cell lysates by VEGFR-1 blocking peptide by w estern blotting. (A) one of
the duplicates membrane probed with I°and 11° antibodies; (B) the 2nd duplicate 
probed with the blocking piptide prior to the addition of the I°and 11° antibodies. 
The same membranes were stripped then reprobed with 11° antibody only (A l) or 
I°and 11° antibodies (Bl).
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The specificity of the VEGFR-2 antibody -  the blockade of the antibody 
binding with a peptide specific to VEGFR-2.
A B
Fantibody
+
IFantibody
r
V
■ \
Blocking peptide 
+
\ Fantibody
f  +
IFantibody
J
Neutralisation of the VEGFR-2 antibody binding in HRPE cell lysates with 
VEGFR-2 blocking peptide by western blotting. A: one of the duplicates 
membrane probed with I°and 11° antibodies; B: another duplicate probed with the 
blocking piptide prior to the addition of the I°and 11° antibodies.
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A p p en d ix  4
The molecular formular and structure of the y-secretase inhibitor (Cat. # S 
2188, Sigma): C33H 57N 5O9F2
o c -V a l- l le -H N .
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Appendix 5 
RT-PCR relevant
Reverse-iT™  1st Strand Synthesis —tw o-stept protocol:
RT1
First strand primer -  anchored oligo dT (500 ng/ul) 1 ul
RNA template 1 ug/1 Oul
Sterile H2O t o l 2 u l
RT2
Add the mix of the following components
5x First Strand Synthesis buffer 4 ul
dNTP mix (5 mM each) 2 ul
Reverse-iT M Rtase Blend 1 ul
DTT(lOOmM) 1 ul
Tris-Borate-EDTA (TBE) buffer (Cat.# T4415, Sigma)
Dilution of the TBE stock concentrates (lOx) in ddFbO to a 1 x TBE running 
buffer results in a buffer containing 
89 mM Tris-borate
2 mM EDTA
pH 8.3
